Authors	Publication title	Date	Journal	Funding acknowledgement	Competing Interests	If relevant: clinical trial ID	Comments	Date of data extractio
Afolabi MO	Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants		Official journal of the American 2016 Society of Gene & Cell Therapy	Tala Patrenship (ISCCIT) and was performed by the Malaria Vectored Vaccine Conscribing (MOVQ), a four and a half year inagrating project funded by the Gropes and Observations (MOVQ), a four and a half year inagrated project funded by the Gropes and Observation (Grover Collect) Trails Patrenship (ISCCIT), grant number IP 2008, 31100,001), the work was to supported by the UK Malarial Institute of Ielash Research, Ninskill through the New Malaria Work of Sometical Research Centre (http://www.welcome.put/) (MSRIL)2007/19 (MSRIL)2	AVSI is a named inventor or appear applications on makes vectored vectors and immunication regions. Author from Bettlers as to employee of radior was obtained in Refflers, which is received by the control of the second of the	NCT01373879, NCT01450293, NCT01635647. PACTR.201204000362870, PACTR.201400000363170, PACTR.20120600404131	, NA	08/12/2020
Alcock R	Long-term thermostabilization of live poxviral and adenoviral vaccine vectors at supraphysiological temperatures in carbohydrate glass		2010 Elselvier - Vaccine	No funding disclosure found	Conflict of interest: SCG is a co-founder of, consultant to and shareholder in Vac-citech plc which is developing vectored influenza and MERS/vaccines.		No funding disclosure found	16/12/20
Alharbi NK	ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice		2017 Vaccine	No funding statement found	SCG is a co-founder of, consultant to and shareholder in Vaccitech plc which is developing vectored influenza and MERS vaccines.	N/A	N/A	21/12/2020
Alharbi NK	Humoral Immunogenicity and Efficacy of a Single Dose of ChAdOx1 MERS Vaccine Candidate in Dromedary Camels		2019 Nature	This study is funded by KAIMRC, project RC16/093 granted to the PI: Naif Khalaf Alharbi; in	SCG is a co-founder of and consultant to Vaccitech, a spin-out company from the University of Oxford which has commercial rights to ChAdOx1 MERS. ChAdOx1 MERS vaccine is registered as an IP, number: WO 2018/215766. The remaining authors declare no potential conflict of interest.	N/A	N/A	18/12/20
Alves E	Evaluation of Plasmodium vivax Cell- Traversal Protein for Ookinetes and Sporozoites as a Preerythrocytic P. vivax Vaccine Clinical assessment of a novel		2017 Clinical and Vaccine Immunology	The work was funded by a Wellcome Trust Career Development Fellowship award(grantnumber 097395/L/11/Z) to A.RS.	N/A	N/A	N/A	08/12/2020
	recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A			The study was funded by grants from the UK MRC, the NIHR through the Oxford Biomedical	T.L is an Oxford Martin fellow. S.C.G and A.V.S.H. are Jenner Investigators. S.C.G, M.D.D., and A.V.S.H are named inventors on a pat-ent application describing the ChAdOx1 vector (GB Patent			
Antrobus RD Asthagiri Arunkumar G	antigens  Vaccination with viral vectors expressing NP, M1 and chimeric hemagglutinin		2014 Molecular Therapy	Research Centre, and the Oxford Martin school.  The study was fundedby an MRC Biomedical Catalyst DPFS_DCS award (MR/N006372/1).in addition, this study was partially funded by the NIAID Centers of Excellence for Influenza Research	Application No. 1108879.6). The Irahn School of Medicine at Mount Sinai has filed patentapplications regarding influenza virus vaccines with FlorianKrammer being an inventor. Sarah Gilbert is an inventor on patentscovering ChAdOx1 and MVA-NP-M1, filed and owned by the University of Oxford, and is a co-founder of and	NCT01623518	N/A	08/12/2020
	induces broad protection against influenza virus challenge in mice		2019 Elselvier Vaccine	and Surveillance contract(CEIRS, HHSN272201400008C). Andriani loannou was supportedby an NAID 132 Virus-Host Interactions training grant(\$132A007647-17).  The work was funded by a Wellicome Trust Career Development Fellowship award(grant 097395/L/11/Z) to A.RS., who is also a Jenner Investigator and an Oxford MartinFellow and is	consultant to Vaccitech, a University of Oxford spin-out company which is undertaking advanced clinical development of viral vectored influenza vaccines.	N/A	N/A	18/12/20
Atcheson E	Tailoring a Plasmodium vivax Vaccine To Enhance Efficacy through a Combination of a CSP Virus-Like Particle and TRAP Viral Vectors	ı	2018 Infection and Immunity	supported by MRC-DPSS (grant MR/N019008/1). A M.S. was funded by WMM-alik's program fundine (PF/70007-013) under grant agreement number 24209.5 E. Ass funded by CAPS from Science without Border program. A.V.S.H. is supported by aWellcome Trust grant (number 095540/2/11/2) and is a Jenner investigator and an OxfortMartin Fellow.	N/A  S. Colloca, A.F., R.C., and A.N. are named inventors on patent applications covering HCV-vectored vaccines and chimpanzee ad-enovirus vectors (WO 2006133911 (A)) hepatitis Cvirus nucleic acid	N/A	N/A	10/12/2020
Barnes E Barnes E	Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man ChAdOx1-HBV therapeutic vaccine:		2012 Science Transitional Medicine	European Urion (Framework VHERACUNAC), Medical Research Coundi (UR); Wellcome Trust, Oxford NHHR Bindecial Research Centre, James Martin School for 21st Century, Oxford; Wellcome Trust Clinical Research Facility, Birmingham; National Institute for Health and Research Liver Biomedical Research Unit, Birmingham; And NHH grant 11/13/AIR82830-01.	vaccine, WO 2005071093 (A); Ohimpanree adenovirus vaccine carriers, WO 03031888 (A) hepathitished Curius vaccine), F. has actedus a consultant to Tibetes and Pitzer on antivitherapy, Authors from Okairos are employees of and/or shareholders in Okairos. The other authors declare that the have no competing interests.		N/A	10/12/2020
	Phase 1 study results in healthy volunteers and patients with chronic hepatitis B Efficacy of a Plasmodium vivax malaria vaccine using ChAd63 and modified		N/A - only on clinicaltrials.gov (https://clinicaltrials.gov/ct2/show/N 2020 CT04297917)	N/A  The work was funded by a Wellrome Trust Career Development Fel-lowship award grant number	N/A	NCT04297917	Study still recruiting	18/12/20
Bauza K	vaccinia Sang ciriodos and infolined vaccinia Ankara expressing thrombospondin-related anonymous protein as assessed with transgenic Plasmodium berghei parasites		2014 Infection and Immunity	The work was furnised by a vencious in state of execution in the work was furnised wash. § and in indicate of possible of poss	N/A	N/A	N/A	10/12/2020
	Optimising immunogenicity with viral vectors: mixing MVA and HAdV-5			Funding was provided by NEWTBVAC (EC FP7). HM is a Wellcome Trust Senior Research Fellow	The authors have read the journal's policy and have the following conflicts: AVSH, AAP, and HM are named inventors in a patent filingrelated to MVABSA and are shareholders in a joint venture, OETC formed for the future development of this vaccine. AVSH and HM are named as co-inventorsonpatents related to heterologous prime-boost immunization. There are no other			
Betts G	expressing the mycobacterial antigen Ag85A in a single injection		2012 Plos One	(www.welicome.ac.uk. WTD/9634MA). HM, AH and ARA's rehmer institute investigation. AR3's with well-one trust Care Development Felology (197250).  Well-one Trust Care Development Felology (197250).  He LWOAD, Life LWOAD, LI	adherence to the journal's policies on sharing data and materials.	N/A	N/A	10/12/2020
Biswas S	Assessment of humoral immune responses to blood-stage malaria antigens following ChAdG3-MVA immunization, controlled human malaria infection and natural exposure		2014 Plos One	GIA work was supported by the PAIM Malaria Vaccine Institute (http://www.malariavsccinc.org/ and the Instrumum longman of the National Institutes of Health, National Institute of Allelagy and Infectious Diseases (http://www.instituth.org/). SHH holds a Wellcome Trust Research Training Fellowship (1979-80/11/21). ASH's and Sol see Innerin Investigations (Iter.//www.inner.ac.ac.k), SB is a NDM Leadership Fellow (http://www.ndm.ox.ac.uk) and Junior Research Fellow of St Catherine's College, Oxford Unionersity (http://www.tcm.ox.ac.uk), SB is a U.K MGC Career Development Fellow (ISJ00027) and Lister Institute Research Prite Fellow (http://www.lstituth.ox.ac.uk), SB instituth.org.uk), Hir hunders had not not lest using design, data collection and analysis, decision to	ScdC, MAC, AVSH and SID are named inventors on patent applications covering malaria vaccines and immunization regimes (Adenoviralvectors encoding a pathogen or tumour antigen, WO/2008/12/813. Viral vector immunogenic compositions, GBID16471.3]. This does not alter the author's afference in ReS ONE Spoiles on Aharing data and marketing.	NCT01095055, NCT01003314, NCT01142765, NCT00890760	N/A	10/12/2020
Ricums S	Transgene optimization, immunogenicity and in vitro efficacy of viral vectored vaccines expressing two alleles of Plasmodium falciparum AMA1	,	2011 Plos One	Six was funded by MulliviTraining, an FIPE funded Marie Curie Action under contract number MCI 2-050-000028. Ted Given view sus supported purely the PRATIVE Middlarif vaccine initiative (MVI) and the intramural Program of the National Institute of Health, National Institute of Allegar and Infectional Diseases and in party the Health VOVAI (European Maller) wis Vaccine Development Association, a European Commission FIPE Funded commontmin, AMA is funded by MyHell Medical Residence of Commission of Professional Commission of Professional Commissional Commission		s N/A	N/A	10/12/2020
Bliss CM	Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP		2018 Scientific Reports	This study was funded by the UK NIHR Biomedical Research Centre (BRC) with additional support from the Wellcome Trust.	Adrian Hill and Sarah Gilbert are named inventors on patent applications and patents relating to malaria vectored vaccines and immunication regimens. Stefano Colloca and Alfredo Nicosia are employees of and/or shareholders in ReiThera, which is developing vectored vaccines for malaria and other diseases.	NCT01364883, 2010-023824-26	N/A	10/12/2020
Bliss CM	Targeting Antigen to the Surface of EVs Improves the In Vivo Immunogenicity of Human and Non-human Adenoviral Vaccines in Mice		2020 Molecular Therapy	This research project was supported in part by fundingfron NI-MAID CRISS (INSN27201400000), and by grantswarder to L. C., Including the US Graduate Women in Science(GWIS) 2017 Nell Mondy and Monlique Braude Fellowship, a URRoyal Society for Tropical Medicine and Higher small grant(Society), and typ A Medicine and Higher small grant(Society), and typ A Medical Research Fund pump-priming grantfrom the University of Oxford (MBF/T72015/2150), UnitedKingdom.	A.V.S.H. is named as an inventor on a patent covering use ofChdd/Dx1-vectored vaccines and is a co- founder of, consultant to and shareholder in Vaccineth pic, which is developing Ad- vectoredvaccines. The remaining authors declare no competing interests. A.N. and S.C. who were employees and shareholders of Olivano and Advent during the conduct of	» N/A	N/A	10/12/2020
Borthwick N	Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1		2014 Molecular Therapy	The work was supported by Medical Research Council (MMC) UK and Department for International Development UK through an Eperimental Medicine call it award 6070266 with contributions from the International AGI Viscotile Initiate, InVI2 infectious melecular clones were obtained from Dr. George Shaw, University of Perestylania. The EEC Control Peptider Fold was Obtained through the NMI AIDS Reagent Program, Division of AIDS, NAID, NMI (ref. no. 1963b).	the study, and are inventors on patents WO 2005071093 (A3), WO 2006133911 (A3) and WO 03031588 (A2), A.L.McM. who reports grants from MRC and NIH, per-sonal fees from International AIDS Vaccine Initiative SAB during the conduct of the study and is an inventor		Tried searching clinicaltrials.gov but could not find registered trial and not in study	16/12/20

Bowyer G	Activation-induced Markers, Detect Vaccine-Specific LOH * Toll Reponnes Not Measured by Assays Conventionally Used in Clinical Trials	2018 Vaccines	Trials Partnership, with additional funding from the NHR Oxford biomedical Research Centre. The Oxford dirical trial was supported by funding from an Enhancement Award to a Wellicome Trust Strategic Award (IoA, V.S. Hill as principal investigator) columined by the UK MedicalResearch Council, the UK Department for international Development, and the European and Owerbedging council, the UK Department for international Development, and the European and Owerbedging the Council of the UK Department for international Development, and the European and Owerbedging Security of Oxford Biomedical Research of Conference and Conference and Conference and the Medical Peace Vision and Security of Conference and Security Security for review the Instances(pt. 1804/N-1802) vaccine CAGA3-1802 Visione and had the opportunity to review the Instances(pt. 1804/N-1802) vaccine CAGA3-1802 Visione and had the opportunity to review the Instances(pt. 1804/N-1802) vaccine CAGA3-1802 Visione and had the opportunity to review the Instances(pt. 1804/N-1802) vaccine CAGA3-1802 Visione and had the opportunity to review the Instances(pt. 1804/N-1802) vaccine CAGA3-1802 Visione and had the opportunity to review the Instances(pt. 1804/N-1802) vaccine CAGA3-1802 Visione and Section (IoA).	A.V.S.H. is a named inventor on patents relating to viral vectored vaccines. All other authors declare no conflicts of interest.	NCT02451891, 2015-000593-3	N/A	21/12/2020
Bowyer G	Reduced Ebola vaccine responses in CMV+ young adults is associated with expansion of CD57+KLRG1+T cells Towards a universal vaccine for avian influenza-protective efficacy of modified Vaccinia virus Ankara and Adenovirus vaccines expressing conserved influenza antigens in chickens	2020 JEM	was biomanufactured for these trisks byfimergent Biosolutions under a contract from Oxford Universitywith funding from the same Enhancement Award. The Sene-galeus trial was largely funded by a furopean Commission In-tron 2000 program award, EbolaVoc. (http://www.abolavac.eu/, grant agreement no. 666005.	N/A	NCT02451891	N/A	18/12/20
Boyd AC	challenged with low pathogenic avian influenza virus Immunity, safety and protection of an Adenovirus 5 primeModified Vaccinia virus Ankara boost subunit vaccine	2013 Elselvier - Vaccine	The Biosechnology and Biological Sciences Research Council and Wellcome Trust are gratefully acknowledged for their financial support.	N/A	N/A	N/A	16/12/20
Bull TJ	against Mycobacterium avium subspecies paratuberculosis infection in calves Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA	2014 Veterinary Research	This work was supported by Biotechnology and Biological Sciences. Recearch Council (BBSKC) grantsofted Biol/h01055/Sg1 ABR/H010715/L1. paye Hope and/erne McGulinnes were supported by Institute Strategic Grant funding from	TJB Is a minor shareholder in HAV Vaccines Ltd.	N/A	N/A	20/12/2020
Capone S	prime-boost immunisation in non- human primates 5T4 oncofoetal glycoprotein: an old	2010 Elselvier - Vaccine	This work was supported by the Wellcome Trust. AVSH is a Wellcome Trust Principal Research Fellow.  This work was supported by Oxford National Institutes for Health Research (NiHR) Biomedical Research Centre, UK (IR); the UK Medical Research Council CLG award (SS), the UK Wellcome Trust	N/A	N/A	N/A	16/12/20
Cappuccini F	target for a novel prostate cancer immunotherapy Safety and immunogenicity of novel ST4 viral vectored vaccination regimens in	2017 Oncotarget	Senior Investigator's Award (AVSH) and the European Union's Seventh Framework Programme under grant agreement No. 602705 ( (FC, EP).	N/A	N/A	N/A	21/12/2020
Cappuccini F	early stage prostate cancer: a phase I clinical trial Immunogenicity and efficacy of the novel cancer vaccine based on simian	Journal for ImmunoTherapy of 2020 Cancer	The VANCE clinical trial was supported by the European Union's Seventh Framework Programme under grant agreement no. 602705.  This work was supported by Oxford National Institutes for Health Research (NIHR) Riomedical	AVSH is a co- founder of and shareholder in Vaccitech Ltd which has supported the Oxford prostate cancer vaccine programme.	NCT02390063	N/A	18/12/20
Cappuccini F	adenovirus and MVA vectors alone and in combination with PD-1 mAb in a mouse model of prostate cancer Microneedle-mediated immunization of an adenovirus-based malaria vaccine	2016 Cancer Immunol Immunother	Research Centre, UK (I. Redchenko); the UK Medical Research Council CiCG award (S. Stribbling), th UK Wellcome Trust Senior Investigator's Award (A.V.S. Hill) and the European Union's Seventh Framework Programme under Grant Agreement No. 602705 (F. Cappuccini, E. Pollock)	e N/A	N/A	N/A	21/12/2020
Carey JB	an adenovirus-based malaria vaccine enhances antigen-specific antibody immunity and reduces anti-vector responses compared to the intradermal route	2014 Scientific Reports	This work wassupported by Enter prise Ireland (Commercialization Fund, CFID07/117) and Science oundation Ireland (National Access Programme 70 and 170). AISS and SID are Internetivestigation, and SID is a LN MKC Career Development Fellow (GI000527) and Lister Institute Research Prize Fellow.	The authors declare no competing financial interests. AVSH and SID are named inventors on patent applications covering malaria vectored vaccines and immunication regimes. BC, AV, COM, AVSH, ACM are named inventors onpatent applications covering micronecelle-mediated vaccine delivery.	N/A HCV vaccine phase 1 trial (HCV001) was registered with the European Clinica	N/A	16/12/20
Colloca S	Vaccine vectors derived from a large collection of similar adenoviruses induce potent cellular immunity across multiple species	2012 Science Transitional Medicine	This work was supported in part by Hepacivac (LSH-2005-1.2.4.2 project 037435) and the Wellcome Trust. AV.5H. was supported by Medicame Trust Principal Research Fell-lowship. E.B. was supported by Medical Research Council (UM, Author)	. NA	ITrial database (EudraCT number: 2007- 004259-12) and with the ClinicalTrials gov database (ID: NCT01070407); malaria vaccine clinical trial (VAC043) was registered with the European Clinical Trial database (EudraCT number: 2010-023824-26) and with the ClinicalTrials.gov database (ID: NCT0136483).		16/12/2020
Colston JM	Modification of Antigen Impacts on Memory Quality after Adenovirus Vaccination	2016 The Journal of Immunology	This work was supported by Wellcome Trust Grants 099897/Z/12/A and 091663MA.	N/A	N/A	N/A	20/12/2020
	Preventing spontaneous genetic rearrangements in the transgene		This work was supported by the European Vascine Initiative, theOxford Martin School, the Gates Foundation through the Foundation for NIII, The Welscome Trust, and the NIIRI Oxford Bornelicalities conference with the Foundation for Allenander's Spenner, internetinistins. University of Bornelical Conference of the Trust of the State Conference of the State Conferenc				
Cottingham MG	Cassettes of adenovirus vectors Heterologous Two-Dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-Lasting Cellular	2012 Biotechnology and Bioengineering	advice. Dr. DavidH. Wylke, Jenner Institute, University of Oxford performed somectoning steps.	adenovirus vaccine vectors.  SG and AVH are co-founders of Vaccitech, a company developingviral vectored vaccines including	N/A	N/A	16/12/20
Coughlan L	Immunity to Influenza Virus A in Healthy Adults  A phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS	2018 Elselvier	Medical Research Council UK, NIHR BMRC Oxford. The study was funded by a grant fromthe European (xacine initiative (CVI))http://www.cvccore.cu/, Antibody cassays were performed atWNAIR and were funded by the Malaris Vaccinentiative. This work was also supported by the UNitational Institute of Health Research through Hofford's Biomedical Research Centre (J48310). Adultivacion and not the Welcom Trust (681131/20/71), SCG and ANSI are Jenner Investigators, ANSI issupported by a Welcome Trust Reinschied Centre (J481016). and SHI hoth Sackelome Trust Research	broadly cross reactive influence area cines. Sh holds stock in Fondolfsetzer which develops and markets in filterare success. Mold recoved a regist from Abbellum analysis of the first success. Mold recoved a regist part from Abbellum analysis of the success of	NCT01818362	N/A	18/12/20
de Barra E	vaccine candidates ChAd63 CS administered alone and with MVA CS	2014 Plos One	Training Fellowship(IDF)980/(Z1/LT). The funders had no role in studydesign, data collection and analysis, decision foundship, or preparation of the manuscript.  S.C.d.C. is a Ph.D. student supported by the European Malaria Vaccine DevelopmentAssociation, a European Commission Framework Programme 6 Horderd consortune(Grant LISPC 72.007-03750). International Commission Framework Programme 6 Horderd Consortune Framework Programme 72.007-03750. Horderd Framework Progra	notal herthes authors' adherence to all PLOS ONE policisson sharing data and materials, as detailed online in the guide for authors.	NCT01450280	N/A	16/12/20
de Cassan SC	The requirement for potent adjuvants to enhance the immunogenicity and protective efficacy of protein vaccines can be overcome by prior immunization with a recombinant adenovirus Oliferential immunogenicity between HAdV-5 and chimpanzee adenovirus with chimpanzee adenovirus when the Chimpanzee and control of the Chimpanzee and control	2011 The Journal of Immunology	Commission FrameworkProgramme 7-Indexid consortium infrastructure grant, and grants to C.E.C. and V.S.C. from the Equatment of Bloethcoding, Government of India, and European Vaccinentistative. C.E.C. is supported by a Taia Innovation Fellowship from the Department Ordinack-Nation, Scorement of India, A.V.S.H. was supported by Wellcome TrustPrincipal Research Fellowship, S.C.G., A.V.S.H., and S.I.D. are Jenner Investigators. S.I.D. is a Medical Research Council Career Development Fellow (Grant G1000027).	Disclosures: S.C.d.C., E.K.F., A.D.D., A.M., S.C.G., A.V.S.H., and S.I.D. are namedimentors on patent applications covering malaria-vectored vaccines and immunication regimes. The other authors have no financial conflicts of	, N/A	N/A	16/12/20
Dicks MD	independent of filter and penton RGD loop sequences in mice  The relative magnitude of transgene-	2015 Scientific Reports	This work has been funded by a grant from the Wellcome Trust (095540/Z/11/Z). AVSH and SCG an Jenner Institute Investigators, AS and MGC are James Martin Fellows. This work has been funded by the Wellcome Trust (095549) with addit-binal funding from the Foundation for the National Institute of Health Mrough the Grand Challenges in Global Health Institute (HUILGSGCMI). MIDID received additional funding from the Euro-peam Malaria Vaccine Institute (HUILGSGCMI). MIDID received additional funding from the Euro-peam Malaria Vaccine (Malaria Malaria Ma	MDID, SCG, AVSH, and MGC are named inventors on a patent application describing the ChAdOx1 vector (US2015044766).	N/A	N/A	20/12/2020
	specific adaptive immune responses						

			through the Grand Challenges in Global Health Initiative, with additional funding from the				
			Wellcome Trust. MDJD received additional funding from the European Malaria Vaccine				
	A novel chimpanzee adenovirus vector with low human seroprevalence:		Development Association (EMVDA). MGCis a fellow of the Oxford Martin School Institute for Vaccine Design. SCG is a Jenner Investigator. AVSH is Director of the Jenner Institute and a	Competing interests: MDJD, SCG, AVSH, and MGC are named inventors on a patent application			
Dicks MD	improved systems for vector derivation	2012 Plos One	Wellcome TrustPrincipal Research Fellow. The funders had no role in study design, data collection	describing the ChAdY25/ChAdOx1 vector (GB PatentApplication No. 1108879.6). This does not alter	N/A		
Dicks MD	and comparative immunogenicity Enhancing blood-stage malaria subunit	2012 Plos One	and analysis, decision to publish, or preparation of the manuscript.	the authors' adherence to all the PLoS ONE policies on sharing data and materials.	N/A	N/A	16/12/20
	vaccine immunogenicity in rhesus		This work was funded by the Wellcome Trust and the European Malaria Vaccine Devlopment				
	macaques by combining adenovirus, poxvirus, and protein-in-adjuvant		Association, a European Commission FP6-funded consortium. S.J.D. is a Junior Research Fellow of Merton College. Oxford. United Kingdom. S.C.G. and A.V.S.H. are Jepper Investigators, and A.V.S.H.	Disclosures: S.J.D, S.C.G, and A.V.S.H. are named inventors on patent applications covering malaria vectored vaccines and immunization regiments. S.C., M.N., A.F., and A.N. are employees of and/or			
Draper SJ	vaccines	2010 The Journal of Immunology	is also a Wellcome Trust Principal Research Fellow.	shareholders in Okairòs, which is developing vecotored vaccines for malarian and other diseases.	N/A	N/A	16/12/20
	Potency of a thermostabilised chimpanzee adenovirus Rift Valley Fever		This study was conducted with support from a grant from the Bill & Melinda Gates Foundation Grand Challenges Exploration Initiative to GMW (OPP1096893) and a Wellcome Trust fellowship to				
Dulal P	vaccine in cattle	2016 Vaccine	GMW (WT098635). B.C. and A.V.S.H. are Jenner Inves-tigators.	N/A	N/A	N/A	20/12/2020
			This work was supported by the UK Medical ResearchCouncil (grant number G0700735); the				
			European Malaria Vaccine Development Association, a European Commis-sion FP6-funded consortium (LSHP-CT-2007-037506); the UK National Institute of Health Research through the Oxford	4			
	Analysis of human B-cell responses		Biomedical Research Centre; the Wellcome Trust(084113/Z/07/Z); and by EVIMalaR funded by the				
	following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria		Euro-pean Community's Seventh Framework Programme (FP7/2007–2013) (Grant agreement No. 242095). AVSH andSJD are Jenner Investigators; and SJD is a UK MRCCareer Development Fellow	SCdC. KAC. AVSH and SID are named inventors on pat-ent applications covering malaria vaccines	NCT01273070 NCT01142765		
Elias SC	infection	2013 Immnunology	(G1000527) and Lister Insti-tute Prize Research Fellow.	and immunization regimens.	NCT0103314, NCT01095055	N/A	20/12/2020
		-		Dr. Ballou, Dr. De Ryck report personal fees and other support from GlaxoSmithKline outside the			
				submitted work. Dr. Colloca, Dr. Cortese, Dr. Nicosia reports a pending patent related to			
				chimpanzee adenoviral-vector based filovirus vaccine (WO/2011/130627). Dr. Draper reports grant support from the UK Medical Research Council during the conduct of the study, and non-financial			
				support from the UK Medical Research Council during the conduct of the study, and non-financial support from GlaxoSmithKline/Okairos outside the submitted work. In addition, Dr. Draper reports			
			Supported by the Wellcome Trust, the United Kingdom Medi-cal Research Council, the United	pending patents related			
			Kingdom Department for Inter-national Development, and the United Kingdom National Insti-tute for Health Research Oxford Biomedical Research Centre. The National Health Service Blood and	to viral vector immunogenic compositions (WO 2012042279 A3) and adenoviral vectors encoding a pathogen or tumor antigen (WO 2008122811 A2). Dr. Gilbert reports patents related to prime			
			Transplant and Public Health England provided funding for the competition ELISA. The ChAd3	boost immunization with viral vectors. Dr. Hill reports a patent related to heterologous prime-			
			vaccine was provided by the Vaccine Research Center of the National Institute of Allergy and	boost immunization, licensed to Oxford BioMedica. Ms. Lella reports other support from the NIHR			
	A Monovalent Chimpanzee Adenovirus		Infectious Diseases (NIAID) and GlaxoSmithKline. MVA-BN Filo was produced under a con-tract (FBS-004-009) between the NIAID and Fisher BioServices and a contract (HHSN272200800044C)	during the conduct of the study. Dr. Levine reports grant support from Oxford University during the conduct of the study. Dr. Pollard reports grant support from the Wellcome Trust during the			
Ewer K	Ebola Vaccine Boosted with MVA	2016 New England Journal of Medicine	between the National Institutes of Health and Fisher Bioservices.	conduct of the study, and grant support from GlaxoSmithKline outside the submitted work.	N/A	N/A	20/12/2020
			The study was funded by grants from the UK MRC, the NIHR through the Oxford Biomedical	Sarah Gilbert, Arturo Reyes-Sandoval, Anna Goodman, Geraldine O'Hara and Adrian Hill are named inventors on patent applications covering malaria vectored vaccines and immunization regimes			
			Research Centre, and the Wellcome Trust AVSH was supported by a Wellcome Trust Principal	including: WO/2008/122811-Adenoviral vectors encoding a pathogen or tumour antigen and			
	Protective CD8 þ T-cell immunity to		Research Fellowship. A.L.G. wassupported by a grant from the MRC (G0600424). A.V.S.H., A.RS.,	WO/2008/122769-Adenoviral vector encoding malaria antigen. Authors from Okairos are			
Ewer K	human malaria induced by chimpanzee adenovirus-MVA immunisation	2013 Nature Communications	S.J.D. and S.C.G.are Jenner Institute Investigators; A.V.S.H. is a Wellcome Trust and NIHR Senior Investigator.	employees of and/or share holders in Okairos which is developing vectored malaria vaccines. All otherauthors declare no competing financial interests.	N/Δ	N/A	16/12/20
Fedosyuk S		2013 Nature Communications	This work was supported by Merck KGaA, the UK MedicalResearch Council (grant MR/P017339/1),	one authors declare no competing manetal interests.	1/2	194	10/11/10
	Simian adenovirus vector production for early-phase clinical trials: A simple		and the UK Engineeringand Physical Sciences Research Council (grant EP/R013756/1).ADD is				
	early-phase clinical trials: A simple method applicable to multiple serotypes		supported by the Wellcome Trust [grants 201477/Z/16/Zand 204826/Z/16/Z] and is a Jenner Investigator. The study was performed in collaboration between the University of Oxford and Merci	k ADD SIM and SCG are named inventors on natent fillings relating to the use of simian			
	and using entirely disposable product-		KGaA; both partners reviewed the manuscript prior to sub-mission. The other funders had no	adenoviruses, but not directly related tothe work described here. SCG is a founder of Vaccitech Ltd,			
	contact components	2019 Elselvier Vaccine	input to the design of the studyor decision to publish.  UK Department of Health and Social Care, using UK Aid funding, managed by the UK National	whichdevelops adenovirus-vectored vaccines.	N/A	N/A	10/12/2020
			Institute for Health Research. This project was funded by the UK Department of Health and Social				
			Care (project number 16/107/01). The views expressed are those of the authors and not				
	Safety and immunogenicity of a		necessarily those of the Department of Health and Social Care. The work was supported by the UK National Institute for Health Research through the Oxford Biomedical Research Centre. The				
	candidate Middle East respiratory		Coalition for Epidemic Preparedness Innovations provided funding for the extended 12 months of				
	syndrome coronavirus viral-vectored		follow-up in this study. This study was also partially supported by the Coordenacao de				
	vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1		Aperfeicoamento de Pessoal de Nivel Superior, Brazil (finance code 001). The pseudovirus neutralising antibody work was funded by a grant from the Korean Ministry of Health and Welfare	AH and SG are co-founders of, consultants for, and shareholders in Vaccitech, which is developing adenoviral vectored vaccines. PMF and TL are consultants for Vaccitech. All other authors declare			
Folegatti P.M.	trial	2020 The Lancet	(HI15C2971)	no competing interests.	NCT03399578	N/A	18/12/20
			UK Research and Innovation, Coalition for Epidemic Preparedness Innovations, National Institute for Health Research (NIHR), NIHR Oxford Biomedical Research Centre, Thames Valley and	SCG is co-founder and board member of Vaccitech (collaborators in the early development of this vaccine candidate) and named as an inventor on apatent covering use of ChAdOx1-vectored			
			South Midland's NIHR Clinical Research Network, and the German Center for Infection Research	vaccines and a patent application covering this SARS-CoV-2 vaccine. TL is named as an inventor on			
			(DZIF), Partner site Gießen-Marburg-Langen. This work is funded by UK Research and Innovation	a patent application covering this SARS-CoV-2 vaccine and consultant to Vaccitech. PMF is a			
			(MC_PC_19055), Engineering and Physical Sciences Research Council (EP/R013756/1), Coalition for Epidemic Preparedness Innovations (CEPI), the National Institute for Health Research (NIHR), the	consultant to Vaccitech. AIP is Chair of the UK Department of Health and Social Care's Joint Committee on Vaccination & Immunisation (JCVI), but does not participate in policy advice on			
			NIHR Oxford Biomedical Research Centre, and the German Center for Infection Research (DZIF),	coronavirus vaccines, and is a member of the WHO Strategic Advisory Group of Experts (SAGE).			
			Partner site Gießen-Marburg-Langen. Additional resources for study delivery were provided by	AVSH is a co-founder of and consultant to Vaccitech and is named as an inventor on a patent		AZ mentioned in acknowledgements -	
	Safety and immunogenicity of the		Partner site Giesen-Marquig-Langen. Additional resources for study delivery were provided by NIHR Southampton Clinical Research Facility and NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust; the NIHR Imperial Clinical Research	AVSH is a co-founder of and consultant to Vaccitech and is named as an inventor on a patent covering design and use of ChAdOx1-vectored vaccines. Af is a member of JCVI, Chair of the WHO European Technical Advisory Group of Experts on Immunisation, an ex-officiomember of WHO		facilitated and funded some assays and	
	ChAdOx1 nCoV-19 vaccine against SARS-		NIHR Southampton Clinical Research Facility and NIHR Southampton Biomedical Research Centre, University Hospital Southampton NIHS Foundation Trust; the NIHR Imperial Clinical Research Facility; and NIHR North West London, South London, Wessex, and West of England Local Clinical	covering design and use of ChAdOx1-vectored vaccines. AF is a member of JCVI, Chair of the WHO European Technical Advisory Group of Experts on Immunisation, an ex-officiomember of WHO SAGE working group on COVID-19 vaccines, and acting director of National Institute for Health	NCT04224606. The study is opening appropriate	facilitated and funded some assays and reviewed the data from the study and	
	ChAdOx1 nCoV-19 vaccine against SARS- CoV-2: a preliminary report of a phase		NIHR Southampton Clinical Research Facility and NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust; the NIHR Imperial Clinical Research Facility; and NIHR North West London, South London, Wessex, and West of England Local Clinical Research Networks and NIHR Oxford Health Biomedical Research Centre. PMF received funding	covering design and use of ChâdOx1-vectored vaccines. AF is a member of JCVI, Chair of the WHO European Technical Advisory Group of Experts on Immunisation, an ex-officiomember of WHO SAGE working group on COVID-19 vaccines, and acting director of National Institute for Health Research West of England Local Clinical Research Network. KMP reports grants from the NIHIR	NCT04324606. The study is ongoing, and was registered at ISRCTN, 15281137, and	facilitated and funded some assays and reviewed the data from the study and	
Folegatti P.M.	ChAdOx1 nCoV-19 vaccine against SARS-	2020 The Lancet	NIHR Southampton Clinical Research Facility and NIHR Southampton Biomedical Research Centre, University Hospital Southampton NIFS Foundation Trust, the NIHR Imperial Clinical Research Facility; and NIHR North West London, South London, Wessex, and West of England Local Clinical Research Networks and NIHR Oxford Health Biomedical Research Centre. PMF received funding from the Coordenace de Aperfectionamento de Pessold de Nivel Superior, Brazil (finance code 001).	covering design and use of ChAdOx1-vectored vaccines. AF is a member of ICVI, Chair of the WHO European Technical Advisory Group of Experts on Immunisation, an ex-officionember of WHO SAGE working group on COVID-19 Secrices, and acting director of National Institute for Health Research West of England Local Clinical Research Network. KMP reports grants from the NIHR Immerial Biomedia Research Centra end Gilled Sciences, and personal res from Sanoff Pasteur.	NCT04324606. The study is ongoing, and was registered at ISRCTN, 15281137, and ClinicalTrials.gov, NCT04324606.	facilitated and funded some assays and reviewed the data from the study and I the final manuscript before submission	
Folegatti P.M. Folegatti PM	ChAdOx1 nCoV-19 vaccine against SARS- CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial	2020 The Lancet	NHH Southampton Clinical Research Facility and NiHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, the NiHR Imperial Clinical Research Facility, and NiHR Nierth West London, South London, Wessex, and West of Fingland Local Clinical Research Networks and NIHR Sourch Institute Biomedical Research Centre, MPI received funding from the Coordenace de Apperiocomments of Personal de West Superior, Enral (Binance code 002). Development of SAMS-COV-2 research was carrially successful by the LS faileding Hintship of Development of SAMS-COV-2 research was carrially successful by the LS faileding Hintship of Control Country of the LS faileding Hintship of the Country of the Country of the Country of the Country of the LS faileding Hintship of the Country of the LS faileding Hintship of the Country of the	covering design and use of ChAGOL1-vectored vaccines. Af is a member of I/SV, Chair of the WHO European Technical Advisory Group of Experts on Immunisations, an ex-officomember of WHO SAGE working group on COWID-19 vaccines, and acting director of National Institute for Health Research West of England Local Clinical Research Network. Chiff Peoplary gands from the NINR Imperial Biomedical Research Centre and Gillead Sciences, and personal fees from Sanofi Pattery, coulded of the submitted work. Mit reconstruction extent from Januaries Chalcomisticillus Mediminume.	was registered at ISRCTN, 15281137, and	facilitated and funded some assays and reviewed the data from the study and I the final manuscript before submission In declaration of interests says royalties	
	ChAdOx1 nCoV-19 vaccine against SARS- CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus		NIHB Southampton Clinical Research Facility and NIHB Southampton Biomedical Research Centre, University Hospital Post Contampton Nitro Grounds Trust, the Nills Reprint Clinical Research Centre Facility; and NIHB North West London, South London, Wessex, and West of England Local Clinical Research Newton's and NIHB Order Health Biomedial Research Centre. PMF research funding from the Condensacion de Aperticeaamento de Presso de Hovel Superior, Brazil Ginance code Ord. Health Condensacion de Aperticeaamento de Presso de Hovel Superior, Brazil Ginance code Ord. He research vas Health Research (NIHB) Order di Bornel Search Centre (BRC). He Research vas Health He research vas Health Research (NIHB) Order di Bornel de Research Centre (BRC). He views expresse er bosor of Research (Ord.) and not necessarily bloss or 16th MISH, MISH or the Department of are those of Research (Ord.) and not necessarily and not the Centre (BRC). The Views of the NIHB Centre of the NIHB Order of Brazil MISH, MISH or the Department of the NIHB ORDER of the NIHB ORDER ORDE	covering design and use of Ch.4GoL1-vectored vaccines. Af is a member of J.KV, Dairs of the Wild Demporal Technical Advisory Group of Experits on Immunisation, an e-erificianement of WHO SAGE working group on COVID-19 waccines, and acting director of National Institute for Health Search West of England Local Clinial Research Neutors. LMP errors grants from the NINR Inspersal Biomedical Research Centre and Gilland Sciences, and personal feet from Sanofi Pasteur, outside of the submitted work. Mit recent reart from Instances. Giodistribilities. Mediment of J.H.Y.T. is the Chief Scientific and Medical Officer for IAV Vaccines Ltd. S.C.G. and AV.S.N. are co-founders of consultants to and Standolens in Vaccines for which is developed in the consultant of the Standolens of the Chief Standolens of the Standolens of the Chief Standole	was registered at ISRCTN, 15281137, and ClinicalTrials.gov, NCT04324606.	facilitated and funded some assays and reviewed the data from the study and the final manuscript before submission Is in declaration of interests says royalties paid to AZ for vectors.	18/12/20
	ChAdOx1 nCoV-19 vaccine against SARS- CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial Safety and Immunogenicity of a Novel	2020 The Lancet	NIHI Southampton Clinical Research Facility and NIHIS Southampton Biomedical Research Central, University Hospital Southampton NIS Groundson Trusts. the NIHIS Imperial Clinical Research Facility, and NiHIS Nerth West London, South London, Wesses, and West of England Local Clinical Facility and NiHIS Nerth West London, South London, Wesses, and West of England Local Clinical Commission of NiHIS International Commission Institute of The research was funded by IAMI Viscolite NiL The research was supported by the Astronomy are those of the submission of the NiHIS on the Department of NiHIS International Commission of The NiHIS on the Department of Health.	covering design and use of Chabita's vectored vaccines. As is a member of LVL, Dairs of the Wild European Technical Advisor Group of Services to immunisation, an e-efficiamember of WHO Slict working group on COVID-19 waccines, and acting director of National Institute for Health Search West of Egiphan Local Clinial Exercise Network. Mar Prostry grants from the Niki Imperial Biomedical Research Centre and Gladed Sciences, and personal free from Sanofi Pasteur, outside of the submitted work. MS recorts areasts from Janssen. Glassifishing Medimune. If JN-T. is the Chief Scientific and Medical Officer for HAV Vaccines Ltd. S.C.G. andAV.SN.	was registered at ISRCTN, 15281137, and	facilitated and funded some assays and reviewed the data from the study and I the final manuscript before submission In declaration of interests says royalties	
	ChAdOx1 nCoV-19 vaccine against SARS- CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus		NIHR Southampton Clinical Research Facility and NIHR Southampton Biomedical Research Centrul, University Hospital Southampton NIS Groundson Trust, the NIRR Imperial Clinical Research Facility, and NIHR North West London, South London, Wessex, and West of England Local Clinical Research Nietwards and Nieth Endon's Health Biomedical Research Centrul, PMF research and Research Nietwards and Nieth Endon's Health Biomedical Research Centrul, PMF research and International Centrul PMF (NIETWARD AND AND AND AND AND AND AND AND AND AN	covering design and use of ChAGAU. vectored vaccines. A Fix a member of JCN, Chair of the Wild Dereporal Technical Advisory Group of Exercise to Immunisation, an e-erificianement of WHU SAGE working group on COVID-19 waccines, and acting director of National Institute for Health SAGE working group on COVID-19 waccines, and acting director of National Institute for Health Imperial Biomedical Research Centre and Gilaed Sciences, and personal feet from Sanofi Pasteur, outside of the submitted work LNF resorts earth from Janausc. Glacisth Milkin. Mediment of LH-IT, is the Chief Scientific and Medical Officer for HAV Vaccines. Ltd. S.C.G. andAV_SH. are co-fundeders of, consultants to and shareholders in Vaccinech pic which is developing adenoviralwectored vaccines.	was registered at ISRCTN, 15281137, and ClinicalTrials.gov, NCT04324606.	facilitated and funded some assays and reviewed the data from the study and the final manuscript before submission Is in declaration of interests says royalties paid to AZ for vectors.	18/12/20
	ChAdOx1 nCoV-19 vaccine against SARS- CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus		NIHI Southampton Clinical Research Scally and NIHIS Southampton Biomedical Research Centrul, University Hospital Southampton N65 organization Trust. the NIHI Imperial Clinical Research (NIHI Control Research Centrul Control Research Centrul Cen	covering design and use of ChAGAU. vectored vaccines. A Fix a member of JCN, Chair of the Wild Dereporal Technical Advisory Group of Exercise to Immunisation, an e-erificianement of WHU SAGE working group on COVID-19 waccines, and acting director of National Institute for Health SAGE working group on COVID-19 waccines, and acting director of National Institute for Health Imperial Biomedical Research Centre and Gilaed Sciences, and personal feet from Sanofi Pasteur, outside of the submitted work LNF resorts earth from Janausc. Glacisth Milkin. Mediment of LH-IT, is the Chief Scientific and Medical Officer for HAV Vaccines. Ltd. S.C.G. andAV_SH. are co-fundeders of, consultants to and shareholders in Vaccinech pic which is developing adenoviralwectored vaccines.	was registered at ISRCTN, 15281137, and ClinicalTrials.gov, NCT04324606.	facilitated and funded some assays and reviewed the data from the study and the final manuscript before submission Is in declaration of interests says royalties paid to AZ for vectors.	18/12/20
	ChAdOx1 nCoV-19 vaccine against SARS- CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus		NIHB Southampton Clinical Research Facility and NIHB Southampton Biomedical Research Centrul, University Hospital Southampton NIS Groundson Trust. the NIHB Impriest Clinical Research Facility, and NIHB North West London, South London, Wessex, and West of England Local Clinical Research Networks and NIHB Charlot Health Biomedical Research Centrul Review of NIHB Charlot Research Networks and NIHB Charlot Health Biomedical Research Centrul Review of NIHB Research Networks and NIHB Charlot Research NIHB NIHB NIHB NIHB NIHB NIHB NIHB NIHB	covering design and use of ChAGAU. vectored vaccines. A Fix a member of JCN, Chair of the Wild Dereporal Technical Advisory Group of Exercise to Immunisation, an e-erificianement of WHU SAGE working group on COVID-19 waccines, and acting director of National Institute for Health SAGE working group on COVID-19 waccines, and acting director of National Institute for Health Imperial Biomedical Research Centre and Gilaed Sciences, and personal feet from Sanofi Pasteur, outside of the submitted work LNF resorts earth from Janausc. Glacisth Milkin. Mediment of LH-IT, is the Chief Scientific and Medical Officer for HAV Vaccines. Ltd. S.C.G. andAV_SH. are co-fundeders of, consultants to and shareholders in Vaccinech pic which is developing adenoviralwectored vaccines.	was registered at ISRCTN, 15281137, and ClinicalTrials.gov, NCT04324606.	facilitated and funded some assays and reviewed the data from the study and the final manuscript before submission Is in declaration of interests says royalties paid to AZ for vectors.	18/12/20
	ChAdOx1 nCoV-19 vaccine against SARS- CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus		NIHI Southampton Clinical Research Scallin and NIHI Southampton Biomedical Research Centrul, University Hospital Governation Notes of the Nitral Scale Scal	covering design and use of ChAGAU. vectored vaccines. A Fix a member of JCN, Chair of the Wild Dereporal Technical Advisory Group of Exercise to Immunisation, an e-erificianement of WHU SAGE working group on COVID-19 waccines, and acting director of National Institute for Health SAGE working group on COVID-19 waccines, and acting director of National Institute for Health Imperial Biomedical Research Centre and Gilaed Sciences, and personal feet from Sanofi Pasteur, outside of the submitted work LNF resorts earth from Janausc. Glacisth Milkin. Mediment of LH-IT, is the Chief Scientific and Medical Officer for HAV Vaccines. Ltd. S.C.G. andAV_SH. are co-fundeders of, consultants to and shareholders in Vaccinech pic which is developing adenoviralwectored vaccines.	was registered at ISRCTN, 15281137, and ClinicalTrials.gov, NCT04324606.	facilitated and funded some assays and reviewed the data from the study and the final manuscript before submission Is in declaration of interests says royalties paid to AZ for vectors.	18/12/20
	Childrix a GoV-34 wacrine against SAS- GoV-2 a prelimitary report of a phase 1/2, single-blind, randomised controlled total Safety and immunogenicity of a Novel Recombrand Sinian Ademovirus Childrix 2 as Vectored Vaccine		NIHB Southampton Clinical Research Facility and NIHB Southampton Biomedical Research Centrul, University Hospital Southampton NIS Groundson Trust the NIHB Imperial Clinical Research Facility, and NiHB Nerth West London, Suchi London, Wessex, and West of Ingland Local Clinical Facility and NiHB Nerth West London, Such London, Wessex, and West of Ingland Local Clinical Development Of SARS Cov)? research was scartially vuscoried by the US National Institute of The research was Indied by IAMP Voscince Table. The research was supported by the National Institute of Health Research (NiNIA) Clorical Biomedical Research Clinical Clinic	covering design and use of ChAGAU. vectored vaccines. A Fix a member of JCN, Chair of the Wild Dereporal Technical Advisory Group of Exercise to Immunisation, an e-erificianement of WHU SAGE working group on COVID-19 waccines, and acting director of National Institute for Health SAGE working group on COVID-19 waccines, and acting director of National Institute for Health Imperial Biomedical Research Centre and Gilaed Sciences, and personal feet from Sanofi Pasteur, outside of the submitted work LNF resorts earth from Janausc. Glacisth Milkin. Mediment of LH-IT, is the Chief Scientific and Medical Officer for HAV Vaccines. Ltd. S.C.G. andAV_SH. are co-fundeders of, consultants to and shareholders in Vaccinech pic which is developing adenoviralwectored vaccines.	was registered at ISRCTN, 15281137, and ClinicalTrials.gov, NCT04324606.	facilitated and funded some assays and reviewed the data from the study and the final manuscript before submission Is in declaration of interests says royalties paid to AZ for vectors.	18/12/20
	ChAdOx1 nCoV-19 vaccine against SARS- CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus		MBH Southampton Clinical Research Facility and NIHR Southampton Biomedical Research Central Winnership Hospital Gouthampton NRS Groundson Trust the NIRR Imperial Clinical Research Facility and NIHR North West London, South London, Wessex, and West of England Local Clinical Research Networks and North March M	covering design and use of ChAGAU. vectored vaccines. A Fix a member of JCN, Chair of the Wild Dereporal Technical Advisory Group of Exercise to Immunisation, an e-erificianement of WHU SAGE working group on COVID-19 waccines, and acting director of National Institute for Health SAGE working group on COVID-19 waccines, and acting director of National Institute for Health Imperial Biomedical Research Centre and Gilaed Sciences, and personal feet from Sanofi Pasteur, outside of the submitted work LNF resorts earth from Janausc. Glacisth Milkin. Mediment of LH-IT, is the Chief Scientific and Medical Officer for HAV Vaccines. Ltd. S.C.G. andAV_SH. are co-fundeders of, consultants to and shareholders in Vaccinech pic which is developing adenoviralwectored vaccines.	was registered at ISRCTN, 15281137, and ClinicalTrials.gov, NCT04324606.	facilitated and funded some assays and reviewed the data from the study and the final manuscript before submission Is in declaration of interests says royalties paid to AZ for vectors.	18/12/20
Fologatti PM	ChAdDx1 a CoV-3 wacrine against SAS- CoV-2 a prelimitary report of a phase 12; single-blind, randomised controlled total  Safety and immunogenicity of a Novel Recombinant Simin Ademoursa ChAdDx2 as a Vectored Vaccine  T cell responses induced by ademovral vectored vaccines can be adjourned by	2019 MDPI	NIHR Southampton Clinical Research Facility and NIHR Southampton Biomedical Research Central University Hospids Guistampton NIST downstand to NIST desirable	covering design and use of ChABOJ. vectored vaccines. At it is a member of EVI, Dairs of the Wild European Technical Advisory George of Equity to innormations, one endificamember of WHO SAGE working group on COVID-19 vaccines, and acting director of National Institute for Health SAGE working group on COVID-19 vaccines, and acting director of National Institute for Health Research West of England Local Clinical Identical Reviews. After Prototy gains from the BRIRR contails of the submitted work NS moots scratter from Institute. On the Institute contails of the submitted work. NS moots scratter from Institute. Glass of the March July 17.1, 1 the Chall Septimize and Medical Officer for HAV Vocation Ms. S.G. and AV.S.M. are co-founders of, consultants to and shareholders in Vaccitoch pic which is developing adenoviral vectored vaccines.	was registered at ISRCTN, 15281137, and ClinicalTrials gov, NCT04324606.  NCT03027193	facilitated and funded some assays and reviewed the data from the study and the final manuscript before submission in declaration of intests says royaltes paid to AE for vectors.  N/A	18/12/20 18/12/20
	ChAldOx1 a CoV-34 vaccine against SABS- CoV-2 a prelimbury report of a phase 1/2, single-blind, randomised controlled total  Safety and immunogenicity of a Novel Recombinant Simina Adenositus ChAldOx2 as a Vectored Vaccine  T cell responses induced by adenoviral vectored vaccines can be adjavanted by		MBH Southampton Clinical Research Facility and NIHR Southampton Biomedical Research Central Winnership Hospital Gouthampton NRS Groundson Trust the NIRR Imperial Clinical Research Facility and NIHR North West London, South London, Wessex, and West of England Local Clinical Research Networks and North March M	covering design and use of ChAGAU. vectored vaccines. A Fix a member of JCN, Chair of the Wild Dereporal Technical Advisory Group of Exercise to Immunisation, an e-erificianement of WHU SAGE working group on COVID-19 waccines, and acting director of National Institute for Health SAGE working group on COVID-19 waccines, and acting director of National Institute for Health Imperial Biomedical Research Centre and Gilaed Sciences, and personal feet from Sanofi Pasteur, outside of the submitted work LNF resorts earth from Janausc. Glacisth Milkin. Mediment of LH-IT, is the Chief Scientific and Medical Officer for HAV Vaccines. Ltd. S.C.G. andAV_SH. are co-fundeders of, consultants to and shareholders in Vaccinech pic which is developing adenoviralwectored vaccines.	was registered at ISRCTN, 15281137, and ClinicalTrials.gov, NCT04324606.	facilitated and funded some assays and reviewed the data from the study and the final manuscript before submission Is in declaration of interests says royalties paid to AZ for vectors.	18/12/20
Fologatti PM	ChAdOx1 at CoV-3 wacrine against SABS- CoV-2 a preliminary report of a phase 1/2, single-blind, randomised controlled trial  Safety and Immunogenitivy of a Novel Recombiants Sitian Adenovirus  ChAdOx2 as a Vectored Vaccine  T cell responses induced by adenoviral vectored vaccines can be adjusted by faction of safetings or the diagnostration faction of safetings or the diagnostration faction for the diagnostration faction for CoV and the diagnostration faction of CoV and the diagnostration faction for CoV and the CoV and the CoV and processes the diagnostration faction for CoV and the CoV	2019 MDPI	NIHR Southampton Clinical Research Facility and NIHR Southampton Biomedical Research Central University Hospids Guistampton NIST downstand to NIST desirable	covering design and use of ChABOJ. vectored vaccines. At it is a member of EVI, Dairs of the Wild European Technical Advisory George of Equity to innormations, one endificamember of WHO SAGE working group on COVID-19 vaccines, and acting director of National Institute for Health SAGE working group on COVID-19 vaccines, and acting director of National Institute for Health Research West of England Local Clinical Identical Reviews. After Prototy gains from the BRIRR contails of the submitted work NS moots scratter from Institute. On the Institute contails of the submitted work. NS moots scratter from Institute. Glass of the March July 17.1, 1 the Chall Septimize and Medical Officer for HAV Vocation Ms. S.G. and AV.S.M. are co-founders of, consultants to and shareholders in Vaccitoch pic which is developing adenoviral vectored vaccines.	was registered at ISRCTN, 15281137, and ClinicalTrials gov, NCT04324606.  NCT03027193	facilitated and funded some assays and reviewed the data from the study and the final manuscript before submission in declaration of intests says royaltes paid to AE for vectors.  N/A	18/12/20 18/12/20
Fologatti PM	ChAGA's n.Cov'3 wacrine against SAS- Cov'2 a preliminary report of a phase 1/2, single-blind, randomised controlled total  Safety and Immunogenicity of a Novel Recombinant Simian Ademotrus  ChAGA's as a Vectored Vaccine  T cell responses induced by ademoviral vectored vaccines can be adjavanted by fusion of antigen to the oligomentation dominal of Clob Berling protein Enhanced Clob T and Immunogenicity Insulators (Clob T and Immunogenicity Insula	2019 MDPI	NIHB Southampton Clinical Research Facility and NIHB Southampton Biomedical Research Centrul, University Hospital Southampton NIS Governation Trusts. Philis Reprinced Clinical Research Centrul Facility, and NIHB North West London, South London, Wessex, and West of Ingland Local Clinical Facility and NIHB North West London, South London, Wessex, and West of Ingland Local Clinical Facility and NIHB North West London, South London, West London, South London, West London, Lond	covering design and use of ChABOJ. vectored vaccines. At it is a member of EVI, Dairs of the Wild European Technical Advisory George of Equity to innormations, one endificamember of WHO SAGE working group on COVID-19 vaccines, and acting director of National Institute for Health SAGE working group on COVID-19 vaccines, and acting director of National Institute for Health Research West of England Local Clinical Identical Reviews. After Prototy gains from the BRIRR contails of the submitted work NS moots scratter from Institute. On the Institute contails of the submitted work. NS moots scratter from Institute. Glass of the March July 17.1, 1 the Chall Septimize and Medical Officer for HAV Vocation Ms. S.G. and AV.S.M. are co-founders of, consultants to and shareholders in Vaccitoch pic which is developing adenoviral vectored vaccines.	was registered at ISRCTN, 15281137, and ClinicalTrials gov, NCT04324606.  NCT03027193	facilitated and funded some assays and reviewed the data from the study and the final manuscript before submission in declaration of intests says royaltes paid to AE for vectors.  N/A	18/12/20 18/12/20
Fologatti PM	ChAdOx1 at CoV-3 wacrine against SABS- CoV-2 a preliminary report of a phase 1/2, single-blind, randomised controlled trial  Safety and Immunogenitivy of a Novel Recombiants Sitian Adenovirus  ChAdOx2 as a Vectored Vaccine  T cell responses induced by adenoviral vectored vaccines can be adjusted by faction of safetings or the diagnostration faction of safetings or the diagnostration faction for the diagnostration faction for CoV and the diagnostration faction of CoV and the diagnostration faction for CoV and the CoV and the CoV and processes the diagnostration faction for CoV and the CoV	2019 MDPI	NIHR Southampton Clinical Research Facility and NIHR Southampton Biomedical Research Central University Hospids Guistampton NIST downstand to NIST desirable	covering design and use of ChABOJ. vectored vaccines. At it is a member of EVI, Dairs of the Wild European Technical Advisory George of Equity to innormations, one endificamember of WHO SAGE working group on COVID-19 vaccines, and acting director of National Institute for Health SAGE working group on COVID-19 vaccines, and acting director of National Institute for Health Research West of England Local Clinical Identical Reviews. After Prototy gains from the BRIRR contails of the submitted work NS moots scratter from Institute. On the Institute contails of the submitted work. NS moots scratter from Institute. Glass of the March July 17.1, 1 the Chall Septimize and Medical Officer for HAV Vocation Ms. S.G. and AV.S.M. are co-founders of, consultants to and shareholders in Vaccitoch pic which is developing adenoviral vectored vaccines.	was registered at ISRCTN, 15281137, and ClinicalTrials gov, NCT04324606.  NCT03027193	facilitated and funded some assays and reviewed the data from the study and the final manuscript before submission in declaration of intests says royaltes paid to AE for vectors.  N/A	18/12/20 18/12/20
Forgest PM  Forbes EK	ChAdDx1 a CoV-3 wacrine against SAS- CoV-2 a prelimitary report of a phase 1/2, single-blind, randomised controlled teal  Safety and immunogenity of a Novel Recombinant Simin Adenovirus  ChAdDx2 as a Vectored Vaccine  T cell responses induced by adenoviral vectored vaccines can be adjourned by well and the safety of the company of the	2019 MDPI 2012 Plos One	NIHR Southampton Clinical Research Facility and NIHR Southampton Biomedical Research Central University Hospital Southampton NSI Goundant Protection Floridation F	covering design and use of ChAdoLi-vectored vaccines. All is a member of EVI, Dairs of the Wild Designed Technical Advisory Group of Equations in immunisation, an ex-efficionmember of WHO SAGE working group on COVID-19 vaccines, and acting director of National Institute for Health SAGE working group on COVID-19 vaccines, and acting director of National Institute for Health SAGE working group on COVID-19 vaccines, and acting director of National Institute for Health SAGE vaccines and SAGE vacci	was registered at ISACTN, 15281137, and ClinicalTrials gov, NCT04324606.  NCT03027193	facilitated and funded some assays and reviewed the data from the study and the final manuscript before submission in declaration of intests says royalters paid to AE for vectors.  N/A  N/A	18/12/20 18/12/20
Forgest PM  Forbes EK  Gibert SC	ChAdDx1 a CoV-3 wacrine against SAS- CoV-2 a prelimitary report of a phase 1/2, single-blind, randomised controlled teal  Safety and immunogenity of a Novel Recombinant Simin Adenovirus  ChAdDx2 as a Vectored Vaccine  T cell responses induced by adenoviral vectored vaccines can be adjourned by well and the safety of the controlled of the combinant of the combin	2019 MDPI 2012 Plos One	NIHR Southampton Clinical Research Scally and NIHR Southampton Blomedical Research Centry, University hospital Southampton NSG objection Trust. the NIHR primaral Clinical Research of NIHR University hospital Southampton NSG objection Trust. The NIHR primaral Clinical Research (NIHR SOUTHAM	covering design and use of ChAdoLi-vectored vaccines. All is a member of EVI, Dairs of the Wild Designed Technical Advisory Group of Equations in immunisation, an ex-efficionmember of WHO SAGE working group on COVID-19 vaccines, and acting director of National Institute for Health SAGE working group on COVID-19 vaccines, and acting director of National Institute for Health SAGE working group on COVID-19 vaccines, and acting director of National Institute for Health SAGE vaccines and SAGE vacci	was registered at ISACTN, 15281137, and ClinicalTrials gov, NCT04324606.  NCT03027193	facilitated and funded some assays and reviewed the data from the study and the final manuscript before submission in declaration of intests says royalters paid to AE for vectors.  N/A  N/A	18/12/20 18/12/20
Forgest PM  Forbes EK  Gibert SC	ChAdDx1 a CoV-3 wacrine against SAS- CoV-2 a prelimitary report of a phase 1/2, single-blind, randomised controlled teal  Safety and immunogenity of a Novel Recombinant Simin Adenovirus  ChAdDx2 as a Vectored Vaccine  T cell responses induced by adenoviral vectored vaccines can be adjourned by well and the safety of the controlled of the combinant of the combin	2019 MDPI 2012 Plos One	NIHB Southampton Clinical Research Facility and NIHB Southampton Biomedical Research Central University Hospital Guical Research Central University Hospital Guical Research Central C	covering design and use of ChAdoLi-vectored vaccines. All is a member of EVI, Dairs of the Wild Designed Technical Advisory Group of Equations in immunisation, an ex-efficionmember of WHO SAGE working group on COVID-19 vaccines, and acting director of National Institute for Health SAGE working group on COVID-19 vaccines, and acting director of National Institute for Health SAGE working group on COVID-19 vaccines, and acting director of National Institute for Health SAGE vaccines and SAGE vacci	was registered at ISACTN, 15281137, and ClinicalTrials gov, NCT04324606.  NCT03027193	facilitated and funded some assays and reviewed the data from the study and the final manuscript before submission in declaration of intests says royalters paid to AE for vectors.  N/A  N/A	18/12/20 18/12/20
Forgest PM  Forbes EK  Gibert SC	ChAdDx1 a CoV-3 wacrine against SAS- CoV-2 a prelimitary report of a phase 1/2, single-blind, randomised controlled teal  Safety and immunogenity of a Novel Recombinant Simin Adenovirus  ChAdDx2 as a Vectored Vaccine  T cell responses induced by adenoviral vectored vaccines can be adjourned by well and the safety of the controlled of the combinant of the combin	2019 MDPI 2012 Plos One	NIHI Southampton Clinical Research Scally and NIHIS Southampton Blomedical Research Centry, University Hospital Southampton N65 Governoton Trust. the NIHI symmetral Clinical Research (NIL) (University Hospital Southampton N65 Governoton Trust, the NIHI symmetral Clinical Research (NIL) (Development of Carbon Control Centry (NIL) (N	covering design and use of Childrol's vectored vaccines. At it is a member of EVI, Olavir of the Wild Designate Technical Advisory George of Equity to informational, on an enfoliationmenter of WHO SAGE working group on COVID-19 vaccines, and eating director of National institute for relating the Childrol of Sage of Childrol of Sage	was registered at ISACTN, 15281137, and ClinicalTrials gov, NCT04324606.  NCT03027193	facilitated and funded some assays and reviewed the data from the study and the final manuscript before submission in declaration of intests says royalters paid to AE for vectors.  N/A  N/A	18/12/20 18/12/20
Forgest PM  Forbes EK  Gibert SC	ChAdDx1 an CoV-34 vaccine against SAS- CoV-2 a prelimitary report of a phase 1/2; single-blind, randomised controlled total  Safety and immunogenicity of a Novel Recombinant Simian Ademotrus  ChAdDx2 as a Vectored Vaccine  T cell responses induced by ademovrial vectored vaccines can be adjuvanted by facision of antigen to the eliginamentation controlled by the composition of the composition of the facision of language to the indigeneration controlled by the composition of the composition of the facision of language cold immunogenicity and protective efficacy in a mouse malarist model using a recombinant ademovarial vaccine in heterologius prime boost immunitation regimes	2019 MDPI 2012 Plos One	NIHR Southampton Clinical Research Facility and NIHR Southampton Blomedical Research Central University Hospital Southampton NSI downstanghous NSI downstang	covering design and use of CMAGD1. vectored vaccines. At it a member of EVI, Olar of the Wild Designat Technical Advisory Group of Equations in Immunisation, and entitlement of MINI SAGE working group on COVID-19 vaccines, and acting director of National Institute for Health SAGE working group on COVID-19 vaccines, and acting director of National Institute for Health SAGE working group on COVID-19 vaccines, and acting director of National Institute for Health SAGE working and CovID-19 vaccines and the Health SAGE vaccine and the	was registered at ISACTN, 15281137, and ClinicalTrials gov, NCT04324606.  NCT03027193	facilitated and funded some assays and reviewed the data from the study and the final manuscript before submission in declaration of intests says royalters paid to AE for vectors.  N/A  N/A	18/12/20 18/12/20
Forgest PM  Forbes EK  Gibert SC	ChAdDx1 a CoV-3 wacrine against SAS- CoV-2 a prelimitary report of a phase 1/2, single-blind, randomised controlled teal  Safety and immunogenity of a Novel Recombinant Simin Adenovirus  ChAdDx2 as a Vectored Vaccine  T cell responses induced by adenoviral vectored vaccines can be adjourned by well and the safety of the controlled of the combinant of the combin	2019 MDPI 2012 Plos One	NIHI Southampton Clinical Research Scally and NIHIS Southampton Blomedical Research Centrul Jovenschy Hospital Gouldampton NES Groundston Trusts. Post Niller Imperat Clinical Research Jovenschy Hospital Gouldampton NeS Groundston Trusts. Post Niller Imperat Clinical Research Research Networks and NIHI Oxford Health Blomedical Research Centru. PMT received funding Research Networks and NIHI Oxford Health Blomedical Research Centru. PMT received funding Research Networks and NIHI Oxford Health Blomedical Research Centru. PMT received funding Development of ASASCAY2 research was centrally susported by the U.S. National Institute of Development of ASASCAY2 research was centrally susported by the U.S. National Institute Instituted Institute Research (NIHIS) Oxford Somedia Research Centrul (ResC). The Verses supersect are those of Research() and oxford research research the NIHI, Oxford ResChild Research Associated Somedia Research (NIHIS) Oxford and the NIHI, Oxford Research Associated Somedia Research (NIHIS) Oxford the NIHI, Oxford Research Development Association, a European Commission PPE funded connorthum. The research Leading Development Association, a European Commission PPE funded connorthum, 1 the research Leading Development Association, a European Commission PPE funded connorthum, 1 the very service of the Centrulation of the PRESEARCH Association of the Centrulation of the Cen	covering design and use of CMADOL vectored vaccines. All is a member of EVI, Olars of the Wild Designed Inchinal Advisory Genergy of Exposition Infimulation, an ex-efficialismenter of WIND SAGE working group on COVID-19 vaccines, and acting director of National Institute for Health SAGE working group on COVID-19 vaccines, and acting director of National Institute for Health SAGE working group on COVID-19 vaccines, and acting director of National National National Institute of National Institute of National Nati	was registered at ISACTN, 15281137, and ClinicalTrials gov, NCT04324606.  NCT03027193	facilitated and funded some assays and reviewed the data from the study and the final manuscript before submission in declaration of intests says royalters paid to AE for vectors.  N/A  N/A	18/12/20 18/12/20
Forgest PM  Forbes EK  Gibert SC	ChAGA's nGO-19 wacrie egiants ASA-CoV-2 a prelimitary report of a phase 1/2. Ingline blind, randomined controlled total state of the prelimitary o	2019 MDPI  2012 Plos One  2002 Elselvier - Vaccine	NIHR Southampton Clinical Research Facility and NIHR Southampton Biomedical Research Central University Hospitals Guistampton Ni Groutsampton	covering design and use of Childrol's vectored vaccines. All is a member of EVI, Olavir of the Wild Designed Inchildral Advisory George of Equity too Intermissions, on entificationments of Wild Sold Working group on COVID-19 vaccines, and eating director of National Institute for Health Sold Working group on COVID-19 vaccines, and eating director of National Institute for Health Sold Working George on Covid-19 vaccines, and eating director of National National Sold Pattern, outside of the submitted work. No records sentant from Instance. Glassoficial Residential Mediatement, outside of the submitted work. No records sentant from Instance. Glassoficial Residential Residential Advisority of the Sold Pattern, outside of the submitted work. No records sentant from Instance. Glassoficial Residential Advisority of the Sold Pattern, outside of the submitted work. No records eating the Sold Pattern, outside of the submitted work. No records eating the Sold Pattern, outside of the submitted work of the Sold Pattern, outside of the submitted of the Sold Pattern, outside of the submitted Sold Pattern Sol	was registered at 158/CTN, 15281137, and ClinicalTrials gov, NCT04224606.  NCT03027193	facilitated and funded some assays and reviewed the data from the study and the final manuscript before submission in declaration differences says regulate paid to AC for vectors.  N/A  N/A	18/12/20 18/12/20 18/12/20 16/12/20
Forgest PM  Forbes EK  Gibert SC	ChAGA's nGO-19 wacrie egiants ASA-CoV-2 a prelimitary report of a phase 1/2. Ingline blind, randomined controlled total state of the prelimitary o	2019 MDPI  2012 Plos One  2002 Elselvier - Vaccine	NIRIS Southampton Clinical Research Facility and NIRIS Southampton Biomedical Research Central University Hospital Southampton NSI Governation Trust. He NiRIS imperial Clinical Research Facility, and NiRIS New Meet Meet and Control, South London, Wesser, and West of England Local Clinical Facility, and NiRIS New Meet Meet and Control Contro	covering design and use of Childrol's vectored vaccines. All is a member of EVI, Olavir of the Wild Designed Inchildral Advisory George of Equity too Intermissions, on entificationments of Wild Sold Working group on COVID-19 vaccines, and eating director of National Institute for Health Sold Working group on COVID-19 vaccines, and eating director of National Institute for Health Sold Working George on Covid-19 vaccines, and eating director of National National Sold Pattern, outside of the submitted work. No records sentant from Instance. Glassoficial Residential Mediatement, outside of the submitted work. No records sentant from Instance. Glassoficial Residential Residential Advisority of the Sold Pattern, outside of the submitted work. No records sentant from Instance. Glassoficial Residential Advisority of the Sold Pattern, outside of the submitted work. No records eating the Sold Pattern, outside of the submitted work. No records eating the Sold Pattern, outside of the submitted work of the Sold Pattern, outside of the submitted of the Sold Pattern, outside of the submitted Sold Pattern Sol	was registered at 158/CTN, 15281137, and ClinicalTrials gov, NCT04224606.  NCT03027193	facilitated and funded some assays and reviewed the data from the study and the final manuscript before submission in declaration differences says regulate paid to AC for vectors.  N/A  N/A	18/12/20 18/12/20 18/12/20 16/12/20
Forgest PM  Forbes EK  Gibert SC	ChAGA's n.Co-V.3 wacrine against SAS-Co-V.2 a prelimitary report of a phase 1/2. Ingline blind, randomined controlled total solution of the controlled total solution of the controlled total solution of the controlled solution of the cont	2019 MDPI  2012 Plos One  2002 Elselvier - Vaccine	MINIS doubstamption Clinical Research Scalling and MINIS Southamption Biomedical Research Centry, University Hospitals doubstamption NSG organization Trust. New MINIS Impressed Clinical Research Centry (Ministry) (Minist	covering design and use of Childrol's vectored vaccines. All is a member of EVI, Olavir of the Wild Designed Inchildral Advisory George of Equity too Intermissions, on entificationments of Wild Sold Working group on COVID-19 vaccines, and eating director of National Institute for Health Sold Working group on COVID-19 vaccines, and eating director of National Institute for Health Sold Working George on Covid-19 vaccines, and eating director of National National Sold Pattern, outside of the submitted work. No records sentant from Instance. Glassoficial Residential Mediatement, outside of the submitted work. No records sentant from Instance. Glassoficial Residential Residential Advisority of the Sold Pattern, outside of the submitted work. No records sentant from Instance. Glassoficial Residential Advisority of the Sold Pattern, outside of the submitted work. No records eating the Sold Pattern, outside of the submitted work. No records eating the Sold Pattern, outside of the submitted work of the Sold Pattern, outside of the submitted of the Sold Pattern, outside of the submitted Sold Pattern Sol	was registered at 158/CTN, 15281137, and ClinicalTrials gov, NCT04224606.  NCT03027193	facilitated and funded some assays and reviewed the data from the study and the final manuscript before submission in declaration differences says regulate paid to AC for vectors.  N/A  N/A	18/12/20 18/12/20 18/12/20 16/12/20
Forgest PM  Forbes EK  Gibert SC	Ch.Addv.1 an Cov-13 wacrone against SAS-Cov-2 a preliminary report of a phase 1/2, single-blind, randomised controlled total  1/2 single-blind, randomised controlled total  Safety and Immunogenity of a Novel Recombinant Simian Adenovirus  Ch.Addv.2 as a Vectored Vaccrine  T cell responses induced by adenoviral vectored vaccrines can be adjuvanted by fusion of antigen to the oligomentation dominary of Cell-berling motion and command of Cell-berling motion and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologicus prime-boost immunisation regimes  Prime and target immunisation protects against Iliver-stage malaria in model uniteration.  A vial vectored prime-boost immunisation immunisation grime targeting the	2019 MDPI  2012 Plos One  2002 Elselvier - Vaccine	NIHI Southampton Clinical Research Scalling and NIHIS Southampton Biomedical Research Centrul Journeysh Hospitals Gouthampton NES Groundston Frust. The NIHI Impressal Clinical Research Journeysh Hospitals Continued to the Continued of the Continued Scale Sca	covering design and use of Childrol's vectored vaccines. All is a member of EVI, Olavir of the Wild Designed Inchildral Advisory George of Equity too Intermissions, on entificationments of Wild Sold Working group on COVID-19 vaccines, and eating director of National Institute for Health Sold Working group on COVID-19 vaccines, and eating director of National Institute for Health Sold Working George on Covid-19 vaccines, and eating director of National National Sold Pattern, outside of the submitted work. No records sentant from Instance. Glassoficial Residential Mediatement, outside of the submitted work. No records sentant from Instance. Glassoficial Residential Residential Advisority of the Sold Pattern, outside of the submitted work. No records sentant from Instance. Glassoficial Residential Advisority of the Sold Pattern, outside of the submitted work. No records eating the Sold Pattern, outside of the submitted work. No records eating the Sold Pattern, outside of the submitted work of the Sold Pattern, outside of the submitted of the Sold Pattern, outside of the submitted Sold Pattern Sol	was registered at 158/CTN, 15281137, and ClinicalTrials gov, NCT04224606.  NCT03027193	facilitated and funded some assays and reviewed the data from the study and the final manuscript before submission in declaration differences says regulate paid to AC for vectors.  N/A  N/A	18/12/20 18/12/20 18/12/20 16/12/20
Forgest PM  Forbes EK  Gibert SC	ChAGA's n.Co-V.3 wacrine against SAS-Co-V.2 a prelimitary report of a phase 1/2. Ingline blind, randomined controlled total solution of the controlled total solution of the controlled total solution of the controlled solution of the cont	2019 MDPI  2012 Plos One  2002 Elselvier - Vaccine	MINIS doubstamption Clinical Research Scalling and MINIS Southamption Biomedical Research Centry, University Hospitals doubstamption NSG organization Trust. New MINIS Impressed Clinical Research Centry (Ministry) (Minist	covering design and use of CMADOL vectored vaccines. At it a member of EVI, Olavir of the Wild Designed Inchinal Advisory Genory of Experison Informations, on meditionism member of WIND SAGE working group on COVID-19 vaccines, and acting director of National Institute for Health SAGE working group on COVID-19 vaccines, and acting director of National Institute for Health SAGE working group on COVID-19 vaccines, and acting director of National National SAGE vaccines, and the CovID-19 vaccines of National Nationa	was registered at 158/CTN, 15281137, and ClinicalTrials gov, NCT04224606.  NCT03027193	facilitated and funded some assays and reviewed the data from the study and the final manuscript before submission in declaration differences says regulate paid to AC for vectors.  N/A  N/A	18/12/20 18/12/20 18/12/20 16/12/20
Foregatt PM  Forbes EK  Gilbert SC  Gulu A	ChAdDx1 a CoV-13 wacrine against SAS-CoV-2 a prelimitary report of a phase 12; single-blind, randomise controlled total 12; single-blind, randomise controlled total Safety and Immunogenicity of a Novel Recombinant Simian Ademovirus ChAdDx2 as a Vectored Vaccine  T cell responses induced by ademoviral vectored vaccines can be adjourned to vectored vaccine can be adjourned to the vectored vaccines can be adjourned to the vector of prime boost immunications regime to perfect the vector of prime boost immunications regime to perfect the vector of prime boost immunications regime to perfect the vector of prime boost immunications regime to perfect the vector of prime boost immunications regime to perfect the vector of prime boost immunications regime to perfect the vector of prime boost immunications regime to perfect the vector of prime boost immunications regime to perfect the vector of prime boost immunications regime to perfect the vector of	2019 MDPI  2012 Plos One  2002 Elsehier - Vaccine  2018 Science Transitional Medicine	MINISTONIA PROGRAMMENT OF THE ACTION OF THE	covering design and use of CMADOL vectored vaccines. At it a member of EVI, Olavir of the Wild Designed Inchinal Advisory Genory of Experison Informations, on meditionism member of WIND SAGE working group on COVID-19 vaccines, and acting director of National Institute for Health SAGE working group on COVID-19 vaccines, and acting director of National Institute for Health SAGE working group on COVID-19 vaccines, and acting director of National National SAGE vaccines, and the CovID-19 vaccines of National Nationa	was registered at 158/CTN, 15281137, and ClinicalTrials gov, NCT04224606.  NCT03027193	facilitated and funded some assays and reviewed the data from the study and the final manuscript before submission in declaration of interest says reyelled to Affor vectors.  N/A  N/A  N/A	18/12/20 18/12/20 16/12/20 14/12/20

			award EP/R013756/1 (VaxHub), UKRI Biotechnology and BiologicalSciences Research Council (BBSRC) Institute Strategic Programme and Core CapabilityGrants to The Pirbright Institute				
			(BBS/E/I/00007031, BBS/E/I/00007034, BBS/E/I/00007037 and BBS/E/I/00007039), and the Bill and				
			Melinda Gates Foundationsupported Pirbright Livestock Antibody Hub'(Grant No. OPP1215550).  Development of SARS-CoV-2 reagents was partially supported by the NIAID Centers of Excellencefor	ır			
	Evaluation of the immunogenicity of		Influenza Research and Surveillance (CEIRS) contract HHSN272201400008C and EPSRC Grant No.				
	prime-boost vaccination with the replication-deficient viral vectored		EP/S025243/1 to the Rosalind Franklin Institute. A.L., G.W., C.B., A.B., and V.M. are supported by the UK Department for Environment Food & Rural Affairs. We thank V. Clark, H. Gray, and R. Snaith				
	COVID-19 vaccine candidate ChAdOx1		for animal husbandry and the Jennerinstitute Vector Core Facility for assistance, and The Pirbright				
Graham SP	nCoV-19	2020 Nature partner journals	Institute Animal ServicesTeam for animal care and provision of samples.	design, data collection, analysis, decision to publish, or preparation of the manuscript.	N/A	N/A	18/12/20
			BRH received funding from the European Union Seventh Framework Programme FP7/2012–2016				
	Development of a Molecular Adjuvant to		under grant agreement n° 316655 (VACTRAIN). Additional funding was provided by a Wellcome Trust Senior Investigator award to AVSH and a Wellcome Trust Strategic Award supporting the viral	A.V.S.H. is a named investigator on US 12/S95 574 and UK PCT/GB2008/01262 novel adenovirus il patent applications covering malaria vectored vaccines and immunisation regimens; A.V.S.H., A.J.S.			
	Enhance Antigen-Specific CD8(+) T Cell		vector core facility. Further funding was provided by a Gates Grand Challenges in Global Health	M.J.C. and B.R.H. are named investigators on UK PCT/GB2014/053596, a novel molecular adjuvant			
Halbroth BR	Responses	2018 Scientific Reports	award through the Foundation for NIH (to AVSH).	application.	N/A	N/A	10/12/2020
			This work was supported by the EMVDA (European Malaria Vaccine Development Association), a European Commission (EC) FP6-funded consortium (LSHP-CT-2007–037506): the UK National				
			Institute of Health Research through the Oxford Biomedical Research Centre (NIHR-BRC) (A91301				
	Combining viral vectored and protein-in-		Adult Vaccine); the Wellcome Trust (084113/Z/07/Z); and EVIMalaR, an EC FP7-funded programme				
	adjuvant vaccines against the blood-		(Grant agreement No. 242095). The GIA work was supported by the PATH Malaria Vaccine Initiative	e .D.D., J.J.I., S.C.dC., A.V.S.H., and S.J.D. are named inventors on patent applica-tions covering			
Hodgson SH	stage malaria antigen AMA1: report on a phase 1a clinical trial	2014 Molecular Therapy	and the Intramural Program of the National Institutes of Health, National Institute of Allergy and Infectious Diseases.	Okairòs, which is developing vectored vaccines for malaria and other diseases.	NCT01351948	N/A	20/12/2020
	Evaluation of the efficacy of ChAd63-	,					
	MVA vectored vaccines expressing		This work was supported by the PATH Malaria Vaccine Initiative, the United Kingdom National	A. V. S. H. and S. C. G. are named inven-tors on patent applications covering malaria vectored			
	circumsporozoite protein and ME-TRAP against controlled human malaria		Institute of Health Re-search, through the Oxford Biomedical Research Centre (grant A91301, Adult Vaccine), and the Wellcome Trust (grants 084113/Z/07/Z and 45488/Z/05 to A. V. S. H. and grant	<ul> <li>vaccines and immu-nization regimens. S. C. and A. N. are employees of and/or shareholders inOkairos, whichis developing vectored vaccines formalariaandother diseases. All other authors</li> </ul>			
Hodgson SH	infection in malaria-naive individuals	2015 The Journal of Infectious Diseases	097940/Z/11/Z to S. H. H.).	report no potential conflicts.	NCT01623557	N/A	20/12/2020
-			Supported by a Medical Research Council (MRC) UK Development Clinical Scheme award	Dr. Colloca, Dr. Folgori, Dr. Cortese, and Dr. Nicosia are named inventors on patent applications			
	Chronic hepatitis C viral infection		(G0701694); by the Wellcome Trust, the Oxford NHIRBRC, and the U19 grant (2U19AI082630-06, to C.K. and P.K.); by an MRC CASE studentship (to L.S.). E.B. is funded as an MRC Senior	covering hepatitisCvirus-vectored vaccines and chimpanzee adenovirus vectors (WO 2006133911  [A3] hepatitis C virus nucleic acid vaccine. WO 2005071093 [A3] chimpanzee adenovirus vaccine			
	subverts vaccine-induced T-cell		C.K. and P.K.); by an MKC CASE studentship (to C.S.). E.B. is funded as an MKC Senior  Clinical Scientist and is supported by the Oxford NHIR BRC, the Oxford Martin School, and the	(A3) nepatitis C virus nucieic acid vaccine, WO 20050/1093 (A3)chimpanzee adenovirus vaccine carrier. WO 03031588 [A2] hepatitis C virus vaccine). Dr. Hill is a coinventor on patent filings and			
Kelly C	immunity in humans	2016 Hepatology	Jenner Institute.	applications related to heterologous prime-boost immunizations.	NCT01094873, 2008-006127-32)	N/A	20/12/2020
		-					
			This work was supported by an award from the European and Developing Countries Clinical	ll .			
			Trials Partnership (EDCTP) and was performed by the Malaria Vectored Vaccines Consortium (MVVC), a four and a half year integrated project funded by the European and Developing				
			Countries Clinical Trials Partnership (EDCTP, grant number IP.2008.31100.001). N.I.V. is an				
			employee of the European Vaccine Initiative (EVI), E.V.I. is the coordinator of the EDCTP				
			funded MVVC project (grant number IP.2008.31100.001). E.V.I. supports salaries of the MVVC project in kind. The work was also supported by the UK National Institute of Health Research				
			through the Oxford Biomedical Research Centre (http://www.oxfordbrc.org/) [A91301 Adult				
	Translating the immunogenicity of prime-		Vaccine], the Wellcome Trust (http://www.wellcome.ac.uk/) (084113/Z/07/Z) and the Medical				
	boost immunization with ChAd63 and		Research Council. S.H.H. holds a Wellcome Trust research training fellowship	A.V.S.H. is a named inventor on patent applications on malaria vectored vaccines and			
Kimani D	MVA ME-TRAP from malaria naive to malaria-endemic populations	2014 Molecular Therapy	(097940/Z/11/Z). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	immunization regimens. Authors from Okairòs are employees of and/or shareholders in Okairòs, which is devel-oping vectored vaccines for malaria and other diseases.	N/Δ	N/A	16/12/20
Killalii D	Immunity against heterosubtypic	2014 Molecular Therapy	decision to publish, or preparation of the manuscript.	which is developing vectored vaccines for maiaria and other diseases.	N/A	NA	10/12/20
	influenza virus induced by adenovirus						
	and MVA expressing nucleoprotein and		AvL was funded by a fellowship of theDr. Saal van Zwanenberg Stichting. Dr. Lambe is supported by	N/Δ	N/A		
Lambe T	matrix protein-1	2013 Scientific Reports	the Oxford Martin School SCG is a Jenner Investigator.  This work has been funded by a grant from the Welkome Trust (095540/Z/11/Z) with additional	N/A	N/A	N/A	16/12/20
	Comparative assessment of vaccine		funding by the Rhodes Trust and a Nuffield Department of Medicine Studentship to support RJL				
	vectors encoding ten malaria antigens		and EVIMalR studentship to support AMS. AVSH is a Jenner Institute Investigator; AJS is a James	AVSH is a named investigator on US 12/595 574 and UK PCT/GB2008/01262 novel adenovirus			
Londev RJ	identifies two protective liver-stage candidates	2015 Scientific Reports	Martin Fellow. CJJ was supported by a grant of the European Community's Seventh Framework	patent applications covering malaria vectored vaccines and immunization regimens; RJL, AMS, CJJ,	***	N/A	20/12/2020
Longley RJ	candidates	2015 Scientific Reports	Programme (FP7/2007-2013) under grant agreement number 242095. Funding for manufacture and quality control release and stability studies of Sanaria's PfSPZ	SMIK, AJS and AVSH are named investigators on filed patent (1318084.9) for novel malaria antigens	N/A	N/A	20/12/2020
			challenge was provided by the National Institute of Allergy and Infectious Diseases				
			(http://www.niaid.nih.gov.) under grant R44Al058375 (Universal Attenuated Malaria Sporozoite				
			Vaccine and Challenge System). The present work was funded by a grant from the Wellcome Trust (grant 095S40/Z/11/Z) to A.V.S.H., with additional funding by the Rhodes Trust and a Nuffield				
			Department of Medicine Studentship to support R.J.L. The human CHMI study (VAC049) was				
			supported by the UK National Institute of Health Research through the Oxford Biomedical Research	h			
			Centre (http://www.oxfordbrc.org/) (A91301 adult vaccine program) and the Wellcome Trust				
	Assessment of the Plasmodium falciparum Preerythrocytic Antigen UIS3		(grant 084113/Z/07/Z). B.R.H. receives funding from the European Union Seventh Framework				
			Programme FP7/2012-2016 under grant agreement 316655 (VACTRAIN) S.H.H. is a Wellcome Trust	A.V.S.H. is a named investigator on novel adenovirus patent applications U.S. 12/595 574 and UK  ### PCT/GR2008/01262 covering malaria vectored vaccines and immunization regimens. # I.I. A.I.S.			
	as a Potential Candidate for a Malaria		Clinical Research Fellow (grant 097940/Z/11/Z). A.V.S.H. is a Jenner Institute Investigator, and A.J.S.	t PCT/GR2008/01262 covering malaria vectored vaccines and immunization regimens. R.I.I. A.I.S.			
Longley RJ	as a Potential Candidate for a Malaria Vaccine	2017 Infection and Immunity	Programme FP7/2012-2016 under grant agreement 316655 (VACTRAIN). S.H.H. is a Wellcome Trust Clinical Research Fellow (grant 097940/Z/11/Z). A.V.S.H. is a Jenner Institute Investigator, and A.J.S. is a James Martin Fellow.	t PCT/GR2008/01262 covering malaria vectored vaccines and immunization regimens. R.I.I. A.I.S.	NCT01465048	N/A	21/12/2020
Longley RJ		2017 Infection and Immunity	Clinical Research Fellow (grant 097940/Z/11/Z). A.V.S.H. is a Jenner Institute Investigator, and A.J.S. is a James Martin Fellow.	t PCT/GB2008/01262, covering malaria vectored vaccines and immunization regimens. R.J.L., A.J.S., and A.V.S.H. are named investigators on patent PCT/GB2014/053077, identifying novel malaria	NCT01465048	N/A	21/12/2020
Longley RJ		2017 Infection and Immunity	Clinical Research Fellow (grant 097940/Z/11/Z). A.V.S.H. is a Jenner Institute Investigator, and A.J.S. is a James Martin Fellow.  This report is independent research funded by the UKDepartment of Health and Social Care	t PCT/GB2008/01262, covering malaria vectored vaccines and immunization regimens. R.J.L., A.J.S., and A.V.S.H. are named investigators on patent PCT/GB2014/053077, identifying novel malaria	NCT01465048	N/A	21/12/2020
Longley RJ		2017 Infection and Immunity	Clinical Research Fellow (grant 097940/Z/11/2), A.V.S.H. is a Jenner Institute Investigator, and A.J.S. is a James Martin Fellow.  This report is independent research funded by the UKDepartment of Health and Social Care through Innovate UK'New vaccines for globalepidemics: development and manufacture" grant global policy (procedure) and procedure and	P.CT/68/05/09/1282, covering malaria vectored vaccions and immunization regimens. R.I.L., A.I.S., and A.V.S.H. are named investigation on patent PCT/68/2014/05/3077, identifying novel malaria vaccine antigens.	NCT01465048	N/A	21/12/2020
Longley RJ	Vaccine	2017 Infection and Immunity	Clinical Beasarch Fellow (grant 097940/L11/2), AV-Sh. is a Jenner Institute Investigator, and A.1.5. is a James Martin Fellow.  This report is independent research funded by the UKDopartiment of Health and Social Care through Involves the Wilew secretion for globuloplednetic, Secretiopenent and manufacturer grant No. 972216 (A.8S.), and also funderform an OOA budget (Global Health (DAA), 16/10/195—Design, OVER 1878). The Company of the	PC/(\$8008/01282, covering malaria vectored vaccines and immunization regimens. R.I.L., A.I.S., and A.V.S.H. are named investigators on patent PCT/(\$82014/053077), identifying novel malaria vaccine antigem.  A.RS. and C.LC. are co-inventors of the Z8a vaccines described in this manuscript. filed by Oxford	NCT01465048	N/A	21/12/2020
Longley RJ	Vaccine  Rational Zlka vaccine design via the	2017 Infection and Immunity	Clinical Research Fellow (grant 079940/2/11/2), A.V.S.H. is a Jenner Institute Investigator, and A.J.S. is a James Martin Fellow (grant 079940/2/11/2), A.V.S.H. is a Jenner Institute Investigator, and A.J.S. is a James Martin Fellow (Fellow). This report is independent research funded by the UKDepartment of Health and Social Care through Innovate UK-Thew secrices for globalepidemics: development and manufacturer grant for 2072216 (A.R.S.), and a both funderform on Albo Margel (Global Health (OA), 1,16/10/756-Design, development and GMP manufacturer of a Zika vaccino) (A.H.P. and A.R.S.). The views expressed in hispublication are those of the author) of an on texessary through of the Department Christish Inspirational Control of the Department Christish (Health Christian Chris	P.CT/GE/DG/GB/DI2R2, covering malaria vectored vaccines and immunization regimens. R.I.L., A.I.S., and A.V.S.H. are named investigation on patient PCT/GE/DI14/GS/DT/, identifying novel malaria vaccine antigem.  A.RS. and C.L. C. are co-inventors of the ZBa vaccines described in this manuscript. Ified by Oxford University innovation Limited in the International/Patient Application No. PCT/GE/DI17/GS/ZDI20 ZBia	NCT01465048	N/A	21/12/2020
	Vaccine		Clinical Research Fellow (grant 07998/Q/11/20, Av.S.H. is a Jenner Institute Investigator, and A.J.S. is a James Martin Fellow.  This report is independent research funded by the UDDepartment of Health and Social Care Writing (Social Research of Programment of Health and Social Care (Social Research of Programment of Health and Social Care (Social Research of Programment of Prog	P. CT/GE/DG/GE/DE2, covering malaria vectored vaccines and immunization regimens. R.I.L., A.I.S., and A.V.S.H. are named investigators on patent P.CT/GE/DE14/GS/DE7, identifying novel malaria vaccine antigens.  A.RS. and C.LC. are co-inventors of the 28th vaccines described in this manuscript. Blief by Oxford University inconvious Limited in the International/Patent Application No. P.CT/GE/DE17/GS/2DE2/DE3/DE3/DE3/DE3/DE3/DE3/DE3/DE3/DE3/DE3			
López-Camacho C	Vaccine  Rational Zika vaccine design via the modulation of antigen membrane	2017 Infection and Immunity  2018 Nature Communications	Clinical Research Fellow (grant 0079400/21/12), A.V.S.H. is a Jenner Institute Investigator, and A.J.S. is a James Martin Fellow (grant 0079400/21/12), A.V.S.H. is a Jenner Institute Investigator, and A.J.S. is a James Martin Fellow (accessed for through innovate IX "The varieties for global pedientic, development and manufacture" grant No. 972226 (A.R.S.), and instrudention are 1000-basego (foliable Health (O.M.), \$1070/1076—Deeps, 972226 (A.R.S.), and instrudention are 1000-basego (foliable Health (O.M.), \$1070/1076—Deeps, 972226 (A.R.S.), and instrudention are 1000-basego (foliable Health (O.M.), \$1070/1076—Deeps, 972226 (A.R.S.), and instrudential foliable states (foliable Health (O.M.), \$1070/1076—Deeps, 972226 (A.R.S.), and instrudential foliable states (foliable Health (O.M.), \$1070/1076, properties of the Peart (O.M.), \$1070/1076, propert	P.CT/GE/DS/GE/DE/DZ-Covering matrial vectored vaccions and immunization regimens. R.I.L., A.I.S., and A.V.S.H. are named investigation on patent PCT/GE/DS/GS/DT/, identifying novel malaria vaccine artigens.  A.RS. and C.LC. are co-inventors of the ZBa vaccines described in this manuscript. filed by Oxford University Innovation Limited in the International/Basent Application file. PCT/GE/DS/DS/ZDZ-DS/DS/DS/ZDZ-DS/DS/DS/ZDZ-DS/DS/DS/ZDZ-DS/DS/DS/ZDZ-DS/DS/DS/ZDZ-DS/DS/DS/ZDZ-DS/DS/DS/ZDZ-DS/DS/DS/ZDZ-DS/DS/DS/ZDZ-DS/DS/DS/ZDZ-DS/DS/DS/ZDZ-DS/DS/DS/ZDZ-DS/DS/DS/DS/DS/DS/DS/DS/DS/DS/DS/DS/DS/D	NCT01465048	N/A	21/12/2020
	Vaccine  Rational Zika vaccine design via the modulation of antigen membrane andictors in otherspances adenoved vectors		Clinical Research Fellow (grant 07998/Q/11/20, Av.S.H. is a Jenner Institute Investigator, and A.J.S. is a James Martin Fellow.  This report is independent research funded by the UDDepartment of Health and Social Care Writing (Social Research of Programment of Health and Social Care (Social Research of Programment of Health and Social Care (Social Research of Programment of Prog	R EC/GE/DG/GI/DI2A; covering matrial vectored vaccions and immunization regimens. R.I.L., A.I.S., and A.V.S.H. are asmed investigation on patent PET/GE/DI3A(SDZP), identifying novel matrial vaccione amignin.  A.RS. and C.LC. are co-inventors of the ZBa vaccines described in this manuscript. Identify by Oxford University innovation. United in the InternationalPatent Application No. PT/GE/DI3A(ZDZ)(ZDZ) DIA Vaccine, A.V.S.H. ox G. Are co-inventors on a patent application. No. PT/GE/DI3A(ZDZ) Oxford Control Child			
López-Camacho C	Vaccine  Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors  Vaccination With Viral Vectors		Clinical Research Fellow (grant 07998/07/11/2), A.V.S.H. is a Jenner Institute Investigator, and A.J. 5. as James Matrin Fellow (grant 07998/07/11/2), A.V.S.H. is a Jenner Institute Investigator, and A.J. 5. as James Matrin Fellow (grant 1994), and the State of St	R PC/GE/DS/GE/DEZ/Covering matrial vectored vaccines and immunization regimens. R.I.L., A.I.S., and A.V.S.H. are made investigation on patient PCF/GE/DS/GS/DT/, identifying novel malaria vaccine antigens.  A.RS. and C.LC. are co-inventors of the Zika vaccines described in this manuscript, filed by Oxford University Innovation Limited in the InternationalPatient Application No. PCF/GE/DS/DS/GS/DS/DS/DS/DS/DS/DS/DS/DS/DS/DS/DS/DS/DS			
López-Camacho C	Vaccine  Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpannee adenoviral vectors  Vaccination Wild Visual Vectors  Expressing Colomics Hemaggleinia, NP and MS Jangiages Potters Ferrets.	2018 Nature Communications	Clinical Research Fellow (grant 07990/2/11/2), A.V.S.H. is a Jenner Institute Investigator, and A.J.S. is a James Martin Fellow.  This report is independent research funded by the UDDepartment of Health and Social Care Windowship (Programment of Health and Social Care 197226 (A.R.S.), and also fundedfrom an ODA hought (blobal Health (ODA), 16/10/95—Design, development and for an about fundedfrom an ODA hought (blobal Health (ODA), 16/10/95—Design, development and OBAP annualisture of 2 Sala years) (A.H.P. and A.S.). The views expressed in this pollutions are those of the substitute of the Obapartment of Install A.P. and A.P. and A.P. The views expressed in this pollution are those of the obapartment of Install A.P. and A.P. and A.P. The views expressed in this pollution are those of the obapartment of Install A.P. and A.S. and A.P. The views expressed in this pollution are those of the obapartment of Install A.P. and A.P. and A.P. The views expressed by an MRC. Newton Fund grant, Gavin Sorreston is a Wellcome Trust Senior Investigator.  The study was fundedly an ARM Elomedical Casalys DRS; DCS award (ARM/DGSZ721), in addition, this study was partally funded by the ARM Control Sections for Infliences Research	R CT/GE/DS/GE/DIZA; covering matrial vectored vaccines and immunization regimens. R.I.L., A.I.S., and A.V.S.H. are maned investigation on patient PCT/GE/DSI4(SSD7), identifying novel malaria vaccine antigem.  A.RS. and C.L. C. are co-inventors of the ZBa vaccines described in this manuscript. Ified by Oxford University innovation Limited in the Internations/Patient Application No. PCT/GE/DSI2/SSZSD 20 bits Vaccine, X.V.S.H. and S.C.G. are co-inventors on a patient application (No/DSI2)/TZZSD7 bits Vaccine, X.V.S.H. and S.C.G. are co-inventors on a patient application (No/DSI2)/TZZSD7 bits Vaccine, X.V.S.H. and S.C.G. are co-inventors on a patient application (No/DSI2)/TZZSD7 bits Vaccine A.V.S.H. and S.C.G. are co-inventors on a patient application regarding patient scale run or competing interests. Mount Scientific State of the Mou	N/A	N/A	21/12/2020
López-Camacho C	Vaccine  Rational Zila vaccine design via the modulation of artigen membrane auchors is chimpanere adenovial vectors  Vaccination With Viral Vectors  Faccination With Viral Vectors  Faccination With Viral Vectors  Faccination With Viral Vectors  Vaccination With Viral Vectors		Clinical Research Fellow (grant 0079-80/2/11/2), A.V.S.H. is a Jenner Institute Investigator, and A.J.S. is a James Martin Fellow (grant 0079-80/2/11/2), A.V.S.H. is a Jenner Institute Investigator, and A.J.S. is a James Martin Fellow success for publicative development of Handha and Social Care. Moraph morassal Fellow was completely development of American and Social Care. Moraph formation of the Social Care. Moraph morals and also funded from an ODA sudget (Global Health (GOA), Editor/056—Design, development and Gelf Martin Martin (GoA), Editor/056—Social Care in this publication are those of the authority) and not necessarily those of the Department of Health and Social Care. We show careful (A.H.P. and A.K.) and MA/NOIS527(A.K.F.), Juntahriphicholopholophops is supported by an MRC. Newton Fund grant, Gave Social Care Martin (GoA), Editor (Grant Grant Gra	R EC/GR200(0)(2)(2)(2), covering malaria vectored vaccions and immunization regimens. R.I.L., A.I.S., and A.V.S.H. are manel wiretigation on patent PCF/GR2014(0S)(07), identifying novel malaria vaccine arringem.  A.R.A. and C.L.C. are co-immenters of the ZBa vaccines described in this manuscript filed by Oxford University Proceedings of the Company			
López-Camacho C	Vaccine  Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpannee adenoviral vectors  Vaccination Wild Visual Vectors  Expressing Colomics Hemaggleinia, NP and MS Jangiages Potters Ferrets.	2018 Nature Communications	Clinical Research Fellow (grant 07998/07/11/20, Av.S.H. is a Jenner Institute Investigator, and A.J.S. is a James Martin Fellow.  This report is independent research funded by the UKDepartment of Health and Social Care brough Involved. We're we across for policylederienic: development and manufacturing grant too. 972256 (A.R.S.), and also fundedfrom an ODA budget (Global Health (Global), 16(20769.—Design, development and/fellom mulacture of 2 size across (Jah.P. S.) and 8-3. The views expression of this policy interest of this publication are those of the authoricity and not necessarily those of the Department of this state of Social Care. We access (Social Care. We also activately explored by the 15 Medical Research Council Mol. (Cl. U.) 2014 Newton Fund grant, Gavin Sorration is a Wellcome Trout Service Investigator.  The state was fundedly as MME Extendical Carelys 1075; 25C sware (Me/ModS7771).  The state was fundedly as MME Extendical Carelys 1075; 25C sware (Me/ModS7771) and Council Carelys 1075; 25C sware (Me/ModS7771) and Carel Carelys 1075; 25C sware (Me/ModS7771) and Carelys 10	R EC/GE/DG/GE/DG/GE/DG/GE/GE/GE/GE/GE/GE/GE/GE/GE/GE/GE/GE/GE	N/A	N/A	21/12/2020
López-Camacho C	Rational Zika vaccine design via the modulation of antigen membrane anothers in chimpane adenoviral vaccins and the second of the second vaccins and the second	2018 Nature Communications	Clinical Research Fellow (grant 07998/07/11/2), A.V.S.H. is a Jenner Institute Investigator, and A.J.S. is a James Matrin Fellow.  This report is independent research funded by the UDDepartment of Health and Social Care with English (Park 18, 18, 18, 18, 18, 18, 18, 18, 18, 18,	R PC/GRADO(00)2324, covering matrial vectored vaccioes and immunization regimens. R.1.L., A.1.S., and A.V.S.1.R. are made investigation on patent PC/GR2D14(0S)077, identifying novel malaria vaccine antigens.  A.RS. and C.LC. are co inventors of the Zika vaccines described in this manuscript filed by Oxford University Innovation Limited in the InternationalPatent Application No. PC/GR2D17(0S)220 Zika Vaccines, X.S.N. and S.C.G. are to inventors on a patent application (NO/2021)727771 on the Oxford Oxford Oxford Control oxf	N/A	N/A	21/12/2020
López-Camacho C	Vaccine  Rational Zika vaccine design via the modulation of antigen membrane androbes in chimpance admonsist and the production of antigen membrane androbes in chimpance admonsist and vaccination With Visal Vectors  Expressing Chimeric Hemagglutnin, NP and MIA Lantigen Protects Ferrets Against Influenza Virus Challenge  Safety and Immunogenicity of Malaria Vectored Vaccines Gene with Routine	2018 Nature Communications	Clinical Research Fellow (grant 07998/07/11/2), A.V.S.H. is a Jenner Institute Investigator, and A.J.S. is a James Martin Fellow.  This report is independent research funded by the UDDepartment of Health and Social Care Writing Involved UPG New accessive of publishedenies: development and manufacturer "grant No. 97226 (A.R.S.), and also fundedfrom an ODA hodget (Islobal Health (IOOA), 16/10/105—Design, developments and offer manufacturer of 28 is sexumed (J.A.H.) and A.S.). The views express and sexual care. We show that the published of the ASI. The views express and Social Care. We sho authorothege funding by the US Medical Research Council M.G. (UJ. 12014 (A.H. 2 and A.K.) and MRX/DISS29/1 (A.S.), buttershipshipshipshipships is supported by an MRC. Newton fund grant, Gaves Soveration a Wellcome Trust Serior Investigator.  The study was fundedby an MRC Biomedical Casalyst DPS, DCS award (IMR/DISS272/1), has decided in the study as grantly funded by the MAIO Centers of Stocellence for Inflamenta Research and Savrellance contract(CERS, HeMX272004000006, grant ALD9946 and grant A142046-01) This work was supported by a Strateger former grant award for the the organess and Development of Tourism of Countries (Clinical Trial's Partnership (ECCPT, grant named 9-2011-11/3124/Scip), with to offending Countries (Clinical Trial's Partnership (ECCPT, grant named 9-2011-11/3124/Scip), with to offending Countries (Clinical Trial's Partnership (ECCPT, grant named 9-2011-11/3124/Scip), with to offending Countries (Clinical Trial's Partnership (ECCPT, grant named 9-2011-11/3124/Scip), with to offending Countries (Clinical Trial's Partnership (ECCPT, grant named 9-2011-11/3124/Scip), with to offending Countries (Clinical Trial's Partnership (ECCPT, grant named 9-2011-11/3124/Scip), with to offending Countries (Clinical Trial's Partnership (ECCPT, grant named 9-2011-11/3124/Scip), with to offending Countries (Clinical Trial's Partnership (ECCPT, grant named 9-2011-11/3124/Scip), with to offending Countries (Clinical Trial's Par	R EC/GRADO(B)1282, covering matrial vectored vaccines and immunization regimens. R.1.L., A.1.S., and A.V.S.1.R. are made investigation on patient PCT/GRAD14(SS)077, identifying novel matrial vaccine antigens.  A.RS. and C.LC. are co-inventors of the Zika vaccines described in this manuscript, filed by Oxford University Innovation Limited in the InternationalPatient Application No. PCT/GRAD17(SS22D) Zika Vaccine, A.V.S.1. and S.C.G. are co-inventors on a patient application (No/DRAD1722777) on the Vaccine, A.V.S.1. and S.C.G. are co-inventors on a patient application (No/DRAD1722777) on the Calculation of the C	N/A	N/A	21/12/2020
López-Camacho C	Rational Zika vaccine design via the modulation of arringen membrane authorists in chimpense advisorial vaccination SVM Vaccination With Vaccination on Immunization Communication Vaccination Vaccination Vaccination Vaccination Vaccination Vaccination on Immunization Vaccination Vaccin	2018 Nature Communications	Clinical Research Fellow (grant 07998/0/21/12), A.V.S.H. is a Jenner Institute Investigator, and A.J.S. is a James Martin Fellow.  This report is independent research funded by the UKDopartiment of Health and Social Cars Windowship (Programment of Land Card Card Card Card Card Card Card Car	R EC/GR/2008/01/2012, covering malaria vectored vaccines and immunization regimes. R.H.L., A.L.S., and A.V.S.H. are mained investigation on patient PCT/GR/2014/GS/077, identifying novel malaria vaccine arringem.  A.RS. and C.LC. are co-inventors of the Zika vaccines described in this manuscript filed by Oxford University Introvation United in the InternationalPatient Application No. PCT/GR/2017/07/2027 Zika Continues of the Zika vaccines described in this manuscript filed by Oxford University Introvation. The remaining authors decire no competing internat.  ChAd/Oxford viral vectorificitiety Oxford University Introvation. The remaining authors decire no competing internat.  The Links About of Medicine at Mount Sinahas filed patient applications regarding refilement avirus vectories with Exiting animenture. Sci. is an inventor on patient covering Chad/Oxford WVA-NP - vaccines with Exiting animenture. Sci. is an inventor on patient covering Chad/Oxford WVA-NP - vaccines with Exiting animenture. Sci. is an inventor on patient special covering Chad/Oxford WVA-NP - vaccines with Exiting animenture. Sci. is an inventor on patient special vaccine in the control oxford special vaccines and vaccines.  The following authors have declared that no conflict of interest exists: VM, Sl, EX, ARN, FO, CB, GB, YB, RM, FO, CB, GB, CB, CB, CB, CB, CB, CB, CB, CB, CB, C	N/A	N/A	21/12/2020
López-Camacho C	Vaccine  Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpane demoval vectors  Association With Varia Vaccurs Expressing Chimmic Hemagdinini, NP and MI Autigners Protects Ferrets  Against influenza Virus Challenge  Safety and Immunoperoity of Maurica Vectorad Vaccines come with Rousine Expanded Program on Immunitation Vaccines in Gambian Infests and	2018 Nature Communications	Clinical Research Fellow (grant 07998/07/11/2), A.V.S.H. is a Jenner Institute Investigator, and A.J.S. is a James Martin Fellow.  This report is independent research funded by the UKDepartment of Heinbh and Social Care Williams (Programment of Heinbh and Social Care Williams). The Company of the Company	R EC/GE/DS/GE/DE/2, covering makair vectored vaccions and immunization regimens. R.I.L., A.I.S., and A.I.S. It is an anti-vector on patent EC/GE/DS/GE/DE/DS/GE/DE/DE/DS/GE/DS	N/A	N/A	21/12/2020
López-Camacho C	Rational Zika vaccine design via the modulation of arringen membrane authorists in chimpense advisorial vaccination SVM Vaccination With Vaccination on Immunization Communication Vaccination Vaccination Vaccination Vaccination Vaccination Vaccination on Immunization Vaccination Vaccin	2018 Nature Communications	Clinical Research Fellow (grant 07998/0/21/12), A.V.S.H. is a Jenner Institute Investigator, and A.J.S. is a James Martin Fellow.  This report is independent research funded by the UKDopartiment of Health and Social Cars Windowship (Programment of Land Card Card Card Card Card Card Card Car	A.P. K. 200 CL. C. zer co-inventors on patent PCT/GB2014(SS)071, desemblying over impacts and immunization regimens. R.J. L. A.J. S., and A. V.S.H. zer mentel investigation on patent PCT/GB2014(SS)071, identifying over impacts vaccine arringens.  A.P. K. 200 CL. C. zer co-inventors of the ZBs vaccines described in this manuscript filed by Oxford University incovation Limited in the International Patent Application No. PCT/GB2014(SS)272.00 lab Vaccine; A.V.S.H. and C.S. C. zer co-inventors on a patent application No. PCT/GB2012(VS)222.00 lab Vaccine; A.V.S.H. and C.S. C. zer co-inventors on a patent application for the CTG-GB2012(VS)222.00 lab Vaccine; A.V.S.H. and C.S. C. zer co-inventors in patent application regarding influence and ChAGOL viral valvectorifiedity Oxford University Innovation. The remaining authors decise no competing interests.  The Lath School of Nacional Months of the State State of the CTG-GB2014 (VS) and VS-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M	N/A	N/A	21/12/2020
Lápez-Camacho C McCklahon M	Rational Zika vaccine design was the modulation of artigen membrane archives in chilippane adenoval vaccines design with the archives in chilippane adenoval vaccina was a second of the artigen and the artigen and the artigen and the artigen archives forest Agginet influenza vivos Challenge Agginet influenza vivos Challenge Agginet influenza vivos Challenge Vectored Vaccines Geore with Rautine Vaccines in Gambian Infinits and Neconster. A Randonized Controlled	3018 Nature Communications 2019 Vaccine	Clinical Research Fellow (grant 07998/07/11/2), A.V.S.H. is a Jenner Institute Investigator, and A.J.S. is a James Martin Fellow.  This report is independent research funded by the UXDepartment of Health and Social Care Whospill Investigators, and the Control of C	R EC/GRADO(00)2024, covering matrial vectored vaccioes and immunization regimens. R.1.L., A.1.S., and A.V.S.1.R. are made investigation on patent PCT/GRAD14(Sh307), identifying novel matrial vaccine artigens.  A.RS. and C.LC. are co inventors of the Zika vaccines described in this manuscript filed by Oxford University innovation Limited in the InternationalPatent Application No. PcT/GRAD31/052220 Zika Vaccines, A.V.S.1. and S.C.G. are co inventors on a patent application (NO/2012)/172777 on the Competing interns.  Vaccines, A.V.S.1. and S.C.G. are co inventors on a patent application (NO/2012)/172777 on the Competing interns.  The Island-School of Medicine at Mount Sinahas fifed patent applications regarding influence vavices with School approximents. To Six a native most open and School of Medicine at Mount Sinahas fifed patent applications regarding influence vavices with School approximents. To Six a native of School of Medicine at Mount Sinahas fifed patent applications regarding influence vavices with School approximents. Six and Mark New H.M.J.Fided and owned by the University of Oxford, and is a confounder disned development of varial vectored vaccines and influence of the Competing of Medicine at Mount Sinahas fifed patent applications regarding Children's avectories.  The Following authorn have declared that no conflict of interest exists: VM, SR, EX, AmN, FO, CB, GR, VB, RB, RB, CB, SC, SC, KC, KC, RC, RC, RC, MC, AmA, Amal Amal and other disease.  The authors declared vaccines confidence on immunization regimens. Act and Nat we employees and/or share-olders in Ref.Text., which develops vectored vaccines for material and other disease.  Part Amal Competing of the Amal Amal Amal Amal Amal Amal Amal Amal	n/a n/a	N/A	21/12/2020
Lápez-Camacho C McCklahon M	Rational Zika vaccine design was the modulation of artigen membrane archives in chilippane adenoval vaccines design with the archives in chilippane adenoval vaccina was a second of the artigen and the artigen and the artigen and the artigen archives forest Agginet influenza vivos Challenge Agginet influenza vivos Challenge Agginet influenza vivos Challenge Vectored Vaccines Geore with Rautine Vaccines in Gambian Infinits and Neconstex: A Randonise Controlled	3018 Nature Communications 2019 Vaccine	Clinical Research Fellow (grant 07998/07/11/2), A.V.S.H. is a Jenner Institute Investigator, and A.J.S. is a James Martin Fellow.  This report is independent research funded by the UXDepartment of Health and Social Care Whospill Investigators, and the Control of C	A.R.A. and C.L.C. are co-inventors of the 28a vaccines described in the memorar selfed by Oxford Vaccines and W.S.H. are mented investigation on patent PCT/GED14(Sh307), identifying novel malaria vaccines and V.S.H. are mented investigation on patent PCT/GED14(Sh307), identifying novel malaria vaccines arringem.  A.R.A. and C.L.C. are co-inventors of the 28a vaccines described in the memoraries filed by Oxford University involvation. In PCT/GED17(Sh307) and Vaccine A.V.S.H. and C.C. are co-inventor and patent application in the PCT/GED17(Sh307) and Vaccine A.V.S.H. and C.G. are co-inventor on a patent application (PCD12(Zh127) on the ChA001 viral vectorified by Oxford University Innovation. The remaining authors declare no competing interests.  The Losh Ashocol of Medicine at Mount Sinahas Field patent applications regarding influents avirus vectors with PC learn gaintenents. Sci is an inventor on patents options regarding influents avirus vectors with PC learn gaintenents. Sci is an inventor on patents options regarding influents avirus vectors with PC learn gaintenents. Sci is an inventor on patents options are part of the Value of Val	n/a n/a	N/A	21/12/2020
Lápez-Camacho C McCklahon M	Rational Zika vaccine design was the modulation of artigen membrane archives in chilippane adenoval vaccines design with the archives in chilippane adenoval vaccina was a second of the artigen and the artigen and the artigen and the artigen archives forest Agginet influenza vivos Challenge Agginet influenza vivos Challenge Agginet influenza vivos Challenge Vectored Vaccines Geore with Rautine Vaccines in Gambian Infinits and Neconstex: A Randonise Controlled	3018 Nature Communications 2019 Vaccine	Clinical Research Fellow (grant 07998/0/11/20, Av.S.H. is a Jenner Institute Investigator, and A.J.S. is a James Martin Fellow.  This report is independent research funded by the UDDepartment of Health and Social Care Windows (Programs of Care Care Care Care Care Care Care Care	A.R. A. and C.L. C. are co-limentary on patent PCT/GED014(Sh07). Solid price and immunization regimes. R.I.L., A.I.S., and A.V.S.H. are and investigation on patent PCT/GED014(Sh07), identifying novel malaria vaccine antigem.  A.R. A. and C.L. C. are co-limentary of the ZBa vaccines described in this manuscript. Bled by Oxford University Innovation Limited in the International Patent Application No. PCT/GED017(7)(27) on the Chaldback via Vectorial Application No. PCT/GED017(7)(27) on the Chaldback via Vectorial Residual Post of the Vectorial Post of the Vectoria	n/a n/a	N/A	21/12/2020
Lápez-Camacho C McCklahon M	Rational Zika vaccine design via the modulation of antigen membrane modulation of antigen membrane vectors .  Vaccination of the control of the control of the vectors of the control of the vaccine of t	3018 Nature Communications 2019 Vaccine	Clinical Research Fellow (grant 07980/21/12), A.V.S.H. is a Jenner Institute Investigator, and A.J.S. is a James Martin Gellow.  This report is independent research funded by the UKDepartment of Health and Social Care Martine (James 1997). The Company of the Co	A.P. A. and C. L. C. are co. important of the ZBa varcines described in this manuscript. Bind by Oxford University Incomplete of the Complete	n/a n/a	N/A	21/12/2020
Lápez-Camacho C McCklahon M	Vaccine  Rational Zika vaccine design via the modulation of antigen membrane androbes in chimps are demoval vaccines design with the modulation of antigen membrane androbes in chimps are demoval vaccins.  Expressing Chimeric Hemagglutinin, NP and M1 Antigens Pottotta Ferrets Against influenza Virus Challenge  Safley and Immunogenicity of Malaria Vectored Vaccines Given with Routine Expanded Program on Immunization Vaccines in Gambian Infrasts and Neonates: A Bandomized Controlled Trail  Safety, Immunogenicity and Efficacy of Prime Boost Vaccination with Child 43	3018 Nature Communications 2019 Vaccine	Clinical Research Fellow (grant 07998/07/11/2), A.V.S.H. is a Jenner Institute Investigator, and A.J.S. is a James Martin Fellow.  This report is independent research funded by the UDDepartment of Health and Social Care Whospilland (Fellow) (Fell	A.R. A. and C.L. C. are co-limentary on patent PET/GED14(S) 2014 (S) 2014 (	n/a n/a	N/A	21/12/2020
Lápez-Camacho C McCklahon M	Rational Zika vaccine design was the modulation of arrigen membrane anchors in chingman endorsare endorsar	3018 Nature Communications 2019 Vaccine	Clinical Research Fellow (grant 07998/07/12/), AV.54. is a Jenner Institute Investigator, and AJ.5. is a James Martin Fellow.  This report is independent research funded by the UXDepartment of Health and Social Care Withouth Involved Care Withouth Invo	A. R. and C. L. C. are co-immenters of the 28a sections described in this memory in and A. V.S. H. are mentel investigation on patent PCT/GED14(Sh07), identifying novel malaria vaccine antigem.  A. R. and C. L. C. are co-immenters of the 28a sections described in this memory is filed by Oxford University Investigation of the 18a sections of the	N/A N/A NCT02083887	N/A	21/12/2020
Lápez-Camacho C McCklahon M	Vaccine  Rational Zika vaccine design via the modulation of antigen membrane androbes in chimps are demoval vaccines design with the modulation of antigen membrane androbes in chimps are demoval vaccins.  Expressing Chimeric Hemagglutinin, NP and M1 Antigens Pottotta Ferrets Against influenza Virus Challenge  Safley and Immunogenicity of Malaria Vectored Vaccines Given with Routine Expanded Program on Immunization Vaccines in Gambian Infrasts and Neonates: A Bandomized Controlled Trail  Safety, Immunogenicity and Efficacy of Prime Boost Vaccination with Child 43	2018 Nature Communications 2019 Vaccine 2019 Frontiers in Immunology	Clinical Research Fellow (grant 07998/07/11/2), A.V.S.H. is a Jenner Institute Investigator, and A.J.S. is a James Martin Fellow.  This report is independent research funded by the UDDepartment of Health and Social Care Whospilland (Fellow) (Fell	A.R. A. and C.L. C. are co-limentary on patent PET/GED14(S) 2014 (S) 2014 (	N/A N/A NCT02083887	N/A	21/12/2020
Laper-Camacho C McAdahon M Merisah VA	Rational Zika vaccine design via the modulation of arrigen membrane modulation of arrigen membrane vectors .  Vaccination With Viral Vectors .  Vaccination A Comment of Com	3018 Nature Communications 2019 Vaccine	Clinical Research Fellow (grant 07998/07/11/2), A.V.S.H. is a Jenner Institute Investigator, and A.J.S. is a James Martin Gellow.  This report is independent research funded by the UKDepartment of Health and Social Care Working (Programment of Health and Social Care Working). In order through Innovate UKP even secricis for pladelyderience: development and manufacturing grant No. 972256 (A.R.S.), and also fundedfrom an OBA budget (Global Health (Global, 1661/07)67—Design, development and GMP manufacture of 2 size avancing I.A.H.P. and A.B.). The views express of this pladelistic are those of the substitution and the substitution of the sub	A.R. A. and C.L. C. are co-limentary on patent PC/FGE/D14(S) 2014 (S) 2014	N/A NCT02083887 PACTR2013-03-000-499-409. (African	N/A N/A	21/12/2020 10/12/2020 21/12/2020
Laper-Camacho C McAdahon M Merisah VA	Rational Zika vaccine design via the modulation of arrigen membrane anothers in chipmane defension of arrigen membrane anothers in chipmane defensive like anothers in chipmane demoval vaccins and M1 Antigens Protects Ferrets Against influenza Virsa Challenge  Safley and immunogenicity of Malaria Vectored Vaccines Given with Routine Expanded Program on Immunization Vaccines (in Geniland Intelligent Controlled Trial  Safley, Immunogenicity and Efficacy of Prime Robots Vaccination with Chiddia and MVIA foroding ME TRAP against Plasmodium Indigunum Infection in Adults in Sengal Protective A Renderment Controlled Trial	2018 Nature Communications 2019 Vaccine 2019 Frontiers in Immunology	Clinical Research Fellow (grant 07998/07/11/2), A.V.S.H. is a Jenner Institute Investigator, and A.J.S. is a James Martin Fellow.  This report is independent research funded by the UDDepartment of Health and Social Care Whospilland (Price Workshop) (Price Works	A.R. A. and C.L. C. are co-limentary on patent PC/FGE/D14(S) 2014 (S) 2014	N/A NCT02083887 PACTR2013-03-000-499-409. (African	N/A N/A	21/12/2020 10/12/2020 21/12/2020
Laper-Camacho C McAdahon M Merisah VA	Rational Zika vaccine design was the modulation of arringen membrane analysis in chingman earliers in chingrane advisorial vaccination With Viral Vectors Expressing Chimeric Hemagalisticini, NP Ascination With Viral Vectors Expressing Chimeric Hemagalisticini, NP Aspiration With Viral Vectors Salayand Hemagalisticini Chimeric Hemagalisticini, NP Aspiration Chimeric Hemagalisticini, NP Aspiration Hemagalisticini Chimeric Managanisticini M	2018 Nature Communications 2019 Vaccine 2019 Frontiers in Immunology	Clinical Research Fellow (grant 07998/07/11/2), AV.54. is a Jenner Institute Investigator, and AJ.5. is a James Matrin Fellow.  This report is independent research funded by the UXDepartment of Health and Social Care World (Price World 1997). The Companion of t	A. F. and C. L. C. are co-immenters of the Zia accoins described in this memory and A. V.S. H. are mentel investigation on patent PCT/GED14(Sh07), identifying novel malaria vaccine antigem.  A. F. and C. L. C. are co-immenters of the Zia accoins described in this memory is fired by Oxford University Investigation (Investigation of the Company Accounts of the Zia accoins described in the TCT/GED14(Sh07)(Sh07) Accounts of the Zia accoins described in the TCT/GED14(Sh07)(Sh07) Accounts of the Zia accoins described in the TCT/GED14(Sh07)(Sh07) Accounts of Zia accounts of the Zia accoins described in the TCT/GED14(Sh07)(S	N/A NCT02083887 PACTR2013-03-000-499-409. (African	N/A N/A	21/12/2020 10/12/2020 21/12/2020
Laper-Camacho C McAdahon M Merisah VA	Rational Zika vaccine design via the modulation of arriging membrane androves in chimpine adversaria manches in chimpine adenoval vaccins and MI Antigens Protects Ferrets Against influenza Virsu Challenge Safety and immunogenicity of Malaria Vectored Vaccines Given with Routine Expanded Program on Immunization Vaccines in Gentland Intelligence Controlled Trial  Safety, immunogenicity and Efficacy of Prime Robots Vaccination with Chiddia and MVIA facoding ME TRAP against Plasmodium Indigunum Infection in Adults in Sengial 1	2018 Nature Communications 2019 Vaccine 2019 Frontiers in Immunology	Clinical Research Fellow (grant 07998/07/11/2), A.V.S.H. is a Jenner Institute Investigator, and A.J.S. is a James Martin Fellow.  This report is independent research funded by the UDDepartment of Health and Social Care Whospilland (Price Workshop) (Price Works	A.R. A. and C.L. C. are co-limentary on patent PC/FGE/D14(S) 2014 (S) 2014	N/A  NCT02083887  PACTR201-303-000-499-409. (African Pan Trial Registry)	N/A N/A	21/12/2020 10/12/2020 21/12/2020
Lóper-Camacho C McMahon M Mensah VA Mensah VA	Rational Zila vaccine design via the modulation of angigen membrane modulation of angigen membrane vectors subsequently and a subsequently vector and via 1 v	2018 Nature Communications 2019 Vectore 2017 Frontiers in Immunology 2016 Plos One	Clinical Research Fellow (grant 07998/07/11/2), A.V.S.H. is a Jenner Institute Investigator, and A.J.S. is a James Martin Fellow.  This report is independent research funded by the UDDepartment of Health and Social Care Horselph Involved UPO (February 1997). The Company of th	A.R. A. and C.L. C. are co-immentary on patent PC/FG/2014(S)/2071, clearlying novel malarial vectored vaccines and immunization regimens. R.J.L., A.J. S., and A. V.S.H. are and investigation on patent PC/FG/2014(S)/2071, clearlying novel malarial vaccine antigen.  A.R. A. and C.L. C. are co-immentary of the 28a vaccines described in this manuscript. Bled by Oxford University Innovation Limited in the International Patent Application No. PC/FG/2012/1972/2071 on the Chald Chair Vector A.J. A. S. and C. C. are co-immentary in provided in No. PC/FG/2012/1972/2071 on the Chald Chair Vector Vector A.J. A. S. and C. C. are co-immentary in Innovation. The remaining authors decide no competing inference virus and the Chald Chair Vector Vector A.J. A. S. and C. C. are co-immentally information. The remaining authors decide no competing inference virus vaccines with R. England and Vector V	N/A  NCT02083887  PACTR201-303-000-499-409. (African Pan Trial Registry)	N/A N/A N/A	21/12/2020 10/12/2020 21/12/2020
Lóper-Camacho C McMahon M Mensah VA Mensah VA	Rational Zila vaccine design via the modulation of angigen membrane modulation of angigen membrane vectors subsequently and a subsequently vector and via 1 v	2018 Nature Communications 2019 Vectore 2017 Frontiers in Immunology 2016 Plos One	Clinical Research Fellow (grant 07998/07/11/2), A.V.S.H. is a Jenner Institute Investigator, and A.J.S. is a James Martin Fellow.  This report is independent research funded by the UDDepartment of Health and Social Care Horselph Involved UPO (February 1997). The Company of th	A.R. A. and C.L. C. are co-immentary on patent PC/FG/2014(S)/2071, clearlying novel malarial vectored vaccines and immunization regimens. R.J.L., A.J. S., and A. V.S.H. are and investigation on patent PC/FG/2014(S)/2071, clearlying novel malarial vaccine antigen.  A.R. A. and C.L. C. are co-immentary of the 28a vaccines described in this manuscript. Bled by Oxford University Innovation Limited in the International Patent Application No. PC/FG/2012/1972/2071 on the Chald Chair Vector A.J. A. S. and C. C. are co-immentary in provided in No. PC/FG/2012/1972/2071 on the Chald Chair Vector Vector A.J. A. S. and C. C. are co-immentary in Innovation. The remaining authors decide no competing inference virus and the Chald Chair Vector Vector A.J. A. S. and C. C. are co-immentally information. The remaining authors decide no competing inference virus vaccines with R. England and Vector V	N/A  NCT02083887  PACTR201-303-000-499-409. (African Pan Trial Registry)	N/A N/A N/A	21/12/2020 10/12/2020 21/12/2020

This study was supported by UKRI Engineering and Physical Sciences ResearchCouncil (EPSRC) award EP/R013756/1 (VaxHub), UKRI Biotechnology and BiologicalSciences Research Council

Nébié I	serotype 63 neutralizing antibodies prior to evaluation of a candidate malaria vaccine regimen based on viral vectors	2014 Clinical and Vaccine Immunology	This work was supported by an award from the European and Developing Countries Clinical Trials Partnership (EDCTP) and wasperformed by the Malaria Vectored Vaccines Consortium (MVVC), an integrated project funded by EDCTP (grant number) P.2008.3110.0001).	N/A	N/A	N/A	16/12/20
			Financial support. This work was supported by an Experimental Medicine grant from the UK Medical Research Council (grant number G0502018) with additional support from the UK National	Potential conflicts of interest S. G., A. RS., A. G., G. O. H., and A. H. are named inventors on patent applications covering malaria-vectored vaccines and immunization regimes. Authors from Okairos are employeesof and/or shareholders in Okairos, which is developing vectored malaria			
	Clinical assessment of a recombinant simian adenovirus ChAd63: a potent		Institute for Health Research Oxford Biomedical Research Centre and the Wellcome Trust. No funding bodies had any role in study design, data collection and analysis, decision to publish, or	other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of PotentialConflicts of Interest. Conflicts that the editors consider relevant to			
O'Hara GA	new vaccine vector	2012 The Journal of Infectious Diseases	preparation of the manuscript.	thecontent of the manuscript have been disclosed.	NCT00890019	N/A	16/12/20
	Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium		number IP.2008.31100.001, to the Malaria Vectored Vaccines Consortium(MVVC), and coordinated	which supports the development and testing of malaria vaccines. N.K.V. is an em-ployee of EVI, and O.L. is executive director of EVI. A.N. is an employee of Okairos and consultsfor GlaxoSmithKline.			
Ogwang C	falciparum infection in Kenyan adults	2015 Science Transitional Medicine	Concordat agreement.  This work was performed by the Malaria Vectored Vaccines Consortium (MVVC), a four year	The other authors declare no competing interests.	NCT01666925, PACTR 201202000356208	N/A	20/12/2020
	Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, Chaddi ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenvan adults	2013 Plos One	integrated project funded by the European and DevelopingCountries Clinical Trials Partnership			N/Δ	16/12/20
Ogwang C Payne RO	and kenyan adults	2013 Flus Unie	This work was supported by a UK Medical Research Council (MRC) grant (number G100088). The study was also supported in part by UK Indical Institute of Heah Research (Rills) finistraturcture through the NIHR Conford Biomedical Research Centre and the Wellcome Trust (094113/2079/L). Of was supported by the Rebed's Trust. This holds a Wellcome Trust Research Training Fellowship (108734/21/5/17, SCC was a PhD student supported by the European Malaria Vaccine Development Association, a European Commission Framework Programme 6—funded consortium	S.C. de Cassan, M.K. Higgins, A.V.S. Hill, and S.J. Draper are named inventors on patent applications (patent nos. GB41530.5, GB016471.3, and W0/2008/122811) covering malaris vaccines and immunization regimen. A. Nicosis was no employee of and harholde in Olasifo (ince acquired		пул	10/12/20
	Human vaccination against Plasmodium		(grant LSHP-CT-2007-037506). TDO is sup-ported by the Wellcome Trust (WT 098051). JSM is supported by an NHMRC Practitioner Fellowship (number 1041802). AVSH and SJD are Jenner	by GlaxoSmithKline), which is developing vectored vaccines for a number of diseases. T. Jørgensen and W.A. de Jongh are employees of, and W.A. de Jongh is a shareholder in, ExpreS2ion			
	vivax Duffy-binding protein induces		Investigators. SID is a Lister Institute Research Prize Fellow and a Wellcome Trust Senior Fellow	Biotechnologies, which has developed and is marketing the ExpreS2 cell expression platform. C.E.			
	strain-transcending antibodies	2017 JCI Insight	(grant number 106917/Z/15/Z).		NCT01816113	N/A	21/12/2020
	Human vaccination against BHS induces neutralizing antimalarial antibodies that		(1977)207-2013) under the grant agreement for MultiMarks (number 302382). The study was also supported in part by URI Mille Infrastructure through the Nillet Ordio Bennetical Research Centre, the MANAE-CA program funded by Danida (the Coroutlative Committee for Development Research, Dennary, and the Welloom Error (grant numbers 09411/2707/) and 2055943. The GAR work was supported by the United States Agency for International Development (CMAID) and the URI CASE AND COROUT COR	G.L. Wright, and A.V.S. Hill are named inventors on patter applications relating to 8HS and/or other malaria vaccines and immunization regimens. L. Sain and S.O. Ib Marco are employees of Refilters (formerly Oskiros), which is currently developing vectored vaccines for a number of diseases. I. A. Ashfield is a Seriestor of Docentia and holds shares in the company, which is developing a therapy for automismous desease. A.M. Amissain has a nimmediate family member who is an inventor of pattern of the series of the continuation regimens and who is a pattern relating to 8HS and/or other malaria vaccines and immunization regimens and who is coloured or dishareholder in and consultant for Sydfolich. S. Basin so of conductors of the series is a coloured or so of the series of the se			
Payne RO	inhibit RH5 invasion complex interactions	2017 JCI Insight	Investigators; and SID is a Lister Institute Research Prize Fellow and a Wellcome Trust Senior Fellow (106917/Z/15/Z)	and shareholder in, SpyBiotech and is a contributor in a patent application relating to multimerisation technology. J. Jin is a cofounder of and shareholder in SpyBiotech.	NCT02181088	N/A	21/12/2020
Pearson FE	Dry-coated live viral vector vaccines delivered by nanopatch microprojections retain long-term thermostability and induce transgene- specific T cell responses in mice	2013 Plos One	This work has been supported by a UK Medical Research Council Capachy Building Studentship (G0600311, www.mrc.ac.uk) and by the Bill and Melindia Gates Foundation (003436, www.gatefoundation.org). The funders had no role in study design, data collection and analysis, decision to publish, properparation of the manuscript.	Competing Interests: Authors MLC, GIFF, XC and MAPK are either liventors or contributors to a patent filings related to the NanopatchTM technology, that isnow licensed to Vaxxax Pty Ltd. These are detailed in Supporting Information - Table S2. Authors MLC, SRY, GIFF and MAPK have employment with Vaxxax. MAPKis a member of the Vaxxax board. There are no further patents, products in development or marketed products to declare. This does not alter the	N/A	N/A	16/12/20
	Induction of CD8(+) T cell responses and						
Pearson FE	protective efficacy following microneedle-mediated delivery of a live adenovirus-vectored malaria vaccine A multi-antigenic adenoviral-vectored	2015 Vaccine	This study was funded by Enterprise Ireland (CFT007/117,http://www.enterprise-ireland.com), Science Foundation Ireland (NAP156andNAP170,www.sfi.le) and the Medical Research Council,United Kingdom (G0600311,www.mrc.ac.uk).	None	N/A	N/A	20/12/2020
	vaccine improves BCG-induced protection of goats against pulmonary		The study was funded by the European Community's 7th Framework Programme (FP7-KBBE- 2007-1-3-04: TB-STEP project under grant agreement212414). The funders had no role in				
	tuberculosis infection and prevents		study design, data collection and analysis, decision to publish, or preparation of the	N/A			
Pérez de Val B	disease progression Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing	2013 Plos One	manuscript.  This work was supported by the PATH Malaria Vaccine Initiative and by the United Kingdom NIHR, through the NIHROxford Biomedical Research Centre, the Southameton NIHR Wellcome Trust	N/A  V. S. H. and S. C. G. are named inven-tors on patent applications covering malairia vectored vaccines and immu-nitation regimens. D. M., M. L., and R. W. B. are employees of GSW, which is developing vectored vaccines for malairia and other diseases. S. K. F. acts otherabil of the University of Southampton/University Hospital Southampton/Univer	N/A	N/A	16/12/20
Rampling T	ME-TRAP	2016 The Journal of Infectious Diseases	Clinical Research Facility, and the Imperial College NIHR WellcomeTrust Clinical Research Facility.		NCT01883609	N/A	20/12/2020
Rampling T	Safety and efficacy of novel malaria vaccine regimens of RTS.S/ASOIB alone, or with concomitant ChAGG-AVVIA- vectored vaccines expressing ME-TRAP	2018 Nature partner journals	This work was funded primarily by the PATH Malara VaccineIndiative [M/II]: in addition, the work was supported by the United Ringione Nationalisativate of Health Research [NiRIII] infrastructures was supported by the United Ringione Nationalisativate of Health Research [NiRIII] infrastructures (Cincil Research Said), and the Imperial Cincil Research Said Continued Research Said, and the Imperial Cincil Research Said Continued Research	vectored vaccines and immunization regimens. D.M.,M.L., and R.W.B are employees of GSK, which is developing vaccines for malaria andother diseases. S.N.F. acts on behalf of the University of Southampton/UniversityHospital Southampton NHS Foundation trust as chief and principal investigator forcinical trials Sponsored by vaccine manufacturers including GSK, but receives	NCT02252640	N/A	18/12/20
	Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective		Work in the Oxford malaria vaccine program is supported by the Wellcome Trust, the UK Medical Research Council, the UK National Institute for Health Research through the Oxford Biomedical Research Centry, the European Commission, the Gates Foundation through a Grand Challenges in Global Health award from the Foundation for NIH, the European Malaria Vaccine Initiative, the				
Reyes-Sandoval A	malaria CD8+ T-cell responses  Mixed vector immunization with	2010 Human Vaccines	Jenner Vacciner Foundation and the European and Developing Countries Clinical Trails Partnerships. We thank the Jenner Institutés vector corte facility for providing the value-retored vaccines and Dr Helen McShame for providing the ad-enourist and MMN vectors expressing antiques 85A. We are also granted to Another Williams for providing the 1-begind parasities and the Mix of a real size of the Another Williams for providing the 1-begind parasities and the Mix of the providing the 1-begind parasities and the Mix of the 1-begind parasities were should provided by 0.0 Given this complete the 1-begind parasities were should provided by 0.0 Given this complete the 1-begind parasities and the 1-begind provided parasities of the 1-begind parasities of t	N/A	N/A	N/A	10/12/2020
	recombinant adenovirus and MVA can improve vaccine efficacy while		A.RS. is a Scientific Leadership Fellow of the Nuffield Department of Medicine and a Wellcome Trust Fellow. C.S.R. is supported by Oxford Biomedical Research Center, The Oxford				
Reyes-Sandoval A	decreasing antivector immunity Single-dose immunogenicity and protective efficacy of simian adenoviral	2010 Therapy	Martin School and Meningitis UK.  The work was supported by a Welkome Trust Principal Research Fellowship award grant number		N/A	N/A	16/12/20
Reyes-Sandoval A	vectors against Plasmodium berghei	2008 European Jounnal of Immunology	076438 to A.V.S.H.	N/A	N/A	N/A	16/12/20

Rollier CS			This work was funded by a grant from the Foundation for the National Institutes of Health through the Grand Challenges in Global Health Initiative of the Glast Foundation, with additional support from the Welchom Frust Nan-human primate sudies were supported by National Center for Research Resources (RCRI) grant #5.5 MODIOSID, and were conducted at a facility constructed for Research Resources (RCRI) grant #5.5 MODIOSID, and were conducted at a facility constructed contribution of the Natibution of Center (RCRI) grant #5.5 MODIOSID, and the supert telp provided by the Animal Services Unit, and the Immunology Services Unit of the Wisconsin National Finniae Research Center, in particular D. Wilston and E. Raksuz CR. Susported by the Nith Biomodical Research Center, protrious of P. Wilston and E. Raksuz CR. Susported by the Nith Biomodical Research Center, and the RCRI of the				
	Modification of Adenovirus vaccine vector-induced immune responses by expression of a signalling molecule	2020 Nature	Oxford, CS, 952 and AV94 are homer institute investigators and AV94 is a Welforcen Evust and NIR Sento Investigator. The funding source Ave do no involvement is study design; collection, analysis and interpretation of data, in the writing of the report and in the decision to submit the availation production. Available of the average of the report and in the decision to submit the variety of the report and in the decision to submit the variety of the report and in the decision to submit the variety of the report and in the decision to submit the variety of the report and the variety of the report and the variety of	A.V.S.H. and S.G.C. are names as co-inventors on patents related to recombinant viral vectors for malaria and other indications.	N/A	N/A	18/12/20
Salman AM	Rational development of a protective P. vivax vaccine evaluated with transgenic rodent parasite challenge models A Multi-Filovirus Vaccine Candidate: Co- Expression	2017 Scientific Reports	S. Ahmed M. Salman was funded by EVMMalaR's Program funding (FP)/2007–2013) under grant agreement N° 24/2095. Adrian Hill is supported by a Wellcome Trust grant number 095540/2/11/2 and is a Jenner Investigator and an Oxford Martin Fellow.	N/A  Teresa Lambe and Sarah Gilbert are Jenner Investigators. All other authors declare noconflicts of interest. Views expressed are those of the authors and do not necessarily reflect those of the	N/A	N/A	21/12/2020
Sebastian S	of Ebola, Sudan, and Marburg Antigens in a Single Vector	2020 MDPI	This research was funded by Innovate UK (Novel multivalent vaccines against haemorrhagic fevers/971510) and MRC (Confidence in Concept CiC 2015-16, MC_PC_15040, Liverpool School of Tropical Medicine).  This work was supported by the European Malaria Vaccine Development Association (EMVDA), a	employinginstitutions. The funders had no role in the design of the study, in the collection, analyses, or interpretation ofdata; in the writing of the manuscript, or in the decision to publish the results.	N/A	N/A	18/12/20
	Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium		European Commission PRé-funded consortium (http://www.emvds.org/) (1,59P-C7.2007-0)75/06); the UN National Institute of Health Research through the Clorifd Genemical Research Center (http://www.wadrotthec.org/) (A93103.4 daily Vaccine); and the Welcome Trust (http://www.madrotthec.org/) (A93103.4 daily Vaccine); and the Welcome Trust (http://www.madrotthec.org/) and the Intramural Program of the Majora Welcome Control (1,50P-M). The Clark of www.supported by the PATH Majora Welcome Institute of Health, National Institute of Health, National Institute of Health, National Institute of Health, National Institute of Alleggingto Infocusional Research (1,50P-M). The Clark of Welcome Trust Program of the National Institute of Alleggingto Infocusional Research (1,50P-M). The Clark was supported by a Welcome Trust Program Research (1,50P-M) (1,50P-M). See National Research (1,50P-M). See	PCT/GB2008/01262, US 12/S95 351 and UK PCT/GB2008/01271 novel adenovirus patent applications covering malaria vectored vaccines and immunization regimes. This does not alter our adherence to all the PLoS ONE-policies on sharing data and materials. Authors from Okairo's are employees of and/or shareholders in Okairos, which is developing vectored vaccines for malaria			
Sheehy SH	falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors	2012 Plos One	Council CareerDevelopment Fellow [G1000527]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This work was supported by the European Malaria Vaccine Development Association, a European	and other diseases. This does not alter our adherence to all the PLoS ONE policies on sharing data and materials.	NCT01095055	N/A	16/12/20
	ChAd63-MVA-vectored blood-stage		Commission FF4-funded connortium (LSIP-CT-2027-GT350); the UK Medical Research Council (grant no. G007037); the UK National Institute of Health Research through the Oxford Blomedical Research Centre (AR3103 Adult Vaccind), and the Southampton Nills Welcome Francis (Grant Commission FF4-funded or programmer (Grant Date (AR3103)). The grant institute commission FF4-funded or programmer (Grant Commission FF4				
Sheehy SH	malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans	The American Society of Gene & Cell 2012 Therapy	Development Fellow (G1000527). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. A.D.D., S.C.G., A.V.S.H., and S.J.D. are named inventors on oatent anolications covering malaria-vectored vaccines and immunization this work was supported by the UK Medical Research Council (IMRC) (grant number G0700735), th		N/A	N/A	16/12/20
	Phase la clinical evaluation of the		This work was supported by the UK Medical Research Council (MRCI) (great number G0700739), the European Malaria Voice Development Association (RMVAD), a long-toppen Commission of Malaria European Malaria Voice Development Association (RMVAD), a long-toppen Commission of Malaria (OARTIA) (AND AND AND AND AND AND AND AND AND AND				
	Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA		patent applications coverin malaria vectored vaccines and immunization regimes. Authors from Okairòs are employees of and/or shareholders in Okairòs which is developing vecotred vaccines for	r			
Sheehy SH	vaccine vectors	2011 The Journal of Immunology	malaria and other diseases.  This work has been funded by grants from the Foundation for the National Institute of Health through the Grand Challenges in Global Health Initiative (Health Charlenge) in Health Initiative (Health Cha	AV5H is a named inventor on WO/2008/122811-Adenoviral vectors encoding a pathogen or number and WO/2008/122801-Adenoviral vectors encoding makins antigen. S. Colloca, AF, and AF are number obscillators WO/2008/1208/1451-Chimanazori.	, N/A	N/A	16/12/20
Spencer AJ	Enhanced vaccine-induced CD8+T cell responses to malaria antigen ME-TRAP by fusion to MHC class il invariant chain	2014 Plos One	additional role in the study design, datacollection and analysis, decision to publish, or preparation of the manuscript. The specific roles of all authors are articulated in the 'author contributions' section.	adenovirusvaccine carriers. Authors from Okairos were employees of and/or share holders in Okairos, this does not alter the authors' adherence to all the PLOS ONE policieson sharing data and materials.	N/A	N/4	16/12/20
Stedman A	,	2014 FIUS URIE	This study was funded by the UK Department of Health and Social Care (UK DHSC, Project 16/107/03), G.M.W. is supported by an Oak foundation fellowship and a Wellcome Trust grant (203077_2_16_2).S.C.G., B.C. and A.V.S.H. are lennerinvestigators. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The views expressed in hispoblication are those of the authors and do not necessarily reflect.	and macross.	TQA	NA	16/12/20
	Safety and efficacy of ChAdOx1 RVF vaccine against Rift Valley fever in pregnant sheep and goats An Ad/MVA vectored Thelleria parva antigen induces schizont-specific CD8(+) central memory T cells and confers	2019 Nature partner journals	those of the URDHSC. We thank for Comins Schmalpfor (USAMRIU), Fort Detrick, MD) for providinghe 4-04 a broubowly. This paper is published with the permission of the Principalitatistics and the Detector of the Kerny Medical Research Instituta- tion with a Trade by the Bill and Medical Acides Foundation (BMAGF) and the Department for international Development (DPIO) of the United Kingdom(DPI-DIOPSE), the Normal Sorting  international Development (DPIO) of the United Kingdom(DPI-DIOPSE), the Normal Sorting  Sorting	S.C.G. and A.V.S.H. are co-founders of, consultants to and shareholders in Vaccitechtad., which is developing ChAdOx1-vectored vaccines. The remaining authors declareno competing interests.	N/A	N/A	18/12/20
Svitek N	partial protection against a lethal challenge A human vaccine strategy based on	2018 Nature partner journals	Agriculture (USDA)-Agricultural Research Service, USA (58-5348-2-117F) and through funding from the GGIAR Research Program on Livestock and Fish (CRP 3.7) Funding-Supported by the Medical Research Council (MRC) UK and the European Union (Framework VI; HEPACIVAC) for funding the studyand the manufacture of MVA-NSmut through an	Competing interests: S. Colloca, A.F., R.C., and A.N. are named inventors on patent applications covering HCV-vectored vaccines and chimpanzeeadenovirus vectors [WO 2006133911 (A3)	N/A	N/A	18/12/20
Swadling L	chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory	2014 Science Transitional Medicine	MRC UK DCS (Developmental Clinical Studies) award. E.B. is supported by the MRC as a Senior Clinical Fellow, the Oxford Martin Schools, and National Institute for Health Research Oxford Biomedical Research Centre. L. Swadling is supported by an MRC CASE studentship. Supported by the Medical Research Council (MRC) UK and the European Union (FrameworkW;	hepatitis C virus nucleic acid vaccine, WO 2005071093(A3) chimpanzee adenovirus vaccine carriers, WO 03031588 (A2) hepatitis C virus vaccine]. P.K. hasacted as a consultant to Tibotec and Pfizer on antiviral therapy. The other authors declare thatthey have no competing interests	N/A	N/A	16/12/20
			HEPACIVAC) for funding the study and the manufacture of MVA-KSmut through an MRC LIK DCS(Developmental Clinical Studies) award (G0701694). Christabel Kelly and Paul Klenerman are supported by the Welkcome Trust, the Oxford NHIR RRC and the U19 grant (2U19AIR026360-00). Leo Swedling is supported by ankRIC CASE studenthilp. Elleanor Barnes is funded as an MRC Senior Clinical Fellow, and is supported by McAordon NHIR Bok, the Oxford NHIR Both of the Mener Clinical Fellow, and is supported by McAordon NHIR Bok, the Oxford NHIR Both of the Mener And the Mener of the Men	2006133911 (A3) hepatitis C virus nucleic acid vaccine, WO 2005071093 (A3) chimpanzee adenovirusvaccine carriers, WO 03031588 (A2) hepatitis C virus vaccine]. Adrian Hill is a co-inventor			
Swadling L	Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-Bb-Filo: a phase 1, single-bilnd, randomised trial, a phase 1b, open-label and double-bilnd, doise-escalation trial, and a nested,	2016 Vaccines	Institute.  This study was funded by a Wellcome Trust Strategic Translation Award, with funding contribution from the Medical Recent Council UK, and the Department for International Development UK supported the primary vacantant of 8th January protections. For January vacantant of 8th January protections. For January Vacantant Planslating protections are January Vacantant Planslating protections. For January Vacantant Planslating protections are provided to the Chald-180.2 A vector and for data priming immunisation of the Malian participants with the Chald-180.2 A vector and for data management was provided by the National Concern Institute, the Federick National Laboratory for	on patent filings and applications related to heterologous prime-boost immunisations.	NCT01296451	N/A	20/12/2020
Tapia MD	randomised, double-blind, placebo- controlled trial	2016 The Lancet Infectious Diseases	a contract (number HHSN26120000001); awareed to Leidos Biomedical Research. The US trial was funded by the Vaccine Research Center, National Institute of Allergy and Infectious Diseases, through a contract to the EMMES Corporation.	Group to the Vaccine Research Center, National Institute of Allergy and Infectious Diseases, and of	NCT02231866, NCT02267109	N/A	20/12/2020

Tiono AB	First field efficacy trial of the CNAdd3 MVA METRAP vectored malaris vaccine candidate in 5-17 months old infants and children Besults from ADVAMCE: A phase I/II open-lated non-randomied safety and efficacy safety of twi	2018 Mos One	This work was supported by an award from the European and Developing Countries Clinical Trials. Partnership (IECET) and was performed by the Malaria Vectored Vaccines Consortium (MNVC), a 1 year Integrated project (Genatumeter Tay 2003, 130, 000.1). The Largoen Nazone Initiative (EV) was the conditiative of the ECET-Planded MNVC project. Co-Funding was also Development Cooperation Agency (1900). A Post-Planded Cooperation Agency (1900). A Austrian Federal Ministry of Science and Research, and thirth Add. Additional support for the Coloried clinical trials stam was provided by the UK WRIN through the Oxford Bismedical Research Centre	: AVSNI is a named inventor on patient applications and issued patients relating to malaria vectored vaccines and immunication regimes. This does not alter the author's adherence to all the PLOS ONE policies on sharing data and materials.  M. Turllik Advisory/Consultancy, Vaccineto limited: Advisory/Consultancy, Speaker Bureau/Expert testimony, BMS, Advisory/Consultancy, Speaker Bureau/Expert testimony, Policy Advisory/Consultancy, Speaker Bureau/Expert testimony, Road-Advisory/Consultancy, Speaker Bureau/Expert testimony, Road-Road-Advisory/Consultancy, Speaker Bureau/Expert testimony, Road-Road-Road-Road-Road-Road-Road-Road-	: NCT01635547, PACTR201208000404131.	. N/A	21/12/2020
	ChAdOx1-MVA 5T4 (VTP-800) vaccine in			Shareholder/Stockholder/Stock options: Vacci-tech Limited. A. Protheroe: Speaker Bureau/Expert			
Tutbill M	combination with PD-1 checkpoint blockade in metastatic prostate cancer	2020 Annals of Oncology (Abstracts)	European Union Seventh Framework Programme under grant AgreementNo. 602705 (Project IMPROVF) and Vaccitech Ltd.	testimony: BMS. A.V.S. Hill: Advisory/Consultancy,Founder Vaccitech: Vaccitech Limited. All other authors have declared no conflicts of interest	NCT03815942	N/A	18/12/20
Tutili W.	Heterologous Combination of ChAdOx1 and MVA Vectors Expressing Protein NS1 as Vaccination Strategy to Induce Durable and Cross-Protective CD8-T	2020 Allilais of Officiology (Abstracts)	This work was supported by grants AGL2017-82570-R from the Spanish Ministry of Science and EUHorizon 2020 Program (European Comission Grant Agreement NO.727393-PALE-Bul). SUT was a recipient of a prodeoctoral fellowship from the Instituto Nacional de Investigación y Tecnología		NC103013342	NA	16/12/20
Utrilla-Trigo S	Cell Immunity to Bluetongue Virus	2020 MDPI	Agraria y Alimentaria, Centro delinvestigación en Sanidad Animal (program FPI-SGIT-201).	N/A	N/A	N/A	18/12/20
	A single dose of ChAdOx1 MERS		This work was supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases (NIAID), NIH (12IAAI001179-01) and the Department of Health and Social Care using UK Aid funding managed by the NIHR.S.C.G. is a Jenner investigator. The views			-4	
	provides protective immunity in rhesus		expressed in this publication are those of the author(s) and not necessarily those of the	S.C.G. is a board member of Vaccitech and named as an inventor on a patent covering use of			
van Doremalen N	macaques	2020 Science Advances	Department of Health and Social Care.	ChAdOx1-vectored vaccines. The other authors declare that they have no competing interests.	N/A	N/A	18/12/20
van Doremalen N	A single-dose ChAdOx1-vectored vaccine		This work was supported by the Intramural Research Program of the National Institute of Allergy				
	provides complete protection against Nipah Bangladesh and Malaysia in		and Infectious Diseases(NIAID), National Institutes of Health(NIH). TAB issupported by the Medical	I have read the journal's policy and the authorsof this manuscript have the following competing			
	Nipah Bangladesh and Malaysia in Syrian golden hamsters	2019 PLOS	Research Council (MR/L009528/1). SCG is a Jenner investigator. The sponsors did not play a role in study design.	interests:SCG is named as an inventor on a patent covering use of ChAdOx1-vectored vaccines.The remaining authors declare no conflict of interest.		N/A	18/12/20
	Syrian golden namsters	2019 PLOS	stady design.	remaining authors declare no connect of interest.	N/A	N/A	10/12/20
van Doremalen N Venkatzaman N	ChAdOx1 nCeV-19 vaccine prevents SAMS-CeV-2 pneumonia in rhesus macrepus	2020 Nature	and Infections Disease (NAMO), National Institutes of Health (NHI) (IZAMODIT)-760 J and the Department of Health and Social Care using Mark fidning finanges by the NHIR. This work was supported by the Wellome Trust, the UK Medical Research Council, the UK Department for International Development, and the UK NHIR Charled Biomedical Wellow (IK Department for International Development, and the UK NHIR Charled Biomedical UK clinical trial was supported by an Enhancement Award to a Wellomen Trust Strategic Award (in AV. S. H. sa) principal investigation of condition by the Medical Research Council, the Department	Ch.AdG.v. vector-based vaccines and a patient application covering a \$A85.CVP. (InCV)*19 (sector) (by pleaset application no. 2020/80.2). It. It amende as an invention on a patient application covering a \$A85.CVP. (InCV)*19 vaccine (IV, patient application no. 2020/80.2). The University covering a \$A85.CVP. (InCV)*19 vaccine (IV, patient application no. 2020/80.2). The University of AA72/80.eve in Avg. (2020 for further devolvement, large-scale mandature and global peoply of the vaccine. Equitable access to the vaccine is a key component of the partnership. Neither Disdred University not Vaccine will receive any systemistic during the partnership. Neither Disdred University not Vaccine will receive any systemistic during the partnership. Neither Disdred University not Vaccine (in event of in the vaccine in developing countries. The other authors declare no competing interests.  F.R. and W. R. B. are employees of GSK and own restricted shares of the company, S. C. G. K. E., and A. V. S. H. are remole inventors on patients relating to visit vector vaccines for maintain and	N/A	AZ in competing interests	18/12/20
	Safety and Immunogenicity of a		Biomedical Research Centre. The Senegal trial was largely funded by a European	other diseases. F. R. and W. R. B. are employees of GSK, which is developing vectored			
	Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal Modeling Combinations of Pre-	2019 The Journal of Infectious Diseases	Commission Horizon 2020 program award EbolaVac (www.ebolavac.eu; grant agreement 666085), which provided additional resources for the MVA-EBO-Z biomanufacture. This study was also supported by GlascomithKline Biologicals SA. Andrew S. Walker, José Lourenço and Sunetra Gupta are funded by the European Research Council	Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.		N/A	18/12/20
Walker AS	erythrocytic Plasmodium falciparum Malaria Vaccines	American Journal of Tropical 2015 Medicine and Hygiene	(ERCAdvanced Grant—Diversity). AVSH is a Jenner Investigator and Wellcome Trust and NIHR Senior Investigator.	N/Δ	N/A	N/A	20/12/2020
Wang C		oune and rygene		-9		-9	-3/11/1010
	A simian-adenovirus-vectored rabies vaccine suitable for thermostabilisation and clinical development for low-cost single-dose pre-exposure prophylaxis	2018 Plos Neglected Tropical Diseases	This work has been supported by the UK Medical Research Council including Confidence in Concreg (grantsLeft, P.2.) jazzla MR/P0712381), Slo, ASSI and ADD are lement investigators; Slo is also a lister institute Research Prise Fellow and a Wellcome Trust Senior Fellow [grant1089172[6]]. ADD ADD is supported by the Wellcome Trust (grant108172[6]). The Inderest had no rise in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This work was conducted with the succonstrict with the Viscous for time the University of Oxford; a Wellcome Trust this work was conducted with the succonstrict with the Viscous for time the University of Oxford; a Wellcome Trust and the Viscous Post of Oxford and Viscous Post of Oxford as Wellcome Trust the Viscous Post of Oxford as Wellcome Trust was provided to the Viscous Post of Oxford as Wellcome Trust the Viscous Post of Oxford Post of Oxford as Wellcome Trust the Viscous Post of Oxford Post of O	ChAdOx2 vector. AVSH and SID are named inventors on a patent relating to the use of the intron- containing promoter used in ChAdOx2 RabG. The University of Oxford and the Wistar Institute have entered into a partnership to share any future revenue from development of the ChAdOx2 RabG	N/A	N/A	21/12/2020
	Chimpanzee Adenovirus Vaccine		fellowship to GMW (WT098635) and grant from the Bill & Melinda Gates Foundation through the				
	Provides Multispecies Protection against		Grand Challenges Exploration Initiative to GMW (OPP1096893). B.C., S.C.G. and A.V.S.H. are Jennes				
Warimwe GM	Rift Valley Fever	2016 Scientific Reports	Investigators.		N/A	N/A	20/12/2020
			This work was supported by a Wellcome Trust fellowship in PublicHealth and Tropical Medicine to				
Warimwe GMLorenzo Yoshida K	Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice	2013 Virology Journal	GMW (grant no. 098635/8/12/Z) and by a Spanish Ministry of Science grant (no. AGL2011-22485) to AB. ELG is a recipient of a pre-doctoral fellowship program from the Spanish Ministry of Science. SCG and AVSH are Jenner Investigators.	vector (GB Patent application number 1108879.6).All other authors declare that they have no	N/A	N/A	16/12/20
	Adenovirus-prime and baculovirus- boost heterologous immunization achieves sterile protection against malaria sporozoite challenge in a murine model	2018 Scientific Reports	This work was supported, in part, by a Grant-in-Add for Young Scientists (B) (JRSF SAMENH grant number 2866/219, a grant from the Olyman Health Foundation, and Cooperathe Research Grant from NEXEX, 2014 (grant number 26-6) and 2015 (grant number 27-5) to M. I.; by Grants-in-Add of Growthin Research (B) (JRSF SAMENH grant numbers 2180/306) and and 25050007) and Grant-in-Add for Challenging Exploratory Research (JRSF SAMESHH grant number 2469840) to S.Y.; and by the U Medical Research (Loront [Javard number MM/00227/21) to S.Y.; and by the U Medical Research (Loront [Javard number MM/00227/21) to S.Y.; and by the U Medical Research (Loront [Javard number MM/00227/21) to S.Y.; and by the U Medical Research (Loront [Javard number MM/00227/21) to S.Y.; and by the U Medical Research (Loront [Javard number MM/00227/21) to S.Y.; and by the U Medical Research (Loront [Javard number MM/00227/21) to S.Y.; and by the U Medical Research (Loront [Javard number MM/00227/21) to S.Y.; and by the U Medical Research (Loront [Javard number MM/00227/21) to S.Y.; and by the U Medical Research (Loront [Javard number MM/00227/21) to S.Y.; and by the U Medical Research (Loront [Javard number MM/00227/21) to S.Y.; and by the U Medical Research (Loront [Javard number MM/00227/21) to S.Y.; and by the U Medical Research (Loront [Javard number MM/00227/21) to S.Y.; and by the U Medical Research (Loront [Javard number MM/00227/21) to S.Y.; and by the U Medical Research (Loront [Javard number MM/00227/21) to S.Y.; and by the U Medical Research (Loront [Javard number MM/00227/21) to S.Y.; and by the U MM/00227/21) to S.Y.; and by the U Medical Research (Loront [Javard number MM/00227/21) to S.Y.; and by the U Medical Research (Loront [Javard number MM/00227/21) to S.Y.; and S.Y.	A.H. are named inventors on flied patents related to immunication with the B.D.E.S. (MV/2007/908)24) and ChAGS6 (MV/0008/122796) anti-makin's vaccines, respectively. Neither of these products has been commercialized. None of the authors have undertaken any consultancies relevant to this study. These conflicts of interest do not alter the authors' adherence to all the cytolices of Scientific Reports on sharing data and materials, as detailed online in the guide for		N/A	21/12/2020

		A							Dalamata Irangan	
Award number	Funder name	Awardee (to whom was the grant?)	Date	Amount	Exchange rate	^	۸ma	ount in GBP	Relevant publications (author and date)	Direct citation from articles
Awaru number	AIDS Vaccine Initiative	grantr)	Date	Amount	LXCHarige rate	6	AIIIC	unt in GBF	Borthwick et al (2014)	The work was supported by
-	Austrian Federal Ministry of Science and	-	-	-					Tiono (2018)	This work was supported by a
BBS/E/I/00001373	BBRSC	Bryan Charleston	Jan 09 - Jan 13	£790,209	1		£	790,209.00	Dicks et al (2015 - 2)	This work was supported by a
BB/H010556/1	BBSRC	Tim Bull	Mar 10 - May 13	£351,371			£	351,371.00	Bull et al (2014)	This work was supported by B
BB/H010330/1 BB/H010718/1	BBSRC	Jayne Hope	-	£235,928			£	235,928.00	Bull et al (2014)	This work was supported by B
DD/ HU1U/ 10/ 1	BBSRC		Sep 11 - Aug 13	1233,920	•		L	255,926.00	Bull et al (2014)	• • • • • • • • • • • • • • • • • • • •
-	BBSRC	Hope J McGuines I	-	-					Bull et al (2014)	This work was supported by B This work was supported by B
LDAD P15820	BBSRC	-		_					Goodman et al (2011)	This work was supported by B
LDAD_F15820	BBSRC		_	_					Goodman et al (2011)	This work was supported prim
OPP1096893	Bill & Melinda Gates Foundation	Warimwe GM		-	7				Dulal et al (2016)	This study was conducted witl
			-	-						•
OPP1096893		Warimwe GM	-	-					Warimwe et al (2016)	This work was conducted with
OPP1078791	Bill and Melinda Gate Foundation	Research Institute		\$ 10,999,924				7,919,945.28	, ,	This work was funded by the I
OPP1215550		The Pirbright Institute	Nov-19	\$ 5,530,900		0.72	£	3,982,248.00	S Graham (2020)	and the Bill and Melinda Gate
3436	Bill and Melinda Gates Foundation	-	-	-					Pearson et al (2013)	This work has been supported
-	Biotechnology and Biological Sciences R	-	-	-					Boyd et al (2013)	The Biotechnology and Biolog
-	Bundesministerium für Bildung und Fors	-	-	-					Mensah (2017)	This work was supported by a
-	Cancer Research	Malinauskas T	-	-					Bauza et al (2014)	The work was funded by a We
-	Cancer Research	Jones EY	-	-					Bauza et al (2014)	The work was funded by a We
-	CAPES	Atcheson E		-					Atcheson (2018)	The work was funded by a We
CRP 3.7	CGIAR Research Program on Livestock as	-	-	-					Svitek (2018)	This work was funded by the I
-	Coalition for Epidemic Preparedness Inne	-	-	-					Folegatti P.M.(2020)	UK Department of Health and
finance code 001	Coordenacao de Aperfeicoamento de Pe	Folegatti P.M	-	-					Folegatti P.M.(2020)	UK Department of Health and
finance code 001	Coordenacao de Aperfeicoamento de Pe	-	-	-					Folegatti P.M.(2020)	UK Department of Health and
-	Dakar University Cheikh Anta Diop	-	-	-					Mensah et al (2016)	This study was supported by a
-	Danida	-	-	-					Payne et al (2017)	This work was supported by fu
	Department for Business, Energy and Inc	lustrial Strategy		£65,500,000.00	)		£	65,500,000.00	https://www.imperial.ac.u	ık/news/197573/covid-19-vacc
	Department for Business, Energy and Inc	lustrial Strategy		£20,000,000.00	)		£	20,000,000.00	https://www.imperial.ac.u	uk/news/197017/imperial-covid
-	Department for International Developme		-	- ' '					Bowyer (2018)	The clinical trial was supporte
-	Department for International Developme	-	-	-					Venkatraman N (2019)	This work was supported
-	Department of Biotechnology, Government	Chauhan VS	-	-					de Cassan et al (2011)	S.C.d.C. is a Ph.D. student sup
-	Department of Biotechnology, Government	Chitnis CE	-	-					de Cassan et al (2011)	S.C.d.C. is a Ph.D. student sup
-	Department of Foreign Affairs and Trade		-	-					Mensah (2017)	This work was supported by a
-	DFID	-	-	-					Tapia et al (2016)	This study was funded by a W
-	DFID	-	-	-					Ewer et al (2016)	Supported by the Wellcome T
-	Division of Intramural Research	-	-	-					Forbes et al (2012)	This work was funded by the \
-	Dr. Saal van Zwanenberg Stichting	van Laarhoven A	-	-					Lambe et al (2013)	AvL was funded by a fellowsh
IP.2008.31100.00	EDCTP	-	-	-					Kimani et al (2014)	This work was supported by
IP.2008.31100.001	EDCTP	-	-	-					Afolabi et al (2016)	Trials Partnership (EDCTP) and
IP.2008.31100.001	EDCTP	_	_	_					Mensah et al (2016)	This study was supported by a
IP.2008.31100.001	EDCTP	-	_	-					Nébié et al (2014)	This work was supported by a
-	EMVDA	Dicks MDJ	-	_					Dicks et al (2012)	This work has been funded by
	EMVDA	Dicks MDJ							Dicks et al (2015 - 2)	This work has been funded by
	EMVDA	-		_					Forbes et al (2012)	This work was funded by the \
LSHP-CT-2007-03750	EMVDA	_	_	_					Biswas et al (2014)	This work was supported by the
25111 C1 2007-05750									5.5.445 Ct ai (2014)	s work was supported by ti
LSHP-CT-2007-037506	EMM/DA								Chooby of al (2011)	This work was supported by the
		-	_	-					Sheehy et al (2011)	This work was supported by the
LSHP-CT-2007-037506		-	-	-					Sheehy et al (2012 - 2)	This work was supported by the
LSHP-CT-2007-037506	EIVIVUA	-	-	-					Sheehy et al (2012)	This work was supported by
LSHP-CT-	54 N/D 4								11. 1 1 (2044)	<b>-</b> 1
2007–037506	EMVDA	-	-	-					Hodgson et al (2014)	This work was supported by the
	EMVDA		-	-					Draper et al (2011)	SB was funded by MalParTrai

EP/R013756/1	Engineering and Physical Sciences Rese	a <u>Tarit K Mukhopadhyay</u>	Apr 18 - Sep 21	£6,968,179	£	6,968,179.00	Folegatti P.M.(2020)	UK Department of Health and
CFTD07/117	Enterprise Ireland	-		-			Pearson et al (2015)	This study was funded by Ente
CFTD07/117	Enterprise Ireland	-		-			Carey et al (2013)	This work wassupported by Er
-	EU HEPACIVAC	-					Swadling (2016)	Supported by the Medical Res
-	European and Developing Countries Clin	ii -					Bowyer G (2020)	The Oxford clinical trial was s
-	European and Developing Countries Clin						Reyes-Sandoval (2010)	Work in the Oxford malaria va
-	European and Developing Countries Clin						Bowyer (2018)	The clinical trial was supporte
-	European and Developing Countries Clin						Venkatraman N (2019)	This work was supported
IP.2008.31100.001	European and Developing Countries Clin						Ogwang et al (2015)	This work was funded by the I
SP.2011.41304.025	European and Developing Countries Clin						Mensah (2017)	This work was supported by a
IP.2008.31100.001	European and Developing Countries Clin						Tiono (2018)	This work was supported by a
	zaropean and beveroping countries can	GLAXOSMITHKLINE					110110 (2010)	mis work was supported by a
66600	35 European Comission	BIOLOGICALS SA	07-Oct-14	€ 15,153,216	0.07 £	12 102 207 02	Venkatraman N (2019)	This work was supported
00000	33 European Comission		07-001-14	€ 13,133,210	0.87 L	13,103,237.32	Venkatianian N (2015)	This work was supported
	DE E	GLAXOSMITHKLINE	07.0.144	6 45 453 346	0.07.0	42 402 207 02	D (2020)	The Original Property of the Control
	35 European Commission	BIOLOGICALS SA	07-Oct-14	€ 15,153,216			Bowyer G (2020)	The Oxford clinical trial was s
24209	95 European Commission	Salman AM	01-Oct-09	€ 12,000,000	U.87 £	10,440,000.00	Atcheson (2018)	The work was funded by a We
		THE UNIVERSITY OF						
727393-PALE-Blu	European Commission	NOTTINGHAM	01-Jun-17	€ 6,039,301.50	0.87 £		Utrilla-Trigo S (2020)	This work was supported by g
60270	05 European Commission	-	-	€ 6,000,000	0.87 £	5,220,000.00	Cappuccini F (2020)	The VANCE clinical trial was s
		THE CHANCELLOR,						
		MASTERS AND SCHOLARS						
		OF THE UNIVERSITY OF						
60270	05 European Commission	OXFORD	01-Apr-14	€ 6,000,000	0.87 £	5,220,000.00	Tuthill M. (2020)	European Union Seventh Fram
31665	55 European Commission	Halbroth BR	01-Nov-12	€ 3,060,467.67				BRH received funding from th
31665	55 European Commission	Halbroth BR		-			Gola (2018)	A.G. is funded by the Wellcom
-	European Commission	-					Reyes-Sandoval (2010)	Work in the Oxford malaria va
IC18-CT95-0019	European Commission	Fellowship to author to J.S		-			Gilbert et al (2002)	Wellcome Trust and the Eu
21241	L4 European Community's 7th Framework	FUNIVERSIDAD COMPLUTENS	01-Oct-08	€ 2,894,759	0.87 £	2,518,440.33	Pérez et al (2013)	The study was funded by the
	95 European Community's Seventh Frame						Longley et al (2015)	This work has been funded by
	95 European Community's Seventh Frame		-	€ 12,000,000	0.87 £	10,440,000.00	Forbes et al (2012)	This work was funded by the \
-	European Malaria Vaccine Developmen			. , ,		, ,	Draper et al (2010)	This work was funded by the \
							.,,	
LSHP-CT-2007-03750	06 European Malaria Vaccine Developmen	t -					Elias et al (2013)	This work was supported by th
25111 01 2007 05750	za zaropean maiana vacome zeveropmen	•					2.105 Ct d. (2015)	inis work was supported by the
LSHP_CT_2007_03750	06 European Malaria Vaccine Developmen	t de Cassan SC					Payne (2017)	This work was supported by a
	06 European Malaria Vaccine Developmen						de Cassan et al (2011)	S.C.d.C. is a Ph.D. student sup
-	European Malaria Vaccine Development		-				Capone et al (2010)	This work was supported by th
_	European Malaria Vaccine Deviopment	<b>r</b> -					Reyes-Sandoval (2010)	Work in the Oxford malaria va
•	European Research Council	Walker A					Walker et al (2015)	Andrew S. Walker, José Loure
•	•						, ,	,
-	European Research Council	Lourenço J	-	•			Walker et al (2015)	Andrew S. Walker, José Loure
-	European Research Council	Gupta S					Walker et al (2015)	Andrew S. Walker, José Loure
	32 European Union	MultiMalVax	01-Oct-12	€ 6,000,000	0.87 £	5,220,000.00	Payne et al (2017)	This work was supported by fu
	55 European Union	Halbroth BR		•			Longley et al (2017)	Funding for manufacture and
	05 European Union	Capuccini F		•			Capuccini et al (2017)	This work was supported by C
	05 European Union	Pollock E		•			Capuccini et al (2017)	This work was supported by C
Framework VI;HEPA	·	-					Barnes et al (2012)	European Union (Framework
	05 European Union's Seventh Framework I	•	01-Apr-14	€ 6,000,000	U.87 £	5,220,000.00		This work was supported by C
60270	05 European Union's Seventh Framework I	Pi Pollock E	•	-			Capuccini et al (2016)	This work was supported by C
-	European Vaccine Initiative	-	-	-			Cottingham et al (2012)	This work was supported by the
-	European Vaccine Initiative	-	-	-			de Barra et al (2014)	The study was funded by a gra
-	European Vaccine Initiative	Chauhan VS	-	-			de Cassan et al (2011)	S.C.d.C. is a Ph.D. student sup
-	European Vaccine Initiative	Chitnis CE	-	•			de Cassan et al (2011)	S.C.d.C. is a Ph.D. student sup
-	European Vaccine Initiative	Viebig NK	-	•			Kimani et al (2014)	This work was supported by
24209	95 EVIMalaR	-	-	-			Biswas et al (2014)	This work was supported by th

2420	95 EVIMalaR	-	_	-			Elias et al (2013)	This work was supported by th
	95 EVIMalaR	-	-	-			Hodgson et al (2014)	This work was supported by th
	95 EVIMalaR	Salman M	-	-			Salman et al (2017)	The work was funded by a W€
	95 EVIMalaR	-	-	-			Sheehy et al (2012)	This work was supported by
-	EVIMalR	Salman AM	_				Longley et al (2015)	This work has been funded by
_	Foundation to NIH	Hill A.V.S	_	_			Halbroth (2018)	BRH received funding from th
-			-	-				_
-	Frederick National Laboratory for Cancel	r <del>-</del>	-	-			Tapia et al (2016)	This study was funded by a W
-	Gates Foundation	-	-	-			Reyes-Sandoval (2010)	Work in the Oxford malaria va
-	Gates Foundation (through the foundati	( -	-	-			Cottingham et al (2012)	This work was supported by the
-	German Center for Infection Research	-	-	-			Folegatti P.M.(2020)	UK Department of Health and
-	Graduate Women in Science	Coughlan L	-	-			Bliss (2020)	This research project was sup
-	Grand Challenges in Global Health	-	-	-			Reyes-Sandoval et al (2010	We thank the Jenner Institu
246594	60 Grant-in-Aid for Challenging Exploratory	Yoshida S	-	-			Yoshida Klyori (2018)	This work was supported, in p
	78 Grant-in-Aid for Young Scientists	-	_	_			Yoshida Klyori (2018)	This work was supported, in p
	26 Grants-in-Aid for Scientific Research	_	-	-			Yoshida Klyori (2018)	This work was supported, in p
	07 Grants-in-Aid for Scientific Research	_	_	_			Yoshida Klyori (2018)	This work was supported, in p
233030	GSK	-	-	-			Venkatraman N (2019)	This work was supported, in p
-		-		-				• • • • • • • • • • • • • • • • • • • •
-	HAV Vaccines Ltd	-	-	-			Folegatti P.M. (2019)	This research was funded by I
-	HEPACIVAC	-	-	-			Swadling et al (2014)	Funding:Supported by the Me
LSH-2005-1.2.4-2 pr	oje Hepacivac	-	-	-			Colloca et al (2012)	This work was supported in pa
-	Imperial College NIHR Wellcome Trust (	-	-	-			Rampling et al (2016)	This work was supported by th
9715	10 Innovate UK	The Jenner Institute, Univers	i Apr 17 - May 18	£483,455	£	483,455.00	Sebastian S (2020)	This research was funded by I
FPI-SGIT-201	Instituto Nacional de Investigación y Teo	Utrilla-Trigo S	-	-			Utrilla-Trigo S (2020)	This work was supported by g
-	Irish Aid	-	-	-			Afolabi et al (2016)	Trials Partnership (EDCTP) and
	Irish Aid	_					Mensah (2017)	This work was supported by a
-	Irish Aid	-	-	-			Mensah et al (2016)	This study was supported by a
-	Irish Aid	-	-	-			Tiono (2018)	This work was supported by a
-	James Martin School for 21st Century, O	t =	-	-			Barnes et al (2012)	European Union (Framework '
-	Jenner Institue	Gilbert SC	-	-			de Cassan et al (2011)	S.C.d.C. is a Ph.D. student sup
-	Jenner Institue	Hill AVS	-	-			Dicks et al (2012)	This work has been funded by
-	Jenner Institue	Hill AVS	-	_			Sheehy et al (2012)	This work was supported by
-	lonnor Instituo	Gilbort SC					Shooby of al (2012)	
	Jenner Institue	Gilbert SC	-	-			Sheehy et al (2012)	This work was supported by
-	Jenner Institute	Reyes-Sandoval A	-	-			Atcheson (2018)	This work was supported by The work was funded by a W $\varepsilon$
-	Jenner Institute Jenner Institute	Reyes-Sandoval A Hill A.V.S	- -	- -			Atcheson (2018) Atcheson (2018)	This work was supported by The work was funded by a W $\varepsilon$ The work was funded by a W $\varepsilon$
- -	Jenner Institute Jenner Institute Jenner Institute	Reyes-Sandoval A Hill A.V.S Hill AVS	- - -	- - -			Atcheson (2018) Atcheson (2018) Bauza et al (2014)	This work was supported by The work was funded by a W $\epsilon$ The work was funded by a W $\epsilon$ The work was funded by a W $\epsilon$
- - -	Jenner Institute Jenner Institute Jenner Institute Jenner Institute	Reyes-Sandoval A Hill A.V.S Hill AVS Reyes-Sandoval A	- - - -	- - - -			Atcheson (2018) Atcheson (2018) Bauza et al (2014) Bauza et al (2014)	This work was supported by The work was funded by a W $\epsilon$
- - - -	Jenner Institute Jenner Institute Jenner Institute Jenner Institute Jenner Institute	Reyes-Sandoval A Hill A.V.S Hill AVS Reyes-Sandoval A McShane H	- - - - -	-			Atcheson (2018) Atcheson (2018) Bauza et al (2014) Bauza et al (2014) Betts et al (2012)	This work was supported by The work was funded by a We The work was funded by a We The work was funded by a We The work was funded by a We Funding was provided by NEW
- - - - -	Jenner Institute Jenner Institute Jenner Institute Jenner Institute	Reyes-Sandoval A Hill A.V.S Hill AVS Reyes-Sandoval A	- - - -	- - - - -			Atcheson (2018) Atcheson (2018) Bauza et al (2014) Bauza et al (2014)	This work was supported by The work was funded by a W $\epsilon$
	Jenner Institute Jenner Institute Jenner Institute Jenner Institute Jenner Institute	Reyes-Sandoval A Hill A.V.S Hill AVS Reyes-Sandoval A McShane H Hill AVS Reyes-Sandoval A	- - - - - -	- - - - - -			Atcheson (2018) Atcheson (2018) Bauza et al (2014) Bauza et al (2014) Betts et al (2012)	This work was supported by The work was funded by a We The work was funded by a We The work was funded by a We The work was funded by a We Funding was provided by NEW
	Jenner Institute Jenner Institute Jenner Institute Jenner Institute Jenner Institute Jenner Institute	Reyes-Sandoval A Hill A.V.S Hill AVS Reyes-Sandoval A McShane H Hill AVS	- - - - - -	- - - - - - -			Atcheson (2018) Atcheson (2018) Bauza et al (2014) Bauza et al (2014) Betts et al (2012) Betts et al (2012)	This work was supported by The work was funded by a We The work was funded by a We The work was funded by a We The work was funded by a We Funding was provided by NEW Funding was provided by NEW
	Jenner Institute	Reyes-Sandoval A Hill A.V.S Hill AVS Reyes-Sandoval A McShane H Hill AVS Reyes-Sandoval A	- - - - - - -	- - - - - - - -			Atcheson (2018) Atcheson (2018) Bauza et al (2014) Bauza et al (2014) Betts et al (2012) Betts et al (2012) Betts et al (2012)	This work was supported by The work was funded by a We The work was funded by a We The work was funded by a We Funding was provided by NEW
	Jenner Institute	Reyes-Sandoval A Hill A.V.S Hill AVS Reyes-Sandoval A McShane H Hill AVS Reyes-Sandoval A Hill AVS	- - - - - - - -				Atcheson (2018) Atcheson (2018) Bauza et al (2014) Bauza et al (2014) Betts et al (2012) Betts et al (2012) Betts et al (2012) Biswas et al (2014)	This work was supported by The work was funded by a We The work was funded by a We The work was funded by a We The work was funded by NEW Funding was provided by NEW Funding was provided by NEW Funding was grovided by NEW This work was supported by the West New Years of the work was supported by the West New Years of the work was supported by the West New Years of the work was supported by the West New Years of the work was supported by the West New Years of
	Jenner Institute	Reyes-Sandoval A Hill A.V.S Hill AVS Reyes-Sandoval A McShane H Hill AVS Reyes-Sandoval A Hill AVS Draper SJ					Atcheson (2018) Atcheson (2018) Bauza et al (2014) Bauza et al (2014) Betts et al (2012) Betts et al (2012) Betts et al (2012) Biswas et al (2014) Biswas et al (2014)	This work was supported by The work was funded by a We Funding was provided by NEW Funding was provided by NEW Funding was provided by NEW This work was supported by tl This work was supported by tl
	Jenner Institute	Reyes-Sandoval A Hill A.V.S Hill AVS Reyes-Sandoval A McShane H Hill AVS Reyes-Sandoval A Hill AVS Draper SJ Hill AVS		- - - - - - - - -			Atcheson (2018) Atcheson (2018) Bauza et al (2014) Betts et al (2012) Betts et al (2012) Betts et al (2012) Biswas et al (2014) Biswas et al (2014) Carey et al (2013) Carey et al (2013)	This work was supported by The work was funded by a We Funding was provided by NEW Funding was provided by NEW Funding was provided by NEW This work was supported by the This work was supported by Er This work wassupported by Er This work wassupported by Er
	Jenner Institute	Reyes-Sandoval A Hill A.V.S Hill AVS Reyes-Sandoval A McShane H Hill AVS Reyes-Sandoval A Hill AVS Corper SJ Hill AVS Gilbert SC Hill AVS					Atcheson (2018) Atcheson (2018) Bauza et al (2014) Bauza et al (2014) Betts et al (2012) Betts et al (2012) Betts et al (2012) Biswas et al (2014) Biswas et al (2014) Carey et al (2013) Carey et al (2013) de Barra et al (2014)	This work was supported by The work was funded by a We Funding was provided by NEW Funding was provided by NEW Funding was provided by NEW This work was supported by the This work was supported by Er This work wassupported by Er This work wassupported by Er This work wassupported by Er The Study was funded by a grant was funded by a grant was supported by Er The Study was funded by a grant was supported by Er The Study was funded by a grant was supported by Er The Study was funded by a grant was supported by Er The Study was funded by a grant was supported by Er The Study was funded by a grant was supported by Er The Study was funded by a grant was supported by Er The Study was funded by a grant was supported by Er The Study was funded by a grant was supported by Er The Study was funded by a grant was supported by Er The Study was funded by a grant was supported by Er The Study was funded by a grant was supported by Er The Study was funded by a grant was supported by Er The Study was funded by a grant was supported by Er The Study was funded by a grant was supported by Er The Study was funded by a grant was supported by Er The Study was funded by a grant was supported by Er The Study was suppo
	Jenner Institute	Reyes-Sandoval A Hill A.V.S Hill A.V.S Hill AVS Reyes-Sandoval A McShane H Hill AVS Reyes-Sandoval A Hill AVS Draper SJ Hill AVS Gilbert SC Hill AVS Gilbert SC					Atcheson (2018) Atcheson (2018) Bauza et al (2014) Betts et al (2012) Betts et al (2012) Betts et al (2012) Biswas et al (2014) Biswas et al (2014) Carey et al (2013) Carey et al (2013) de Barra et al (2014) de Barra et al (2014)	This work was supported by The work was funded by a We Funding was provided by NEW Funding was provided by NEW Funding was provided by NEW This work was supported by the This work was supported by the This work was supported by ET The work was supported by ET The study was funded by a grathestudy was funded b
	Jenner Institute	Reyes-Sandoval A Hill A.V.S Hill AVS Reyes-Sandoval A McShane H Hill AVS Reyes-Sandoval A Hill AVS Ges-Sandoval A Hill AVS Geses-Sandoval A Hill AVS Gilbert SC Hill AVS Gilbert SC Hill AVS					Atcheson (2018) Atcheson (2018) Bauza et al (2014) Betts et al (2012) Betts et al (2012) Betts et al (2012) Betts et al (2012) Biswas et al (2014) Garey et al (2013) Carey et al (2013) de Barra et al (2014) de Barra et al (2014) de Cassan et al (2011)	This work was supported by The work was funded by a We Funding was provided by NEW This work was supported by the This work was supported by Er This work wassupported by Er This work wassupported by Er This study was funded by a grant for the Study was funded by a grant study was f
	Jenner Institute	Reyes-Sandoval A Hill A.V.S Hill AVS Reyes-Sandoval A McShane H Hill AVS Reyes-Sandoval A Hill AVS Ges-Sandoval A Hill AVS Gilbert SC Hill AVS Gilbert SC Hill AVS Draper SJ Draper SJ Draper SJ Draper SJ Draper SJ					Atcheson (2018) Atcheson (2018) Bauza et al (2014) Betts et al (2012) Betts et al (2012) Betts et al (2012) Biswas et al (2014) Biswas et al (2014) Carey et al (2013) Carey et al (2013) de Barra et al (2014) de Cassan et al (2011)	This work was supported by The work was funded by a We The work was funded by a We The work was funded by a We The work was funded by We Funding was provided by NEW Funding was provided by Unding was supported by the This work was supported by Er This work wassupported by Er The study was funded by a grangly supported by Er The Study was funded by a grangly supported by Er The Study was funded by a grangly supported by Er The Study was funded by a grangly supported by Er The Study was funded by a grangly supported by Er The Study was funded by a grangly supported by Er The Study was funded by a grangly supported by Er The Study was funded by a grangly supported by Er The Study was funded by a grangly supported by Er The Study was funded by a Brangly supported by Er The Stud
	Jenner Institute	Reyes-Sandoval A Hill A.V.S Hill AVS Reyes-Sandoval A McShane H Hill AVS Reyes-Sandoval A Hill AVS Draper SJ Hill AVS Gilbert SC Hill AVS Gilbert SC Hill AVS Draper SJ Gilbert SC Hill AVS Gilbert SC Hill AVS Gilbert SC Gilbert SC					Atcheson (2018) Atcheson (2018) Bauza et al (2014) Betts et al (2012) Betts et al (2012) Betts et al (2012) Biswas et al (2014) Biswas et al (2014) Carey et al (2013) Ge Barra et al (2014) de Barra et al (2014) de Cassan et al (2011) de Cassan et al (2011) Dicks et al (2012)	This work was supported by The work was funded by a We The work was funded by a We The work was funded by a We The work was funded by We Funding was provided by NEW This work was supported by this work was supported by Er This work wassupported by Er The study was funded by a grathe study was funded by a grathe study was funded by a grathe Sc.C.d.C. is a Ph.D. student sup S.C.d.C. is a Ph.D. student sup This work has been funded by
	Jenner Institute	Reyes-Sandoval A Hill A.V.S Hill AVS Reyes-Sandoval A McShane H Hill AVS Reyes-Sandoval A Hill AVS Reyes-Sandoval A Hill AVS Graper SJ Hill AVS Gilbert SC Hill AVS					Atcheson (2018) Atcheson (2018) Bauza et al (2014) Betts et al (2012) Betts et al (2012) Betts et al (2012) Biswas et al (2014) Biswas et al (2014) Carey et al (2013) Carey et al (2013) de Barra et al (2014) de Cassan et al (2011) de Cassan et al (2011) Dicks et al (2012) Dicks et al (2015)	This work was supported by The work was funded by a We Funding was provided by NEW Funding was provided by NEW Funding was provided by NEW This work was supported by this work was supported by this work was supported by ET This work was supported by ET The study was funded by a grant study was funded by a gra
	Jenner Institute	Reyes-Sandoval A Hill A.V.S Hill AV.S Hill AV.S Hill AVS Reyes-Sandoval A McShane H Hill AVS Reyes-Sandoval A Hill AVS Gilbert SC Hill AVS Gilbert SC Hill AVS Gilbert SC Hill AVS Gilbert SC					Atcheson (2018) Atcheson (2018) Bauza et al (2014) Betts et al (2012) Betts et al (2012) Betts et al (2012) Betts et al (2012) Biswas et al (2014) Carey et al (2013) Carey et al (2013) Carey et al (2013) de Barra et al (2014) de Cassan et al (2011) de Cassan et al (2011) Dicks et al (2012) Dicks et al (2015)	This work was supported by The work was funded by a We Funding was provided by NEW This work was supported by the This work was supported by Er This work wassupported by Er The study was funded by a grand the study was funded by the study was funded by the study was been funded by this work has been funded by this work has been funded by
	Jenner Institute	Reyes-Sandoval A Hill A.V.S Hill AVS Reyes-Sandoval A McShane H Hill AVS Reyes-Sandoval A Hill AVS Reyes-Sandoval A Hill AVS Gibert SC Hill AVS Gilbert SC Hill AVS Draper SJ Gilbert SC Hill AVS Gilbert SC					Atcheson (2018) Atcheson (2018) Bauza et al (2014) Betts et al (2012) Betts et al (2012) Betts et al (2012) Betts et al (2012) Biswas et al (2014) Biswas et al (2014) Carey et al (2013) Carey et al (2013) de Barra et al (2014) de Cassan et al (2011) Dicks et al (2012) Dicks et al (2015) Dicks et al (2015) Draper et al (2015)	This work was supported by The work was funded by a We Funding was provided by NEW Funding was provided by ET his work was supported by the This work was supported by ET This work wassupported by ET This work was funded by a grant Study was funded by a grant Study was funded by This work has been funded by This work was funded by the New Yellow Washing W
	Jenner Institute	Reyes-Sandoval A Hill A.V.S Hill AVS Reyes-Sandoval A McShane H Hill AVS Reyes-Sandoval A Hill AVS Reyes-Sandoval A Hill AVS Graper SJ Hill AVS Gilbert SC Hill AVS Draper SJ Gilbert SC Hill AVS					Atcheson (2018) Atcheson (2018) Bauza et al (2014) Betts et al (2012) Betts et al (2012) Betts et al (2012) Biswas et al (2014) Biswas et al (2014) Carey et al (2013) Carey et al (2013) de Barra et al (2014) de Cassan et al (2014) de Cassan et al (2011) Dicks et al (2015) Dicks et al (2015) Dicks et al (2015) Draper et al (2010) Draper et al (2010)	This work was supported by The work was funded by a We Funding was provided by NEW Funding was provided by NEW Funding was provided by NEW This work was supported by the This work was supported by the This work was supported by ET The study was funded by a grace of the Study was funded by the Student supported by ET The study was funded by a grace of the Student supported by ET The study was funded by a grace of the Student supported by ET The study was funded by This work has been funded by This work was funded by This work was funded by the Nork was funded by t
	Jenner Institute	Reyes-Sandoval A Hill A.V.S Hill AVS Reyes-Sandoval A McShane H Hill AVS Reyes-Sandoval A Hill AVS Reyes-Sandoval A Hill AVS Draper SJ Hill AVS Gilbert SC Hill AVS Hill AVS Hill AVS Hill AVS					Atcheson (2018) Atcheson (2018) Bauza et al (2014) Betts et al (2012) Betts et al (2012) Betts et al (2012) Biswas et al (2014) Biswas et al (2014) Garey et al (2013) Garey et al (2013) de Barra et al (2014) de Cassan et al (2011) dic Cassan et al (2011) Dicks et al (2012) Dicks et al (2015) Dicks et al (2015) Draper et al (2015) Draper et al (2010) Dual et al (2010)	This work was supported by The work was funded by a We Funding was provided by NEW Funding was provided by NEW Funding was provided by NEW This work was supported by this work was supported by this work was supported by ET This work was supported by ET The study was funded by a grangle of the study was funded by This work has been funded by This work was funded by the this work was funded by the this study was conducted witl
	Jenner Institute	Reyes-Sandoval A Hill A.V.S Hill AVS Reyes-Sandoval A McShane H Hill AVS Reyes-Sandoval A Hill AVS Reyes-Sandoval A Hill AVS Graper SJ Hill AVS Gilbert SC Hill AVS Draper SJ Gilbert SC Hill AVS					Atcheson (2018) Atcheson (2018) Bauza et al (2014) Betts et al (2012) Betts et al (2012) Betts et al (2012) Biswas et al (2014) Biswas et al (2014) Carey et al (2013) Carey et al (2013) de Barra et al (2014) de Cassan et al (2014) de Cassan et al (2011) Dicks et al (2015) Dicks et al (2015) Dicks et al (2015) Draper et al (2010) Draper et al (2010)	This work was supported by The work was funded by a We Funding was provided by NEW Funding was provided by NEW This work was supported by the This work was supported by the This work was supported by the This work was supported by ET The study was funded by a grace of the Study was funded by a grace of the Study was funded by a grace of the Study was funded by the Student supported by ET The study was funded by a grace of the Student supported by ET The study was funded by a grace of the Student supported by ET The study was funded by This work has been funded by This work was funded by the Nork wa

-	Jenner Institute	Hill AVS	-	-
-	Jenner Institute	Draper SJ	-	-
-	Jenner Institute	Hill AVS	-	-
-	Jenner Institute	Draper SJ	-	-
-	Jenner Institute	Gilbert SC	-	-
-	Jenner Institute	Reyes-Sandoval A	-	-
-	Jenner Institute	Hill AVS	-	-
-	Jenner Institute	Draper SJ	-	-
-	Jenner Institute	Draper SJ	-	-
-	Jenner Institute	Hill A.V.S	-	-
-	Jenner Institute	Barnes E	-	-
-	Jenner Institute	Gilbert SC	-	-
-	Jenner Institute	Hill AVS	-	-
_	Jenner Institute	Hill AVS	_	-
-	Jenner Institute	Hill A.V.S	_	-
_	Jenner Institute	Draper SJ	-	_
	Jenner Institute	Hill AVS	_	
	Jenner Institute	Draper SJ		
_	Jenner Institute	Biswas S	_	_
_	Jenner Institute	Reyes-Sandoval A	_	_
-	Jenner Institute	Hill AVS	-	-
-			-	-
-	Jenner Institute	Gilbert SC	-	-
-	Jenner Institute	Hill AVS	-	-
-	Jenner Institute	Draper SJ	-	-
-	Jenner Institute	Gilbert SC	-	-
-	Jenner Institute	Draper SJ	-	-
-	Jenner Institute	Draper SJ	-	-
-	Jenner Institute	Gilbert S.C.	-	-
-	Jenner Institute	Charleston B	-	-
-	Jenner Institute	A.V.S Hill	-	-
-	Jenner Institute	Barnes E	-	-
-	Jenner Institute	Hill AVS	-	-
-	Jenner Institute	Hill A.V.S	-	-
-	Jenner Institute	Draper AD	-	-
-	Jenner Institute	Douglas SJ	-	-
-	Jenner Institute	Hill AVS	-	-
-	Jenner Institute	Gilbert SC	-	-
_	Jenner Institute	Hill AVS	-	-
_	Jenner Institute	Gilbert SC	-	-
_	Jenner Institute	Charleston B	_	
	Jenner Institute	Hill AVS		1
-	Jenner Institute	Gilbert S.C.	-	-
-			-	-
-	Jenner Institute	Douglas AD	-	-
-	Jenner Institute	Rollier C	-	-
-	Jenner Institute	Hill A.V.S.	-	-
-	Jenner Institute	Gilbert S.C.	-	-
-	Jenner Institute	Gilbert S.C.	-	-
-	Jenner Vaccine Foundation	-	-	-
RC16/093	KAIMRC	Naif Khalaf Alharbi	-	-
HI15C2971	Korean Ministry of Health and Welfare	-	-	-
-	Lister Institute	Draper SJ	-	-
-	Lister Institute	Draper SJ	-	-
-	Lister Institute	Draper SJ	-	-
-	Lister Institute	Draper SJ	-	-
-	Lister Institute	Draper SJ	-	-

Liid3 et ai (2013)	This work was supported by ti
Elias et al (2013)	This work was supported by the
Ewer et al (2013)	The study was funded by gran
Ewer et al (2013)	The study was funded by gran
Ewer et al (2013)	The study was funded by gran
Ewer et al (2013)	The study was funded by gran
Forbes et al (2012)	This work was funded by the \
Forbes et al (2012)	This work was funded by the \
Goodman et al (2011)	This work was supported prim
Goodman et al (2011)	This work was supported prim
Kelly et al (2016)	Supported by a Medical Resea
Lambe et al (2013)	AvL was funded by a fellowsh
Longley et al (2015)	This work has been funded by
Longley et al (2017)	Funding for manufacture and
Payne (2017)	This work was supported by a
Payne (2017)	This work was supported by a
Payne et al (2017)	This work was supported by fu
Payne et al (2017)	This work was supported by fu
Payne et al (2017)	This work was supported by fu
Salman et al (2017)	The work was funded by a We
Salman et al (2017)	The work was funded by a We
Sheehy et al (2011)	This work was supported by the
Sheehy et al (2011)	This work was supported by the
Sheehy et al (2011)	This work was supported by the
Sheehy et al (2012 - 2)	This work was supported by the
Sheehy et al (2012 - 2)	This work was supported by the
Sheehy et al (2012)	This work was supported by
Stedman (2019)	This study was funded by the
Stedman (2019)	This study was funded by the
Stedman (2019)	This study was funded by the
Swadling (2016)	Supported by the Medical Res
Walker et al (2015)	Andrew S. Walker, José Loure
Wang (2018)	This work has been supported
Wang (2018)	This work has been supported
Wang (2018)	This work has been supported
Warimwe et al (2013)	This work was supported by a
Warimwe et al (2013)	This work was supported by a
Warimwe et al (2016)	This work was conducted with
Warimwe et al (2016)	This work was conducted with
Warimwe et al (2016)	This work was conducted with
Sheehy et al (2012 - 2)	This work was supported by the
Alharbi (2019)	This study is funded by KAIMR
Fedosyuk S (2019)	This work was supported by N
Rollier C (2020)	This work was funded by a gra
Rollier C (2020)	This work was funded by a gra
Rollier C (2020)	This work was funded by a gra
van Doremalen N (2019)	This work was supported by the
Reyes-Sandoval (2010)	Work in the Oxford malaria va
Alharbi (2019)	This study is funded by KAIMR
Folegatti P.M.(2020)	UK Department of Health and
Biswas et al (2014)	This work was supported by the
Elias et al (2013)	This work was supported by the
Payne (2017)	This work was supported by a
Payne et al (2017)	This work was supported by fu
Carey et al (2013)	This work wassupported by Er

This work was supported by th

Elias et al (2013)

	Lister Institute	Douglas SJ					Wang (2018)	This work has been supported
-	Malaria Vaccine Initiative	Douglas 31	-	-			de Barra et al (2014)	The study was funded by a gra
•	Malaria Vaccine initiative  Malaria Vaccine Vaccines Consortium	,	-	-			Ogwang et al (2015)	This work was funded by the I
- MEST-CT-2005-	Maiaria vectored vaccines consortium	( -	-	-			Ogwang et al (2013)	This work was fullued by the t
020492	MalParTraining	Biswas S					Draper et al (2011)	SB was funded by MalParTrain
G0600424			Sep 06 - Oct 09	5150.000		150.000.00		•
00000424	Medical Research Council	Anna Louise Goodman	3ep 06 - Oct 09	£159,968	£	159,968.00	Goodman et al (2011)	This work was supported prim
-	Meningitis UK	Rollier CS	-	-				OWe thank the Jenner Institu
-	Merck KGaA	- D	-	-			Fedosyuk S (2019)	This work was supported by N
-	Merton College, Oxford	Draper SJ	-	-			Draper et al (2010)	This work was funded by the \
-	Merton College, Oxford	Draper SJ	-	-			Draper et al (2011)	SB was funded by MalParTrain
-	MEWA, Saudi Arabia MRC	-	-	-			Alharbi (2019) Bowyer (2018)	This study is funded by KAIMR The clinical trial was supporte
-	MRC	-	-	-	-		Coughlan L (2018)	Medical Research Council UK,
•	MRC	Juthathip Mongkolsapaya	-	-	-		Lopez-Camacho (2018)	This report is independent res
-	MRC	Jutilatilip Moligkoisapaya	-	-	-		Mensah (2017)	This work was supported by a
•	MRC	- Warimwe GM	-	-	-		Munster (2017)	This work was supported by a
_	MRC	-		-			Venkatraman N (2019)	This work was supported
MC UU 12014	MRC	Patel AH, Kohl A	_		_		Lopez-Camacho (2018)	This report is independent res
MR/P017339/1	MRC	Alexander Donald Douglas	Apr 17 - Mar 22	£2,228,194	£	2,228,194.00		·
MR/P017339/1 MR/P017339/1	MRC	Alexander Donald Douglas		£2,228,194	£	2,228,194.00	Fedosyuk S (2019)	This work was supported by N This work has been supported
			Apr 17 - Mar 22					• • • • • • • • • • • • • • • • • • • •
MR/N019008/1	MRC	Reyes-Sandoval A	Aug 16 - Feb 22	£1,792,688	£		Atcheson (2018)	The work was funded by a We
MR/N019008/1	MRC	Reyes-Sandoval A	Aug 16 - Feb 22	£1,792,688			Salman et al (2017)	The work was funded by a We
G0701669	MRC	Tomas Hanke	Oct 08 - Oct 12	£1,300,519	£		Borthwick et al (2014)	The work was supported by
MR/L009528/1	MRC	Thomas Alexander Bowden		£1,144,287	£		van Doremalen N (2019)	This work was supported by the
G1000527	MRC	Draper SJ	Aug 10 - Jul 15	£1,104,645			Biswas et al (2014)	This work was supported by the
G1000527	MRC	Draper SJ	Aug 10 - Jul 15	£1,104,645	£		Carey et al (2013)	This work wassupported by Er
G1000527	MRC	Draper SJ	Aug 10 - Jul 15	£1,104,645	£		Elias et al (2013)	This work was supported by the
G1000527	MRC	Draper SJ	Aug 10 - Jul 15	£1,104,645	£		Sheehy et al (2012 - 2)	This work was supported by the
G1100086	MRC	Simon Draper	Jul 11 - Jun 14	£895,438	£		Payne (2017)	This work was supported by a
G0700735	MRC	Adrian Hill	Jan 08 - Dec 10	£748,840	£	748,840.00	Biswas et al (2014)	This work was supported by the
G0700735	MRC	Adrian Hill	Jan 08 - Dec 10	£748,840	£	748,840.00	Elias et al (2013)	This work was supported by th
MR/N006372/1	MRC	Sarah Catherine Gilbert	Mar 16 - May 18	£679,559	£	679,559.00	Asthagiri Arunkumar (201	9 The study was fundedby an M
MC_PC_13073	MRC	Chas Bountra	Mar 14 - Sep 15	£650,000	£	650,000.00	Wang (2018)	This work has been supported
G0502018	MRC	Adrian Hill	Oct 06 - Jan 09	£647,586	£	647,586.00	O'Hara et al (2012)	Financial support. This work w
		Andrew Michael						This work was supported, in p
MR/N00227X/1	MRC	Blagborough	Jan 16 - Apr 19	£549,297	£	549,297.00	Yoshida Klyori (2018)	
MC_PC_15040	MRC	Stephen Ward	Mar 16 - Feb 18	£500,000	£	500,000.00	Sebastian S (2020)	This research was funded by I
G0701694	MRC	Eleanor Barnes	Aug 09 - Jul 12	£250,000	£	250,000.00	Kelly et al (2016)	Supported by a Medical Resea
G0701694	MRC	Eleanor Barnes	Aug 09 - Jul 12	£250,000	£	250,000.00	Swadling (2016)	Supported by the Medical Res
MR/N017552/1	MRC	Kohl A	Jan 16 - Jan 19	£221,947	£	221,947.00	Lopez-Camacho (2018)	This report is independent res
G0600424	MRC	SJD	-	-	£	159,968.00	Goodman et al (2011)	This work was supported prim
G0600424	MRC	Goodman A	Sep 06 - Oct 09	£159,968	£	159,968.00	Ewer et al (2013)	The study was funded by gran
-	MRC	-	- '	-			Afolabi et al (2016)	Trials Partnership (EDCTP) and
-	MRC	-	-	-			Antrobus et al (2014)	The study was funded by gran
-	MRC	-	-	-			Barnes et al (2012)	European Union (Framework '
-	MRC	Jones EY	-	-			Bauza et al (2014)	The work was funded by a Wε
-	MRC	Malinauskas T	-	-			Bauza et al (2014)	The work was funded by a We
-	MRC	-	-	-			Bowyer G (2020)	The Oxford clinical trial was s
-	MRC	Stribbling S	-	-			Capuccini et al (2016)	This work was supported by O
-	MRC	Stribbling S	-	-			Capuccini et al (2017)	This work was supported by C
-	MRC	Bartiromo M	-	-			Colloca et al (2012)	This work was supported in pa
-	MRC	-	-	-			Ewer et al (2013)	The study was funded by gran
-	MRC	Draper SJ	-	-			Forbes et al (2012)	This work was funded by the \

	1400	D				C (2011)	<b>This is a second of the secon</b>
-	MRC	Draper SJ	-	-		Goodman et al (2011)	This work was supported prim
-	MRC	Goodman AL	-	-		Goodman et al (2011)	This work was supported prim
-	MRC	Barnes E	-	-		Kelly et al (2016)	Supported by a Medical Resea
-	MRC	-	-	-		Kimani et al (2014)	This work was supported by
-	MRC	-	-	-		Mensah et al (2016)	This study was supported by a
-	MRC	-	-	-		Ogwang et al (2013)	This work was performed by t
-	MRC	-	-	-		Swadling (2016)	Supported by the Medical Res
-	MRC	Swadling L	-	-		Swadling (2016)	Supported by the Medical Res
-	MRC	Barnes E	-	-		Swadling (2016)	Supported by the Medical Res
-	MRC	-	-	-		Swadling et al (2014)	Funding:Supported by the Me
-	MRC	Barnes E	-	-		Swadling et al (2014)	Funding:Supported by the Me
-	MRC	Swadling L	-	-		Swadling et al (2014)	Funding:Supported by the Me
-	MRC	-	-	-		Tapia et al (2016)	This study was funded by a W
-	MRC	-	-	-		Ewer et al (2016)	Supported by the Wellcome T
-	MRC	Swadling L	-	-		Kelly et al (2016)	Supported by a Medical Resea
G0600311	MRC	-	-	-		Pearson et al (2013)	This work has been supported
G0600311	MRC	-	-	-		Pearson et al (2015)	This study was funded by Ente
G0600424	MRC	ALG	Sep 06 - Oct 09	£159,968		Goodman et al (2011)	This work was supported prim
G0700735	MRC	_	-	-		Sheehy et al (2011)	This work was supported by th
G1000157	MRC	Draper SJ	_	_		Sheehy et al (2011)	This work was supported by th
G1000137 G1000527	MRC	Draper SJ	_	_		de Cassan et al (2011)	S.C.d.C. is a Ph.D. student sup
MR/K017632/1)	MRC	Alanine DGW		_		Payne et al (2017)	This work was supported by fu
U117532067	MRC	Holder AA				Draper et al (2011)	SB was funded by MalParTrail
-	MRC and DFID	-		_		Afolabi et al (2016)	Trials Partnership (EDCTP) and
•	WINC and DEID	•	-			Aloiabi et al (2010)	mais Faithership (EDCIF) and
_	MRC and DFID		_	_		Afolabi et al (2016)	Trials Partnership (EDCTP) and
_	MRC and DFID	Bejon P	_	_		Ogwang et al (2015)	This work was funded by the E
	National Cancer Institute	-		_		Tapia et al (2016)	This study was funded by a W
P51 RR000167	National Center for Research Resources			_		Rollier C (2020)	This work was funded by a gra
RR020141	National Center for Research Resources		•	-		Rollier C (2020)	This work was funded by a gra
RR15459	National Center for Research Resources			_		Rollier C (2020)	This work was funded by a gra
P51 RR000167	National Centre for Research Resources		•	-		Spencer et al (2014)	This work has been funded by
RR020141	National Centre for Research Resources		-			Spencer et al (2014)	This work has been funded by
RR15459	National Centre for Research Resources		•	-		Spencer et al (2014)	This work has been funded by
-	National Health Service Blood and Trans					Ewer et al (2016)	Supported by the Wellcome T
_	National Insitute of Health and Research		-			Tiono (2018)	This work was supported by a
	National Institute of Allergy and Infectiou			_		Sheehy et al (2012 - 2)	This work was supported by the
_	National Institute for Health and Resear		-			Barnes et al (2012)	European Union (Framework)
•	National Institute for Health Research		•	-		Bowyer G (2020)	The Oxford clinical trial was s
•	National Institute for Health Research	_	1	-		de Cassan et al (2011)	S.C.d.C. is a Ph.D. student sup
•	National Institute for Health Research	<u>-</u>	1-	-		Folegatti P.M.(2020)	UK Department of Health and
•	National Institute for Health Research		•	-		Rollier C (2020)	This work was funded by a gra
•		Hill A.V.S.	•	-		Rollier C (2020)	This work was funded by a gra
	National Institute for Health Research	Tilli A.V.3.				van Doremalen N (2020)	This work was supported by th
•	National Institute for Health Research		•	-		van Doremalen N (2020)	This work was supported by the
•	National Institute of Allergy and Infectio		•	-		Sheehy et al (2012)	This work was supported by
- LUCN 272201400009C	National Institute of Allergy and Infectio		09/01/2014	¢79 100 000	0.72 £ 56,232,000.00		Development of SARS-CoV-2 r
	National Institute of Allergy and Infectio		05/01/2014	-	0.72 L 30,232,000.00	Biswas et al (2014)	This work was supported by the
-	National Institute of Allergy and Infectio		-	_		Sheehy et al (2014)	This work was supported by the
-	National Institute of Allergy and Infectio		-	-		Tapia et al (2011)	This study was funded by a W
-			-	-			
- UUCNI261200000001F	National Institute of Allergy and Infectio		-	-		Tapia et al (2016)	This study was funded by a W
R44AI058375	National Institute of Allergy and Infectio		-	-		Tapia et al (2016)	This study was funded by a W
1,444II0303/3	National Institute of Allergy and Infectio	·-	-	-		Longley et al (2017)	Funding for manufacture and
	National Institute of Allergy and					D	CD formated by Mail D. T
	Infectious Diseases		-	-		Draper et al (2011)	SB was funded by MalParTrai

	ALASTA ALIAN SALAMAN AND AND AND AND AND ALIAN SALAMAN AND AND AND AND AND AND AND AND AND A						D	TIO
	National Institute of Allergy and Infection		-	-			Payne et al (2017)	This work was supported by fu
	National Institute of Allergy and Infection		-	-			van Doremalen N (2019)	This work was supported by the
-	National Institute of Allergy and Infection		-	-			van Doremalen N (2020)	This work was supported by the
-	National Institute of Allergy and Infection		-	-			van Doremalen N (2020)	This work was supported by the
HHSN2/2201400008C	National Institute of Allergy and Infection	) -	-	-			van Doremalen N (2020)	This work was supported by the
-	National Institute of Health	-	-	-			Biswas et al (2014)	This work was supported by the
-	National Institute of Health	-	-	-			Folegatti P.M. (2019)	This research was funded by I
-	National Institute of Health	Hill A.V.S	-	-			Gola (2018)	A.G. is funded by the Wellcom
-	National Institute of Health National Institute of Health	-	-	-			Reyes-Sandoval (2010) Rollier C (2020)	Work in the Oxford malaria va This work was funded by a gra
•	National Institute of Health	-	-	-			Sheehy et al (2012)	This work was supported by
•		-	-	-				
-	National Institute of Health	-	-	-			Sheehy et al (2012 - 2)	This work was supported by the
HHSN2/2201400008C	National Institute of Health	-	-	-			Bliss (2020)	This research project was sup
	National Institute of Health		-	-			Draper et al (2011)	SB was funded by MalParTrain
HILL05GCGH0	National Institute of Health		-	-			Spencer et al (2014)	This work has been funded by
-	National Institute of Health and Research		-	-			Bowyer (2018)	The clinical trial was supporte
-	National Institute of Health and Research		-	-			Coughlan L (2018)	Medical Research Council UK,
-	National Institute of Health and Research		-	-			Venkatraman N (2019)	This work was supported
-	National Institute of Health and Research		-	-			Bliss (2018)	This study was funded by the
-	National Institutes of Allergy and Infecti		-	-			Forbes et al (2012)	This work was funded by the \
1ZIAAI001179-01	National Institutes of Health	MUNSTER, VINCENT		2013 \$877,861	0.72 £	632,059.92	van Doremalen N (2020)	This work was supported by the
-	National Institutes of Health	-	-	-			Forbes et al (2012)	This work was funded by the \
-	National Institutes of Health	-	-	-			Sheehy et al (2011)	This work was supported by the
-	National Institutes of Health, National In		-	-			Hodgson et al (2014)	This work was supported by the
-	NDM	Biswas S	-	-			Biswas et al (2014)	This work was supported by th
26-6.	NEKKEN	Iyori M		2014 -			Yoshida Klyori (2018)	This work was supported, in p
27-5.	NEKKEN	Iyori M		2015 -			Yoshida Klyori (2018)	This work was supported, in p
EC FP7	NEWTBVAC	-	-	-			Betts et al (2012)	Funding was provided by NEW
1041802		McCarthy JS	-	-			Payne (2017)	This work was supported by a
10418020		McCarthey JS	-	-			Payne et al (2017)	This work was supported by fu
5T32AI007647-17	NIAID	PALESE, PETER		04-May-16 \$523,884	0.72 £	377,196.48	Asthagiri Arunkumar (2019	The study was fundedby an M
1R03AI142046-01	NIAID	ALBRECHT, RANDY A.		01-Dec-18 \$84,750	0.72 £	61,020.00	McHanon M (2019)	The study was fundedby an M
-	NIAID	Gola A	-	-			Gola (2018)	A.G. is funded by the Wellcon
-	NIAID	Uderhardt S	-	-			Gola (2018)	A.G. is funded by the Wellcon
-	NIAID	Germain RN	-	-			Gola (2018)	A.G. is funded by the Wellcon
-	NIAID	-	-	-			Munster (2017)	This work is published withthe
AI109946	NIAID	-	-	-			McHanon M (2019)	The study was fundedby an M
HHSN272201400008C	NIAID	-	-	-			Asthagiri Arunkumar (2019	The study was fundedby an M
HHSN272201400008C	NIAID	-	-	-			McHanon M (2019)	The study was fundedby an M
1U19AI082630-01	NIH	CHUNG, RAYMOND T		07-Jun-09 \$3,086,377	0.72 £	2,222,191.44	Barnes et al (2012)	European Union (Framework '
2U19AI082630-06	NIH	CHUNG, RAYMOND T		30-May-14 \$2,351,111	0.72 £	1,692,799.92	Kelly et al (2016)	Supported by a Medical Resea
-	NIH	-	-	-			Munster (2017)	This work is published withthe
2U19AI082630-06	NIH	Klenerman P	-	-			Kelly et al (2016)	Supported by a Medical Resea
2U19AI082630-06	NIH	Kelly C	_	-			Swadling (2016)	Supported by the Medical Res
2U19AI082630-06	NIH	Klenerman P	_	_			Swadling (2016)	Supported by the Medical Res
HILL05GCGH0	NIH	-	_	_			Dicks et al (2015 - 2)	This work has been funded by
-	NIH foundation	-	_	-			Dicks et al (2012)	This work has been funded by
-	NIHR	_	_	_			Mensah (2017)	This work was supported by a
-	NIHR	_	_	_			Payne (2017)	This work was supported by a
-	NIHR	Hill AVS	_	_			Walker et al (2015)	Andrew S. Walker, José Loure
-	NIHR	Hill AVS	-	-			Ewer et al (2013)	The study was funded by gran
-	NIHR		_	-				OWe thank the Jenner Institu
-	NIHR (Oxford Biomedical Research Cent	1-	_	-			O'Hara et al (2012)	Financial support. This work w
	,						()	

AQ1301 Adult Vaccine	NIHR (through Oxford Biomedical Resea	_	_	_
AJIJOI Addit Vaccine	NIHR Oxford Biomedical Research Centr			
•	NIHR Oxford Biomedical Research Centr		•	-
•	NIHR Oxford Biomedical Research Centr		•	-
-			-	-
-	NIHR Oxford Biomedical Research Centr		-	-
-	NIHR Oxford Biomedical Research Centr		-	-
084113/Z/07/Z	NIHR Oxford Biomedical Research Centr		-	-
A91301 Adult Vaccine	NIHR Oxford Biomedical Research Centr	1-	-	-
A91301 Adult Vaccine	NIHR Oxford Biomedical Research Centr	ı <b>-</b>	-	-
A91301 Adult Vaccine	NIHR Oxford Biomedical Research Centr	ı-		-
A91301 Adult Vaccine	NIHR Oxford Biomedical Research Centr	ı <del>-</del>	-	_
AQ1301 Adult Vaccine	NIHR Oxford Biomedical Research Centr	1-	_	_
AJIJOI Addit Vaccine	Willin Oxford Biolifedical Nesearch Centi	,-	-	_
A91301 Adult Vaccine	NIHR Oxford Biomedical Research Centr	1-	-	-
A91301,Adult Vaccine	NIHR Oxford Biomedical Research Centr	1-	-	-
-	NIHR Oxford BRC	-	-	-
-	NIHR Oxford BRC	-	-	-
-	NIHR Oxford BRC	-	-	-
-	NIHR Oxford BRC	-		-
-	NIHR Oxford BRC	_	_	-
_	NIHR Oxford BRC	Kelly C		_
	NIHR Oxford BRC	Klenerman P		
-			-	-
-	NIHR Oxford BRC	Barnes E	-	-
91301 Adult Vaccine	NIHR Oxford BRC	-	-	-
58-5348-2-117F	Norman Borlaug Commemorative Resea	1-	-	-
-	Nuffield Department of Medicine	Reyes-Sandoval A	-	-
-	Nuffield Department of Medicine	Longley RJ	-	-
-	Nuffield Department of Medicine	Longley RJ	-	-
-	Oak Foundation	-	-	-
16/107/05	ODA budget	Reyes-Sandoval A, Patel AH	_	_
10, 107, 05	Ohyama Health Foundation	-		_
_	Oxford Biomedical Research Centre	_		_
	Oxford Biomedical Research Centre	Rollier CS		
-	Oxford Martin Institute		-	-
-		Spencer AJ	-	-
-	Oxford Martin Institute	Hill AVS	-	-
-	Oxford Martin School	Reyes-Sandoval A	-	-
-	Oxford Martin School	Hill A.V.S	-	-
-	Oxford Martin School	Reyes-Sandoval A	-	-
-	Oxford Martin School	-	-	-
-	Oxford Martin School	Barnes E	-	-
-	Oxford Martin School	Lambe T	-	-
-	Oxford Martin School	Spencer AJ	-	-
-	Oxford Martin School	Reves-Sandoval A	-	_
-	Oxford Martin School	Barnes E	-	-
_	Oxford Martin School	Hill AVS	_	_
_	Oxford Martin School	-	_	_
	Oxford Martin School	Spancar Al		
-		Spencer AJ	-	-
-	Oxford Martin School	Cottingham MG	-	-
-	Oxford Martin School	Cottingham MG	-	-
-	Oxford Martin Schools	Barnes E	-	-

Sheehy et al (2011) Antrobus et al (2014) Cottingham et al (2012) Elias et al (2013) Swadling et al (2014) Ewer et al (2013) Biswas et al (2014) de Barra et al (2014) Kimani et al (2014)	This work was supported by the The study was funded by gran This work was supported by the This work was supported by the Funding: Supported by the Merice Study was funded by gran This work was supported by the Study was funded by a gran This work was supported by the Study was funded by a gran This work was supported by the Study was funded by a gran This work was supported by
Ogwang et al (2013) Sheehy et al (2012 - 2)	This work was performed by t This work was supported by th
Sheehy et al (2012)	This work was supported by
Hodgson et al (2014)	This work was supported by the
Longley et al (2015) Longley et al (2017) Stedman (2019) Lopez-Camacho (2018) Yoshida Klyori (2018) de Cassan et al (2011)	This work was supported by the This work was supported by C Supported by the Wellcome T Funding for manufacture and This work was supported by the Supported by the Medical Res Supported by the Inis work was funded by the I owe thank the Jenner Institu This work has been funded by Funding for manufacture and This study was funded by the This report is independent res This work was supported, in p S.C.d.C. is a Ph.D. student suplow thank the Jenner Institu Funding for manufacture and The work was funded by a We This work was supported by the Medical Resea Avl. was funded by a Fellowsh This work has been funded by The work was funded by a We Supported by the Medical Resea The work was funded by a We Supported by the Medical Resea The work was funded by a We Supported by the Medical Resea The work was funded by a We Supported by the Medical Resea The work was funded by a We
Antrobus et al (2014) Dicks et al (2015) Dicks et al (2015) Dicks et al (2012) Swadling et al (2014)	The study was funded by gran This work has been funded by This work has been funded by This work has been funded by Funding:Supported by the Mei

Mary Number	-	PATH Malaria Vaccine Initiative	-	-	-			Forbes et al (2012)	This work was funded by the \
Marth Malaria Vaccine Institutive	_		_	_	_				· · · · · · · · · · · · · · · · · · ·
PATH Malaria Vaccine Institutive	_		_	_	_			. ,	• • • • • • • • • • • • • • • • • • • •
PATH Malaria Vaccine Initiative	_		-	_	_				·
PATH Malaria Vaccine Initiatative   -	_		_	_	_				
PATH Malaria Vaccine Initiative   More   Security	_		_	-	-				
PATH Malaria Vaccine initiatative	-		-	-	-				• • • • •
PATH-MW Malaria Vaccine Initiative	-	PATH MalariaVaccine Initiative	-	-	-				
Public Health England	-		-	-	-				
Rhodes Trust		PATH-MVI Malaria Vaccine Initiative	-	-	-			Draper et al (2011)	SB was funded by MalParTrain
Robes Trust	-	Public Health England	-	-	-			Ewer et al (2016)	Supported by the Wellcome T
Robes Trust	-	ReiThera (formerly Okairos)	Nicosia A	-	-			Mensah et al (2016)	This study was supported by a
	-	Rhodes Trust	-	-	-				
Science Foundation Ireland	-	Rhodes Trust	Longley RJ	-	-			Longley et al (2017)	Funding for manufacture and
NAP156   Science Foundation Ireland	-	Rhodes Trust	Llewellyn D	-	-			Payne (2017)	This work was supported by a
Second   S	-	Science Foundation Ireland	-	-	-			Carey et al (2013)	This work wassupported by Er
Southampton NIHR Wellome Trust Clin	NAP156	Science Foundation Ireland	-	-	-			Pearson et al (2015)	This study was funded by Ente
Southampton NiIRK Wellcome Trust Clin	NAP170	Science Foundation Ireland	-	-	-			Pearson et al (2015)	This study was funded by Ente
Spanish Ministry of Science	-	Southampton NIHR Wellcome Trust Clini	-	-	-			Sheehy et al (2012)	This work was supported by
Spanish Ministry of Science   Lopez-Gil E   Copez-Gil E	-	•	-	-	-				
AGIZ011-22485   Spanish Ministry of Science   Brun AV	AGL2017-82570-R	· ·	-		-				
St Catherine's College, Oxford   Biswas S   Swedish International Development Cool   Swedish International Developmen	-		•	-	-			• •	• • • • •
Swedish International Development Coo -	AGL2011-22485	· ·		-	-				
Swedish International Development Cool	-	<del>-</del> ·		-	-				
Swedish International Development Coo	-			-	-			, ,	, , , ,
Swedish International Development Coo    Fib Coalition for Epidemic Preparedness	-			-	-				
The Coalition for Epidemic Preparedness	-			-	-				
The Oxford Martin School   Rollier CS   -       Reyes-Sandoval et al (2011)   This work was supported print	•				_				
FP7   Transmolbloc		· · ·		_					•
EU FP7 Transmolbloc	FILEP7		-						
TRANSVAC			_	_	_				
UK Department for International Develor	-		_						
Project 16/107/03 UK Department of Health and Social Can- 16/107/01 UK Engineering and Physical Sciences Re:- 16/107/01 UK Medical Research Council 16/107/01 UK National Institute for Health Researc- 17/107/01 UK National Institute for Health Researc- 18/107/01 UK Research and Innovation Sarah Catherine Gilbert Apr 20 - Sep 21	-		-		-			• •	·
Project 16/107/03 UK Department of Health and Social Can- 16/107/01 UK Department of Health and Social Can- 16/107/01 UK Engineering and Physical Sciences Re:- 16/1037/56/1 UK Research Council 17/103 UK Medical Research Council 18/1037/56/1 UK Medical Research Council 19/1037/56/1 UK Research and Innovation Sarah Catherine Gilbert Apr 20 - Sep 21 f2,174,847 19/1038/56/1 UK Royal Society for Tropical Medicine a Coughlan L 19/1038/56/1 UKR Nayal Society for Tropical Medicine a Coughlan L 19/1038/56/1 UKR Nayal Society for Tropical Medicine a Coughlan L 1048/56/1038/	_			_	_				
16/107/01 UK Department of Health and Social Car- EP/R013756/1 UK Engineering and Physical Sciences Re:  UK Medical Research Council UK National Institute for Health Researc- UK National Institute for Health Researc- UK Research and Innovation Sarah Catherine Gilbert MC_PC_19055 UK Research and Innovation Sarah Catherine Gilbert WK Reyes-Sandoval A Oct 16 - Sep 17 Folegatti P.M.(2020) Work in the Oxfor malaria ve Folegatti P.M.(2020) UK Department of Health and Folegatti P.M.(2020) UK Department of Health and Work was supported by N Reyes-Sandoval (2010) Work in the Oxfor malaria ve Folegatti P.M.(2020) UK Department of Health and Folegatti P.M.(2020) UK Research and Innovation Folegatti P.M.(2020) UK Research and Innovatio	Project 16/107/03	·		-	-			, ,	• • • • • • • • • • • • • • • • • • • •
EP/R013756/1 UK Engineering and Physical Sciences Re: £6,968,179 £ 6,968,179.0 Fedosyuk S (2019) This work was supported by Nork and Institute for Health Research Council		•		-	-				
LK Research and Innovation Sarah Catherine Gilbert Apr 20 - Sep 21 £2,174,847 £ 2,174,847.0 Folegatti P.M.(2020) UK Department of Health and Apr 20 - Sep 21 £2,174,847.0 Folegatti P.M.(2020) UK Department of Health and De		•		-	£6,968,179	f	£ 6,968,179.00		•
MC_PC_19055 UK Research and Innovation Sarah Catherine Gilbert Apr 20 - Sep 21 £2,174,847 £ 2,174,847.00 Folegatti P.M.(2020) UK Research and Innovation, (1) GR000550 UK Royal Society for Tropical Medicine a Coughlan L	-	UK Medical Research Council	-	-	-	-		Reyes-Sandoval (2010)	Work in the Oxford malaria va
GR000550 UKR Royal Society for Tropical Medicine a Coughlan L Bliss (2020) This research project was sup 972216 UKRI Reyes-Sandoval A Oct 16 - Sep 17 £498,870 £ 498,870.00 Lopez-Camacho (2018) This report is independent res 1411,388.00 £ 411,388.00 £ 411,388.00 £ 411,388.00 £ 411,388.00 £ 411,388.00 £ 411,388.00 £ 400,000.00 £ 200,000 £ 200	-	UK National Institute for Health Researc	-	-	-	-		Folegatti P.M.(2020)	UK Department of Health and
972216 UKRI Reyes-Sandoval A Oct 16 - Sep 17 £498,870 £ 498,870.0 Lopez-Camacho (2018) This report is independent res UKRI Alexandar Douglas £411,388.00 £ 411,388.00 £ 411,388.00 https://www.ukri.org/research/c This COVID-19 Rapid Respons UKRI Sandy Douglas £400,000.00 £ 400,000.00 https://www.ukri.org/research/c This COVID-19 Rapid Respons Https://www.ukri.org/re	MC_PC_19055	UK Research and Innovation	Sarah Catherine Gilbert	Apr 20 - Sep 21	£2,174,847	f	£ 2,174,847.00	Folegatti P.M.(2020)	UK Research and Innovation, (
UKRI Alexandar Douglas £411,388.00 £ 411,388.00 https://www.ukri.org/research/c This COVID-19 Rapid Respons £400,000.00 £ 400,000.00 £ 400,000.00 £ 400,000.00 £ 400,000.00 £ 400,000.00 £ 400,000.00 £ 400,000.00 £ 246,000.00 £	GR000550	UK Royal Society for Tropical Medicine a	Coughlan L	-	-	-	-	, ,	This research project was sup
UKRI Sandy Douglas £400,000.00 £ 400,000.00 £ 246,000.00 S Graham (2020) UKRI Biotechnology and BiologicalScienc Simon Thomas Carpenter Apr 17 - Mar 20 £6,662,753 £ 2,665,273.00 \$ S Graham (2020) UKRI Biotechnology and BiologicalScienc Philippa Beard Apr 17 - Mar 20 £2,965,523 £ 2,965,523.00 \$ S Graham (2020) UKRI Biotechnology and BiologicalScienc Philippa Beard S Graham (2020) UKRI Biotechnology and BiologicalScienc Philippa Beard S Graham (2020) UKRI Biotechnology and BiologicalScienc Philippa Beard S Graham (2020) UKRI Biotechnology and BiologicalScienc Philippa Beard S Graham (2020) UKRI Biotechnology and BiologicalScienc Philippa Beard S Graham (2020) UKRI Biotechnology and BiologicalScienc Philippa Beard S Graham (2020) UKRI Biotechnology and BiologicalScienc Philippa Beard S Graham (2020) UKRI Biotechnology and BiologicalScienc Philippa Beard S Graham (2020) UKRI Biotechnology and BiologicalScienc Philippa Beard S Graham (2020) UKRI Biotechnology and BiologicalScienc Philippa Beard S Graham (2020) UKRI Biotechnology and BiologicalScienc Philippa Beard S Graham (2020) UKRI Biotechnology and BiologicalScienc Philippa Beard S Graham (2020) UKRI Biotechnology and BiologicalScienc Philippa Beard S Graham (2020) UKRI Biotechnology and BiologicalScienc Philippa Beard S Graham (2020) UKRI Biotechnology and BiologicalScienc Philippa Beard S Graham (2020) UKRI Biotechnology and BiologicalScienc Philippa Beard S Graham (2020) UKRI Biotechnology and BiologicalScienc Philippa Beard S Graham (2020) UKRI Biotechnology and BiologicalScienc Philippa Beard S Graham (2020) UKRI Biotechnology and BiologicalScienc Philippa Beard S Graham (2020) UKRI Biotechnology and BiologicalScienc Philippa Beard S Graham (2020) UKRI Biotechnology and BiologicalScienc Philippa Beard	972216		•	Oct 16 - Sep 17			,		
UKRI Graham Ogg £246,000.00 £ 246,000.00 £ 246,000.00 £ 246,000.00 https://www.ukri.org/rese This £246k award is to procure EBS/E/I/00007037 UKRI Biotechnology and BiologicalScienc Michael Johnson Apr 17 - Mar 20 £17,455,044 £ 17,455,044.00 \$ Graham (2020) UKRI Biotechnology and BiologicalScienc Simon Thomas Carpenter Apr 17 - Mar 20 £6,662,753 £ 2,965,523.00 \$ Graham (2020) UKRI Biotechnology and BiologicalScienc Philippa Beard Apr 17 - Mar 20 £2,965,523 £ 2,965,523.00 \$ Graham (2020) UKRI Biotechnology and BiologicalScienc Philippa Beard BiologicalScienc Philippa Beard Apr 17 - Mar 20 £2,965,523 £ 2,965,523.00 \$ Graham (2020) UKRI Biotechnology and BiologicalScienc Philippa Beard BiologicalScienc Philippa BiologicalScienc Ph			-				,		
BBS/E/I/00007037 UKRI Biotechnology and BiologicalScienc <u>Michael Johnson</u> Apr 17 - Mar 20 £17,455,044 £ 17,455,044.00 \$ Graham (2020) UKRI Biotechnology and BiologicalScienc <u>Simon Thomas Carpenter</u> Apr 17 - Mar 20 £6,662,753 £ 6,662,753.00 \$ Graham (2020) UKRI Biotechnology and BiologicalScienc <u>Philippa Beard</u> Apr 17 - Mar 20 £2,965,523 £ 2,965,523.00 \$ Graham (2020) UKRI Biotechnology and BiologicalScienc <u>Philippa Beard</u> UKRI Biotechnology and BiologicalScienc <u>Philippa Beard</u> Apr 17 - Mar 20 £2,965,523 £ 2,965,523.00 \$ Graham (2020) UKRI Biotechnology and BiologicalScienc <u>Philippa Beard</u> UKRI Biotechnology and BiologicalScienc <u>Philippa Beard</u> Apr 17 - Mar 20 £2,965,523 £ 2,965,523.00 \$ Graham (2020) UKRI Biotechnology and BiologicalScienc <u>Philippa Beard</u> UKRI Biotechnology and BiologicalScienc <u>Philippa Beard</u> Apr 17 - Mar 20 £2,965,523 £ 2,965,523.00 \$ Graham (2020) UKRI Biotechnology and BiologicalScienc <u>Philippa Beard</u> UKRI Biotechnology and BiologicalScienc <u>Philippa Beard</u> Apr 17 - Mar 20 £2,965,523 £ 2,965,523.00 \$ Graham (2020) UKRI Biotechnology and BiologicalScienc <u>Philippa Beard</u> UKRI Biotechnology and BiologicalScienc <u>Philippa Beard</u> Apr 17 - Mar 20 £2,965,523 £ 2,965,523.00 \$ Graham (2020) UKRI Biotechnology and BiologicalScienc <u>Philippa Beard</u> UKRI Biotechnology and BiologicalScience <u>Philippa Beard</u> Apr 17 - Mar 20 £2,965,523 £ 2,965,523.00 \$ Graham (2020) UKRI Biotechnology and BiologicalScience <u>Philippa Beard</u> UKRI Biotechnology and BiologicalScience <u>Philippa Beard</u> Apr 17 - Mar 20 £2,965,523 £ 2,965,523.00 \$ Graham (2020) UKRI Biotechnology and BiologicalScience <u>Philippa Beard</u> UKRI Biotechnology and BiologicalScience <u>Philippa Beard</u> Apr 17 - Mar 20 £2,965,523 £ 2,965,523.00 \$ Graham (2020) UKRI Biotechnology and BiologicalScience <u>Philippa Beard</u> UK					,		,		
BBS/E/I/00007039 UKRI Biotechnology and BiologicalScienc Simon Thomas Carpenter BBS/E/I/00007031 UKRI Biotechnology and BiologicalScienc Philippa Beard Apr 17 - Mar 20 £2,965,523 £ 2,965,523.00 \$ Graham (2020) UKRI Biotechnology and BiologicalScienc Philippa Beard BiologicalScienc Philippa Beard BiologicalScienc Philippa Beard Apr 17 - Mar 20 £2,965,523 £ 2,965,523.00 \$ Graham (2020) UKRI Biotechnology and BiologicalScienc Philippa Beard BiologicalScienc Philippa Beard BiologicalScienc Philippa Beard BiologicalScienc Philippa Beard BiologicalScience Philippa							,		•
BBS/E/I/00007031 UKRI Biotechnology and BiologicalScienc Philippa Beard Apr 17 - Mar 20 £2,965,523 £ 2,965,523.00 S Graham (2020) UKRI Biotechnology and BiologicalScienc			·	•					<del>-</del> -
· · · · · · · · · · · · · · · · · · ·		ο, σ		•	, ,	-		, ,	٥,
BBS/E/I/00007034 UKRI Biotechnology and BiologicalScienc Simon Thomas Carpenter Apr 17 - Mar 20 £2,728,186 £ 2,728,186.00 S Graham (2020) UKRI Biotechnology and Biological Science Simon Thomas Carpenter Apr 17 - Mar 20				•			,,-	, ,	
	BBS/E/I/00007034	UKKI Biotechnology and BiologicalScienc	Simon Thomas Carpenter	Apr 17 - Mar 20	£2,728,186	f	£ 2,728,186.00	S Graham (2020)	UKKI Biotechnology and Biolc

EP/R013756/1	UKRI Engineering and Physical Sciences	Tarit K Mukhopadhyay	Apr 18 - Sep 21	£6,968,179	£	6,968,179.00	S Graham (2020)	This study was supported by L
EP/S025243/1	UKRI Engineering and Physical Sciences	James Henderson Naismith	Nov 18 - May 20	£1,649,512	£	1,649,512.00	S Graham (2020)	andEPSRC Grant No. EP/S025
-	University of Oxford	-	-	-			Warimwe et al (2016)	This work was conducted with
MRF/TT2015/2150	University of Oxford	Coughlan L	-	-			Bliss (2020)	This research project was sup
	USAID	-	-	-			Payne et al (2017)	This work was supported by fu
-	Vaccine Research Center	-	-	-			Tapia et al (2016)	This study was funded by a W
-	Vaccitech Ltd	-		-			Tuthill M. (2020)	European Union Seventh Fran
-	Wellcome Trust	-	-	-			Ewer et al (2013)	The study was funded by gran
76438	Wellcome Trust	-	-	-	-		Reyes-Sandoval et al (2010	We thank the Jenner Institu
206194	Wellcome Trust	-	-	-	-		Payne et al (2017)	This work was supported by fu
-	Wellcome Trust	-	-	-	-		Bowyer G (2020)	The Oxford clinical trial was s
-	Wellcome Trust	AVSH	-	-	-		Capone et al (2010)	This work was supported by th
-	Wellcome Trust	-	-	-	-		Capone et al (2010)	This work was supported by th
-	Wellcome Trust	Hill AVS	-	-	-		Capuccini et al (2017)	This work was supported by O
-	Wellcome Trust	-	-	-	-		Reyes-Sandoval (2010)	Work in the Oxford malaria va
-	Wellcome Trust	Reyes-Sandoval A	-	-	-		Reyes-Sandoval et al (2010	) We thank the Jenner Institu
-	Wellcome Trust	-	-	-	-		Rollier C (2020)	This work was funded by a gra
-	Wellcome Trust	Hill A.V.S.	-	-	-		Rollier C (2020)	This work was funded by a gra
-	Wellcome Trust	-	-	-	-		Venkatraman N (2019)	This work was supported
084113/Z/07/Z	Wellcome Trust	-	-	-	-		Afolabi et al (2016)	Trials Partnership (EDCTP) and
084113/Z/07/Z	Wellcome Trust	-	-	-	-		Longley et al (2017)	Funding for manufacture and
084113/Z/07/Z	Wellcome Trust	-	-	-	-		Payne et al (2017)	This work was supported by fu
095540/Z/11/Z	Wellcome Trust	Hill AVS	-	-	-		Longley et al (2017)	Funding for manufacture and
095540/Z/11/Z	Wellcome Trust	Hill AVS	-	-	-		Salman et al (2017)	The work was funded by a W€
097395/Z/11/Z	Wellcome Trust	Reyes-Sandoval A	-	-	-		Alves et al (2017)	The work was funded by a W $\varepsilon$
097395/Z/11/Z	Wellcome Trust	Reyes-Sandoval A	-	-	-		Salman et al (2017)	The work was funded by a W $\varepsilon$
097940/Z/11/Z	Wellcome Trust	Hodgson SH	-	-	-		Longley et al (2017)	Funding for manufacture and
106917/Z/15/Z	Wellcome Trust	Draper SJ	-	-	-		Payne et al (2017)	This work was supported by fu
204826/Z/16/Z	Wellcome Trust	Prof Matthew Freeman	07/09/2016		£		Fedosyuk S (2019)	This work was supported by N
106917/Z/15/Z	Wellcome Trust	Prof Simon Draper	01/04/2015	£1,901,424.00	£	1,901,424.00	Wang (2018)	This work has been supported
095540/Z/11/Z	Wellcome Trust	Hill A.V.S	10/05/2011	£1,372,456.00	£	1,372,456.00	Atcheson (2018)	The work was funded by a W $\varepsilon$
95540/Z/11/Z	Wellcome Trust	Prof Adrian Hill	10/05/2011	, ,			Dicks et al (2015 - 2)	This work has been funded by
97395/Z/11/Z	Wellcome Trust	Reyes-Sandoval A	12/12/2011	£1,081,461.00	£	1,081,461.00	Bauza et al (2014)	The work was funded by a W€
201477/Z/16/Z	Wellcome Trust	Dr Alexander Douglas	18/05/2016	£414,492.00	£	414,492.00	Wang (2018)	This work has been supported
201477/Z/16/Z	Wellcome Trust	Douglas AD	18/05/2016		£		Fedosyuk S (2019)	This work was supported by N
098635/B/12/Z	Wellcome Trust	Warimwe GM	21/06/2012	,	£	,	Dulal et al (2016)	This study was conducted witl
098635/B/12/Z	Wellcome Trust	Warimwe GM	21/06/2012		£		Warimwe et al (2013)	This work was supported by a
094449/Z/10/Z	Wellcome Trust	Duncan CJ	31/08/2010		£		Sheehy et al (2012)	This work was supported by
089455/Z/09/Z	Wellcome Trust	Douglas AD	29/05/2009		£		Payne et al (2017)	This work was supported by fu
97395/Z/11/A	Wellcome Trust	Reyes-Sandoval A	01/08/2013		£	203,200.00		
097940/Z/11/Z	Wellcome Trust	Hodgson SH	29/03/2012		£		Kimani et al (2014)	This work was supported by
	Wellcome Trust	Prof Adrian Hill	16/09/2008		£			The work was supported by a
098635/Z/12/Z	Wellcome Trust	Warimwe GM	21/06/2012	£74,551.00	£	74,551.00	Dulal et al (2016)	This study was conducted with
-	Wellcome Trust	-	-	-			Barnes et al (2012)	European Union (Framework '

-	Wellcome Trust	-	-	-
-	Wellcome Trust	-	-	-
-	Wellcome Trust	Hill AVS	-	-
-	Wellcome Trust	-	-	-
-	Wellcome Trust	-	-	-
-	Wellcome Trust	Hill AVS	-	-
-	Wellcome Trust	-	-	-
-	Wellcome Trust	Hill AVS	-	-
-	Wellcome Trust	Hill A.V.S	-	-
-	Wellcome Trust	Hill A.V.S.	-	-
-	Wellcome Trust	Gilbert SC	_	-
-	Wellcome Trust	-	_	-
-	Wellcome Trust	Hill AVS	-	-
-	Wellcome Trust	-	-	-
-	Wellcome Trust	Hill AVS	-	-
-	Wellcome Trust	Hill A.V.S	_	-
-	Wellcome Trust	Hill A.V.S	_	-
-	Wellcome Trust	Hill A.V.S.	_	-
-	Wellcome Trust	-	_	-
-	Wellcome Trust	_	_	-
	Wellcome Trust	Gavin Screaton	_	_
	Wellcome Trust	-		
-	Wellcome Trust	_	_	-
	Wellcome Trust	Hill AVS	_	
	Wellcome Trust	Hill A.V.S		
	Wellcome Trust	Hill AVS	_	
	Wellcome Trust	-	_	
	Wellcome Trust	Kelly C	_	
_	Wellcome Trust	Klenerman P	-	-
084113/Z/07/Z	Wellcome Trust	-	-	-
084113/Z/07/Z	Wellcome Trust		_	
084113/Z/07/Z 084113/Z/07/Z	Wellcome Trust	-	•	-
	Wellcome Trust	- LEIL AVC	-	-
084113/Z/07/Z		Hill AVS	-	-
084113/Z/07/Z	Wellcome Trust	-	-	-
084113/Z/07/Z	Wellcome Trust	-	-	-
084113/Z/07/Z	Wellcome Trust		-	-
084113/Z/07/Z	Wellcome Trust	Prof Adrian Hill	-	-
091663MA	Wellcome Trust	-	-	-
095540/Z/11/Z	Wellcome Trust	-	-	-
095540/Z/11/Z	Wellcome Trust	-	-	-
095540/Z/11/Z	Wellcome Trust	-	-	-
097940/Z/11/Z	Wellcome Trust	Hodgson SH	-	-
097940/Z/11/Z	Wellcome Trust	Hodgson SH	-	-
097940/Z/11/Z)	Wellcome Trust	Hodgson SH	-	-
099897/Z/12/A	Wellcome Trust	-	-	-
45488/Z/05	Wellcome Trust	Hill AVS	-	-
45488/Z/05	Wellcome Trust	Hill AVS	-	-
45488/Z/05	Wellcome Trust	Hill AVS	_	-
45488/Z/05	Wellcome Trust	Hill AVS	-	-
45488/Z/05	Wellcome Trust	Hill AVS	_	-
RTEI0	Wellcome Trust	Duncan CJ	_	_
WT076943MA	Wellcome Trust	McShane H	_	_
WT098051	Wellcome Trust	-	_	_
WT098635	Wellcome Trust	Warimuo GM		
VV 1030000	wencome must	Warimwe GM	-	-

Bliss (2018) This study was funded by the Boyd et al (2013) The Biotechnology and Biolog Capuccini et al (2016) This work was supported by O Colloca et al (2012) This work was supported in pa Cottingham et al (2012) This work was supported by the de Cassan et al (2011) S.C.d.C. is a Ph.D. student sup Dicks et al (2012) This work has been funded by Dicks et al (2015 - 2) This work has been funded by Draper et al (2010) This work was funded by the \ Draper et al (2011) SB was funded by MalParTrain Draper et al (2011) SB was funded by MalParTrain Ewer et al (2013) The study was funded by gran Ewer et al (2013) The study was funded by gran Forbes et al (2012) This work was funded by the \ Forbes et al (2012) This work was funded by the \ Gola (2018) A.G. is funded by the Wellcon Gola (2018) A.G. is funded by the Wellcon Goodman et al (2011) This work was supported prim Halbroth (2018) BRH received funding from th Kelly et al (2016) Supported by a Medical Resea Lopez-Camacho (2018) This report is independent res Tapia et al (2016) This study was funded by a W Tapia et al (2016) This study was funded by a W Walker et al (2015) Andrew S. Walker, José Loure Halbroth (2018) BRH received funding from th Colloca et al (2012) This work was supported in pa Ewer et al (2016) Supported by the Wellcome T Swadling (2016) Supported by the Medical Res Swadling (2016) Supported by the Medical Res de Barra et al (2014) The study was funded by a gra Elias et al (2013) This work was supported by the Hodgson et al (2014) This work was supported by th Hodgson et al (2015) This work was supported by th Kimani et al (2014) This work was supported by Sheehy et al (2011) This work was supported by th Sheehy et al (2012 - 2) This work was supported by th This work was supported by Sheehy et al (2012) Colston et al (2016) This work was supported by V Dicks et al (2015) This work has been funded by Longley et al (2015) This work has been funded by Spencer et al (2014) This work has been funded by de Barra et al (2014) The study was funded by a gra Hodgson et al (2015) This work was supported by th Biswas et al (2014) This work was supported by th Colston et al (2016) This work was supported by V de Barra et al (2014) The study was funded by a gra This work was supported by the Hodgson et al (2015) Sheehy et al (2011) This work was supported by th Sheehy et al (2012 - 2) This work was supported by th Sheehy et al (2012) This work was supported by Sheehy et al (2012 - 2) This work was supported by th Betts et al (2012) Funding was provided by NEW Bauza et al (2014) The work was funded by a We Warimwe et al (2016) This work was conducted with

9739	5 Wellcome Trust	Reyes-Sandoval A	-	-		-		Betts et al (2012)	Funding was provided by NEW
-	Wellcome Trust	Hill AVS	-	-		-		Dicks et al (2012)	This work has been funded by
-	Wellcome Trust	-	-	-		-		O'Hara et al (2012)	Financial support. This work w
084113/Z/07/Z	Wellcome Trust	-	-	-		-		Ogwang et al (2013)	This work was performed by t
WT 098051	Wellcome Trust	Otto TD	-	-		-		Payne (2017)	This work was supported by a
203077/Z/16/Z	Wellcome Trust	Prof Philip Bejon		30/06/2016	£26,595,243.00	£	26,595,243.00	Stedman (2019)	This study was funded by the
									·
084113/Z/07/Z	Wellcome Trust	Prof Adrian Hill		07/11/2007	£3,400,000.00	£	3.400.000.00	de Cassan et al (2011)	S.C.d.C. is a Ph.D. student sup
, , - ,				, ,	-,,		-,,	,	
084113/Z/07/Z	Wellcome Trust	Prof Adrian Hill		07/11/2007	£3,400,000.00	£	3,400,000.00	Payne (2017)	This work was supported by a
106325/Z/14/A	Wellcome Trust	A.V.S Hill		19/12/2014	£2,100,000.00	£	2,100,000.00	Venkatraman N (2019)	This work was supported
106917/Z/15/Z	Wellcome Trust	Draper SJ		01/04/2015	£1,901,424.00	£	1,901,424.00	Payne (2017)	This work was supported by a
097395/Z/11/Z	Wellcome Trust	Reves-Sandoval A		12/12/2011	£1,081,461.00	£	1,081,461.00	Atcheson (2018)	The work was funded by a We
108734/Z/15/Z	Wellcome Trust	Rawlinson TA		24/06/2015	£271,399.00	£	271,399.00	Payne (2017)	This work was supported by a
-	Wellcome Trust	A.V.S Hill	-	-	,		,	Bowyer (2018)	The clinical trial was supporte
-	Wellcome Trust	Gola A	-	-				Gola (2018)	A.G. is funded by the Wellcon
-	Wellcome Trust	-	-	-				Mensah (2017)	This work was supported by a
-	Wellcome Trust Clinical Research Facil	lit -	-	-				Barnes et al (2012)	European Union (Framework
								, ,	